Author Index to Volume 43*

A

Abraldes JG (*see* Hernández-Guerra M et al). 2006;43:27-33, 485-491
— (*see* Turnes J et al). 2006;43:34-41
Achermann F (*see* Bonvin M et al). 2006; 43:1364-1374
Ackrill AM (*see* Jensen DM et al). 2006;43: 954-960, 1410 (Correction)
Adachi M (*see* Mennone A et al). 2006;43: 1013-1021
Adams DH (*see* Aspinall AI and Adams DH). 2006;43:20-23 (Editorial)
Adamson G (*see* Levy GA et al). 2006;43: 581-591
Afdhal N (*see* Wilson LE et al). 2006;43: 788-795
Afdhal NH (*see* Kamal SM et al). 2006;43: 771-779, 923-931 (Rapid Communication)
Agrawal A (*see* Kuiken C et al). 2006;43: 1157-1165 (Special Article)
Ahmado I (*see* Ala A et al). 2006;43:525-531
Aittomäki K (*see* Ropponen A et al). 2006; 43:723-728
Ajuebor M (*see* Kerfoot S et al). 2006;43: 1401-1402 (Reply)
Ajuebor MN (*see* Kerfoot SM et al). 2006; 43:154-162
Akashi K (*see* Nagaya M et al). 2006;43: 1053-1062
Al Tawil A (*see* Kamal SM et al). 2006;43: 771-779
Ala A, Stanca CM, Bu-Ghanim M, Ahmado I, Branch AD, Schiano TD, Odin JA, Bach N. Increased prevalence of primary biliary cirrhosis near Superfund toxic waste sites. 2006;43:525-531
Alain S (*see* Chemin I et al). 2006;43:195 (Correspondence)
Albillos A, Muñoz L, Nieto M, Úbeda M, de-la-Hera A, Alvarez-Mon M. Systemic effects of TNF-α secreted by circulating monocytes and fatigue in cirrhosis. 2006;43:1399 (Correspondence)
Alison MR (*see* Vig P et al). 2006;43:316-324
Almuna R (*see* Reyes H et al). 2006;43: 715-722
Alonso J (*see* Mínguez B et al). 2006;43: 707-714
Al-Osaimi AMS and Caldwell SH. Intermittent disconjugate gaze: A novel finding in nonalcoholic steatohepatitis. 2006;43:883 (Reply)
Alter H. Hepatology Highlights. 2006;43: 643-645
—. Viral hepatitis. 2006;43:S230-S234 (Highlights of the Highlights)
Alter HJ (*see* Umemura T et al). 2006;43: 91-99
Alvarez-Barrientos A (*see* Quintana-Bustamante O et al). 2006;43:108-116
Alvarez-Mon M (*see* Albillos A et al). 2006; 43:1399 (Correspondence)
Amadei B (*see* Kennedy PTF et al). 2006; 43:602-611
Amigo L (*see* Klein A et al). 2006;43:126-133
Amoruso A (*see* Castellaneta A et al). 2006; 43:807-816
Anan A, Baskin-Bey ES, Bronk SF, Werneburg NW, Shah VH, Gores GJ. Proteasome inhibition induces hepatic stellate cell apoptosis. 2006; 43:335-344
Anania FA (*see* Ding X et al). 2006;43:173-181
Ananthanarayanan M (*see* Arrese M et al). 2006;43:191-193 (Hepatology *Elsewhere*)
Ando M (*see* Iwasaki Y et al). 2006;43:54-63
Ansari AA (*see* Lan RY et al). 2006;43:729-737
Anzai N (*see* Brandoni A et al). 2006;43: 1092-1100
Apostolov EO (*see* Napirei M et al). 2006; 43:297-305
Appel N and Bartenschlager R. A novel function for a micro RNA: Negative regulators can do positive for the hepatitis C virus. 2006;43:612-615 (Hepatology Elsewhere)
APRICOT Clinical Investigators (*see* Sterling RK et al). 2006;43:1317-1325
Arai K (*see* Mizukoshi E et al). 2006;43: 1284-1294
Arakawa T (*see* Ikura Y et al). 2006;43:506-514
Araki Y (*see* Iwasaki Y et al). 2006;43:54-63
Arbuthnot P (*see* Lian Z et al). 2006;43: 415-424
Areias JA (*see* Sokal EM et al). 2006;43: 225-232
Arenas F (*see* Banales JM et al). 2006;43: 266-275
Arias IM. Reflections on the first five years of HEPATOLOGY, 1981-1986. 2006;43: S3-S4
Arihiro K (*see* Ishiyama K et al). 2006;43: 362-372
Armeanu S (*see* Pathil A et al). 2006;43: 425-434
Arrese M, Miquel JF, Ananthanarayanan M. βKlotho: A new kid on the bile acid biosynthesis block. 2006;43:191-193 (Hepatology *Elsewhere*)
Asahara T (*see* Ishiyama K et al). 2006;43: 362-372
Aspinall AI and Adams DH. Sickness behaviors in chronic cholestasis: An immune-mediated process? 2006;43: 20-23 (Editorial)
Asselah T (*see* Saadoun D et al). 2006;43: 1337-1345
Associazione Italiana Studio Fegato (AISF) Cooperative Group (*see* Raimondo G et al). 2006;43:100-107
Astemborski J (*see* Wilson LE et al). 2006; 43:788-795
Aukerman L (*see* Kneteman NM et al). 2006;43:1346-1353
Ausó E (*see* Jover R et al). 2006;43:1257-1266
Avgernos A (*see* Triantos C et al). 2006;43: 196-197 (Correspondence)

B

Bach N (*see* Ala A et al). 2006;43:525-531
Bacq Y (*see* Zucman-Rossi J et al). 2006; 43:515-524
Badia IB (*see* Sokal EM et al). 2006;43: 225-232
Bae SH (*see* Jang JW et al). 2006;43:233-240
Balabaud C (*see* Zucman-Rossi J et al). 2006;43:515-524
Balasubramanian K (*see* Natarajan SK et al). 2006;43:1248-1257
Balasubramanian KA (*see* Natarajan SK et al). 2006;43:837-846
Ball JK (*see* Tarr AW et al). 2006;43:592-601
Banales JM, Arenas F, Rodríguez-Ortigosa CM, Sáez E, Uriarte I, Doctor RB, Prieto J, Medina JF. Bicarbonate-rich choleresis induced by secretin in normal rat is taurocholate-dependent and involves AE2 anion exchanger. 2006;43:266-275
Banas C (*see* Sanyal AJ et al). 2006;43:682-689
Bankuti C (*see* Lackner C et al). 2006;43: 378-379 (Correspondence)
Bansal MB (*see* Friedman SL and Bansal MB). 2006;43:S82-S88
Bantel H (*see* Volkmann X et al). 2006;43: 1311-1316
Barbe L (*see* Nahmias Y et al). 2006;43: 257-265

**January, 1-206; February 207-382; Supplement to February S1-S250; March, 383-642; April 643-886; May, 887-1174; June, 1175-1450.*

Barberà JA (*see* Gómez FP et al). 2006;43:1084-1091
Barker M (*see* Wasmuth HE et al). 2006;43:738-741 (Concise Communication)
Barone M (*see* Castellaneta A et al). 2006;43:807-816
Bartenschlager R (*see* Appel N and Bartenschlager R). 2006;43:612-615 (Hepatology Elsewhere)
— (*see* Paeshuyse J et al). 2006;43:761-770
—(*see* Tarr AW et al). 2006;43:592-601
Bartolacci S (*see* Bortolotti F et al). 2006;43:556-562
Basivireddy J (*see* Natarajan SK et al). 2006;43:837-846, 1248-1257
Baskin-Bey ES (*see* Anan A et al). 2006;43:335-344
Basnakian AG (*see* Napirei M et al). 2006;43:297-305
Battezzati PM (*see* Wesierska-Gadek J et al). 2006;43:1135-1144
Bauer B (*see* Lackner C et al). 2006;43:378-379 (Correspondence)
Baumert TF (*see* Fang X et al). 2006;43:1326-1336
— (*see* Neumann-Haefelin C et al). 2006;43:563-572
Beaugrand M (*see* Corpechot C et al). 2006;43:1118-1124
Bedolli M (*see* Sekine S et al). 2006;43:817-825
Bedossa P (*see* Saadoun D et al). 2006;43:1337-1345
Bell D (*see* Levy GA et al). 2006;43:581-591
Bellot P (*see* Hernández-Guerra M et al). 2006;43:27-33, 485-491
— (*see* Turnes J et al). 2006;43:34-41
Bendavid C (*see* Lainé F et al). 2006;43:377-378 (Correspondence)
Bender D (*see* Keiding S et al). 2006;43:42-50
Benhamou Y, Fleury H, Trimoulet P, Pellegrin I, Urbinelli R, Katlama C, Rozenbaum W, Le Teuff G, Trylesinski A, Piketty C, TECOVIR Study Group. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. 2006;43:548-555
— (*see* Poynard T et al). 2006;43:374-375 (Correspondence)
Benson JT (*see* Kim WR et al). 2006;43:345-351
Berbel P (*see* Jover R et al). 2006;43:1257-1266
Berg T (*see* Wiegand J et al). 2006;43:250-256
Bergasa NV (*see* Floreani A et al). 2006;43:1152-1154 (Concise Communication)
Berk PD. An editor's look-back. 2006;43:S13-S30
Bernat JL (*see* van Leeuwen DJ and Bernat JL). 2006;43:1195-1201 (Sounding Board)
Bernstein LR. Does nucleolin bind the NF kappa B DNA binding motif? 2006;43:376 (Correspondence)
Bertet J (*see* Castera L et al). 2006;43:373-374 (Correspondence)
Berthiaume F (*see* Nahmias Y et al). 2006;43:257-265
Bertoletti A (*see* Kennedy PTF et al). 2006;43:602-611
Besselink MGH (*see* Venneman NG et al). 2006;43:1276-1283
Betrossian A (*see* Cholongitas EB et al). 2006;43:881 (Correspondence)
Beuers U and Pusl T. Intrahepatic cholestasis of pregnancy — A heterogeneous group of pregnancy-related disorders? 2006;43:647-649 (Editorial)
Bhala N (*see* Jones DEJ et al). 2006;43:633 (Correspondence)
Bianchi L (*see* Kamal SM et al). 2006;43:771-779
Biessels P (*see* Levy GA et al). 2006;43:581-591
Bigger CB (*see* Lanford RE et al). 2006;43:961-972
Bilodeau M (*see* Zwingmann C and Bilodeau M). 2006;43:454-463
Binh VQ (*see* Toan NG et al). 2006;43:1375-1384
Bioulac-Sage P (*see* Zucman-Rossi J et al). 2006;43:515-524
Bissell DM (*see* Rockey DC and Bissell DM). 2006;43:S113-S120
Bissell DM (*see* Rockey DC and Bissell DM). 2006;43:1402 (Reply)
— (*see* Schenker S et al). 2006;43:S6-S12
Bitzer M (*see* Pathil A et al). 2006;43:425-434
Blasco A, Forns X, Carrión JA, García-Pagán JC, Gilabert R, Rimola A, Miquel R, Bruguera M, García-Valdecasas JC, Bosch J, Navasa M. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. 2006;43:492-499
Blatt LM (*see* Patel K et al). 2006;43:241-249
Blei AT. 25 years of *Hepatology*. 2006;43:S1
—. Who reads the paper? 2006;43:1 (Editor's Corner)
— (*see* Schenker S et al). 2006;43:S6-S12
Blum HE (*see* Fang X et al). 2006;43:1326-1336
Blum HF (*see* Neumann-Haefelin C et al). 2006;43:563-572
Bock CT (*see* Toan NG et al). 2006;43:1375-1384
Boecher W (*see* Wiegand J et al). 2006;43:250-256
Boermeester MA (*see* Venneman NG et al). 2006;43:1276-1283
Bonis PA and Kaplan M. Methotrexate for treatment of primary biliary cirrhosis. 2006;43:632 (Correspondence)
Bonvin M, Achermann F, Greeve I, Stroka D, Keogh A, Inderbitzin D, Candinas D, Sommer P, Wain-Hobson W, Vartanian JP, Greeve J. Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication. 2006;43:1364-1374
Borg B (*see* Perumalswami P et al). 2006;43:780-787
Bortolotti F, Guido M, Bartolacci S, Cadrobbi P, Crivellaro C, Noventa F, Morsica G, Moriondo M, Gatta A. Chronic hepatitis B in children after e antigen seroclearance: Final report of a 29-year longitudinal study. 2006;43:556-562
Bosch J (*see* Blasco A et al). 2006;43:492-499
— (*see* Hernández-Guerra M et al). 2006;43:27-33, 485-491
— (*see* Mínguez B et al). 2006;43:707-714
— (*see* Turnes J et al). 2006;43:34-41
Boullier A (*see* von Hahn T et al). 2006;43:932-942
Bowlus CL (*see* Lan RY et al). 2006;43:729-737
Boyer JL (*see* Mennone A et al). 2006;43:1013-1021
Boyer TD. Wedged hepatic vein pressure (WHVP): Ready for prime time. 2006;43:405-406 (Editorial)
Boyko EJ (*see* Ioannou GN et al). 2006;43:1145-1151
Braeuning A (*see* Hailfinger S et al). 2006;43:407-414
Braksy KM (*see* Lanford RE et al). 2006;43:961-972
Branch AD (*see* Ala A et al). 2006;43:525-531
Branda M and Wands JR. Signal transduction cascades and hepatitis B and C related hepatocellular carcinoma. 2006;43:891-902 (Science Frontier)
Brandoni A, Villar SR, Picena JC, Anzai N, Endou H, Torres AM. Expression of rat renal cortical OAT1 and OAT3 in response to acute biliary obstruction. 2006;43:1092-1100
Brandt L (*see* Stokkeland K et al). 2006;43:500-505
Brasic N (*see* Callender GG et al). 2006;43:973-981
Breitkopf K (*see* Wiercinska E et al). 2006;43:1032-1041
Brenner DA (*see* Purohit V and Brenner DA). 2006;43:872-878 (Special Article)
Broeders IAMJ (*see* Venneman NG et al). 2006;43:1276-1283
Bronk SF (*see* Anan A et al). 2006;43:335-344
Brookes S (*see* Levy GA et al). 2006;43:581-591

Brown RJP (*see* Tarr AW et al). 2006;43:592-601
Bruguera M (*see* Blasco A et al). 2006;43:492-499
Brunetto MR (*see* Raimondo G et al). 2006;43:100-107
Bruno S (*see* Cammà C et al). 2006;43:64-71
Bucher BT (*see* Kaizu T et al). 2006;43:464-473
Buchman AL, Iyer K, Fryer J. Parenteral nutrition–associated liver disease and the role for isolated intestine and intestine/liver transplantation. 2006;43:9-19 (Perspectives in Clinical Hepatology)
Buchmann A (*see* Hailfinger S et al). 2006;43:407-414
Bueren JA (*see* Quintana-Bustamante O et al). 2006;43:108-116
Buggisch P (*see* Wiegand J et al). 2006;43:250-256
Bu-Ghanim M (*see* Ala A et al). 2006;43:525-531
Bugianesi E and Marchesini G. Correlation between insulin resistance and hepatitis C viral load. 2006;43:1168-1169 (Reply)
Burgos F (*see* Gómez FP et al). 2006;43:1084-1091
Burroughs A (*see* Triantos C et al). 2006;43:196-197 (Correspondence)
Burroughs AK (*see* Cholongitas EB et al). 2006;43:881 (Correspondence)
Byun KS (*see* Lee HS et al). 2006;43:982-988

C

Cacoub P (*see* Saadoun D et al). 2006;43:1337-1345
Cadamuro M (*see* Fabris L et al). 2006;43:1001-1012
Cadrobbi P (*see* Bortolotti F et al). 2006;43:556-562
Cai SY (*see* Mennone A et al). 2006;43:1013-1021
Caldwell SH (*see* Al-Osaimi AMS and Caldwell SH). 2006;43:883 (Reply)
Callender GG, Rosen HR, Roszkowski JJ, Lyons GE, Li M, Moore T, Brasic N, McKee MD, Nishimura MI. Identification of a hepatitis C virus–reactive T cell receptor that does not require CD8 for target cell recognition. 2006;43:973-981
Cammà C, Bruno S, Di Marco V, Di Bona D, Rumi M, Vinci M, Rebucci C, Cividini A, Pizzolanti G, Minola E, Mondelli MU, Colombo M, Pinzello G, Craxì A. Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. 2006;43:64-71
Campbell JS (*see* Fausto N et al). 2006;43:S45-S53
Candela A (*see* García-Ayllón MS et al). 2006;43:444-453
— (*see* Jover R et al). 2006;43:1257-1266
Candinas D (*see* Bonvin M et al). 2006;43:1364-1374
Carderi I (*see* Floreani A et al). 2006;43:1152-1154 (Concise Communication)
Carpenter HA (*see* Czaja AJ and Carpenter HA). 2006;43:532-538
Carrión JA (*see* Blasco A et al). 2006;43:492-499
Casali M (*see* Nahmias Y et al). 2006;43:257-265
Cassader M, Gambino R, Musso G, Durazzo M, Pagano G. Association between postprandial LDL conjugated dienes and the severity of liver fibrosis in NASH. 2006;43:1169-1170 (Correspondence)
Cassia Correa M (*see* Sterling RK et al). 2006;43:1317-1325
Castaing D (*see* Zucman-Rossi J et al). 2006;43:515-524
Castellaneta A, Di Leo A, Francavilla R, Margiotta M, Barone M, Amoruso A, Troiani L, Thomson AW, Francavilla A. Functional modification of CD11c+ liver dendritic cells during liver regeneration after partial hepatectomy in mice. 2006;43:807-816
Castera L, Foucher J, Bertet J, Couzigou P, de Ledinghen V. FibroScan and FibroTest to assess liver fibrosis in HCV with normal aminotransferases. 2006;43:373-374 (Correspondence)
Cauli O (*see* Jover R et al). 2006;43:1257-1266
Cederbaum AI (*see* Dey A and Cederbaum AI). 2006;43:S63-S74
— (*see* Gong P and Cederbaum AI). 2006;43:144-153
Chang FY (*see* Tan PC et al). 2006;43:690-697, 1410 (Correction)
Chang UI (*see* Jang JW et al). 2006;43:233-240
Chao YC (*see* Liu CJ et al). 2006;43:742-749
Charavay C (*see* Kuiken C et al). 2006;43:1157-1165 (Special Article)
Charlton MR, Pockros PJ, Harrison SA. Impact of obesity on treatment of chronic hepatitis C. 2006;43:1177-1186 (Perspectives in Clinical Hepatology)
Chaudhry S (*see* Mandac JC et al). 2006;43:661-672 (Perspectives in Clinical Hepatology)
Chavez D (*see* Lanford RE et al). 2006;43:961-972
Chazouillères O (*see* Corpechot C et al). 2006;43:1118-1124
Chemin I, Alain S, Margeridon S, Mrani S, Kay A, Trépo C. What is really ongoing during occult HBV reactivation? 2006;43:195 (Correspondence)
Chen CL (*see* Liu CJ et al). 2006;43:742-749
Chen DS (*see* Kao JH and Chen DS). 2006;43:373 (Correspondence)
— (*see* Liu CJ et al). 2006;43:742-749
Chen J (*see* Kamal SM et al). 2006;43:923-931 (Rapid Communication)
Chen PC (*see* Tsai MH et al). 2006;43:673-681
Chen PJ (*see* Liu CJ et al). 2006;43:742-749
Chen THH (*see* Lai MS et al). 2006;43:1295-1302
Chen XC (*see* Huang Y et al). 2006;43:81-90
Chen YC (*see* Tsai MH et al). 2006;43:673-681
Cheng C (*see* Lan RY et al). 2006;43:729-737
Chiang JYL (*see* Li T et al). 2006;43:1202-1210
— (*see* Song KH and Chiang JYL). 2006;43:117-125
Chiche L (*see* Zucman-Rossi J et al). 2006;43:515-524
Chignard N (*see* Demeilliers C et al). 2006;43:1125-1134
Chiu YH (*see* Lai MS et al). 2006;43:1295-1302
Cho SH (*see* Jang JW et al). 2006;43:233-240
Choi JY (*see* Jang JW et al). 2006;43:233-240
— (*see* Jung CR et al). 2006;43:1042-1052
Cholongitas EB, Betrossian A, Leandro G, Shaw S, Patch D, Burroughs AK. King's criteria, APACHE II, and SOFA scores in acute liver failure. 2006;43:881 (Correspondence)
Chong WP, To YF, Ip WK, Yuen MF, Poon TP, Wong WHS, Lai CL, Lau YL. Mannose-binding lectin in chronic hepatitis B virus infection. 2006;43:199 (Correction)
Christen V (*see* Duong FHT et al). 2006;43:796-806
Chu IS (*see* Jung CR et al). 2006;43:1042-1052
Chuang YH (*see* Lan RY et al). 2006;43:729-737
Chung YH (*see* Lee HS et al). 2006;43:982-988
— (*see* Lee YS et al). 2006;43:1385-1391
Cividini A (*see* Cammà C et al). 2006;43:64-71
Clare M (*see* Patel K et al). 2006;43:241-249
Clària J (*see* García-Ayllón MS et al). 2006;43:444-453
Clavien PA (*see* Hoekstra H et al). 2006;43:1022-1031
Clayton M (*see* Lian Z et al). 2006;43:415-424
Clemens MG (*see* Kamoun WS et al). 2006;43:182-190

Clumeck N (*see* Sterling RK et al). 2006; 43:1317-1325
Cobbold JFL, Lim A, Wylezinska M, Cunningham C, Crossey ME, Thomas HC, Patel N, Cox IJ, Taylor-Robinson SD. Magnetic resonance and ultrasound techniques for the evaluation of hepatic fibrosis. 2006; 43:1401-1402 (Correspondence)
Collett M (*see* Kneteman NM et al). 2006; 43:1346-1353
Colletta C, Smirne C, Fabris C, Toniutto P, Pirisi M. Diagnostic value of FibroTest with normal serum aminotransferases. 2006;43:375-376 (Reply)
Colombo M (*see* Cammà C et al). 2006;43: 64-71
— (*see* Sangiovanni A et al). 2006;43:1303-1310
Combes B and Emerson SS. Methotrexate for treatment of primary biliary cirrhosis. 2006;43:632-633 (Reply)
— and PUMPS Group. Reflections on therapeutic trials in primary biliary cirrhosis: A quality of life oriented counter-view. 2006;43:634 (Reply)
Combet C (*see* Kuiken C et al). 2006;43: 1157-1165 (Special Article)
Compañ A (*see* García-Ayllón MS et al). 2006;43:444-453
— (*see* Jover R et al). 2006;43:1257-1266
Conrad A (*see* Patel K et al). 2006;43:241-249
Contos MJ (*see* Sanyal AJ et al). 2006;43: 682-689
Coppel RL (*see* Lan RY et al). 2006;43: 729-737
Córdoba J (*see* Mínguez B et al). 2006;43: 707-714
Cornberg M (*see* Volkmann X et al). 2006; 43:1311-1316
— (*see* Wiegand J et al). 2006;43:250-256
Corpechot C, El Naggar A, Poujol-Robert A, Ziol M, Wendum D, Chazouillères O, de Lédinghen V, Dhumeaux D, Marcellin P, Beaugrand M, Poupon R. Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. 2006;43:1118-1124
Cosset FL (*see* Dreux M and Cosset FL). 2006;43:903-905 (Editorial)
Costa RH (*see* Yoshida Y et al). 2006;43: 276-286
Coterrell A (*see* Sanyal AJ et al). 2006;43: 682-689
Couzigou P (*see* Castera L et al). 2006;43: 373-374 (Correspondence)
Cox IJ (*see* Cobbold JFL et al). 2006;43: 1401-1402 (Correspondence)
Craxì A and Licata A. Acute hepatitis C: In search of the optimal approach to cure. 2006;43:221-224 (Editorial)
— (*see* Cammà C et al). 2006;43:64-71
Crespo J (*see* Martínez-Bauer E et al). 2006;43:72-80
Crisan D (*see* Kuiken C et al). 2006;43: 1157-1165 (Special Article)
Crivellaro C (*see* Bortolotti F et al). 2006; 43:556-562
Crossey ME (*see* Cobbold JFL et al). 2006; 43:1401-1402 (Correspondence)
Cullen C (*see* Talal AH et al). 2006;43: 943-953
Cunningham C (*see* Cobbold JFL et al). 2006;43:1401-1402 (Correspondence)
Czaja AJ and Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. 2006;43:532-538
Czaja MJ (*see* Schattenberg JM et al). 2006; 43:163-172

D

Dabeva MD (*see* Shafritz DA et al). 2006; 43:S89-S98
Dalwani A (*see* Kuiken C et al). 2006;43: 1157-1165 (Special Article)
Dammacco F (*see* Sansonno D et al). 2006; 43:1167-1168 (Reply)
Darlington GJ (*see* Yoshida Y et al). 2006; 43:276-286
Davern TJ (*see* Larson AM et al). 2006;43: 882 (Reply)
Davis GL. Tailoring antiviral therapy in hepatitis C. 2006;43:909-911 (Editorial)
Dawson PA (*see* Lee S et al). 2006;43: 1241-1247
De Clercq E (*see* Paeshuyse J et al). 2006; 43:761-770
de Franchis R. Endoscopy critics vs. endoscopy enthusiasts for primary prophylaxis of variceal bleeding. 2006; 43:24-26 (Editorial)
de Lédinghen V (*see* Castera L et al). 2006; 43:373-374 (Correspondence)
de Lédinghen V (*see* Corpechot C et al). 2006;43:1118-1124
De Re V (*see* Sansonno D et al). 2006;43: 1167-1168 (Reply)
Del Ninno E (*see* Sangiovanni A et al). 2006;43:1303-1310
dela Peña A (*see* Yu J et al). 2006;43:826-836
de-la-Hera A (*see* Albillos A et al). 2006;43: 1399 (Correspondence)
Deleage G (*see* Kuiken C et al). 2006;43: 1157-1165 (Special Article)
Demeilliers C, Jacquemin E, Varbu V, Mergey M, Paye F, Fouassier L, Chignard N, Housset C, Lomri NE. Altered hepatobiliary gene expressions in PFIC1: ATP8B1 gene defect is associated with CFTR downregulation. 2006;43:1125-1134
Denecke B (*see* Wiercinska E et al). 2006; 43:1032-1041
Depla E (*see* Fang X et al). 2006;43:1326-1336
Deugnier Y (*see* Lainé F et al). 2006;43: 377-378 (Correspondence)
Deulofeu R (*see* Hernández-Guerra M et al). 2006;43:485-491
Devière J (*see* Gustot T et al). 2006;43: 989-1000
— (*see* Moreno C et al). 2006;43:879-880 (Reply)
Devlin J (*see* Stapelbroek JM et al). 2006; 43:51-53 (Concise Communication)
Dey A and Cederbaum AI. Alcohol and oxidative liver injury. 2006;43:S63-S74
Dhumeaux D (*see* Corpechot C et al). 2006;43:1118-1124
Di Bona D (*see* Cammà C et al). 2006;43: 64-71
Di Leo A (*see* Castellaneta A et al). 2006; 43:807-816
Di Marco V (*see* Cammà C et al). 2006;43: 64-71
Dickson ER (*see* Kim WR et al). 2006;43: 345-351
Dienes HP (*see* Untergasser A et al). 2006; 43:539-547
Dieterich DT (*see* Sterling RK et al). 2006; 43:1317-1325
Ding X, Saxena NK, Lin S, Gupta N, Anania FA. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. 2006;43:173-181
D'Mello C (*see* Kerfoot S et al). 2006;43: 1401-1402 (Reply)
— (*see* Kerfoot SM et al). 2006;43:154-162
Doctor RB (*see* Banales JM et al). 2006;43: 266-275
Dombrowski F, Flaschka C, Klotz L, von Netzer B, Schulz C, Lehnert H, Evert M. Hepatocellular neoplasms after intrahepatic transplantation of ovarian fragments into ovariectomized rats. 2006;43:857-867
Donauer J (*see* Fang X et al). 2006;43: 1326-1336
Dooley S (*see* Wiercinska E et al). 2006;43: 1032-1041
Douglas D (*see* Kneteman NM et al). 2006; 43:1346-1353
Dreux M and Cosset FL. HCV and lipoproteins: Is oxLDL an Achilles' Heel of the Trojan horse? 2006;43: 903-905 (Editorial)
Dumont JM (*see* Paeshuyse J et al). 2006; 43:761-770
Duong FHT, Christen V, Filipowicz M, Heim MH. S-Adenosylmethionine and betaine correct hepatitis C virus induced inhibition of interferon signaling *in vitro*. 2006;43:796-806
Durazzo M (*see* Cassader M et al). 2006; 43:1169-1170 (Correspondence)
Dusheiko G (*see* Kennedy PTF et al). 2006;43:602-611
Duy DN (*see* Toan NG et al). 2006;43: 1375-1384

E

Ebert MPA (*see* Yu J et al). 2006;43:134-143
Edwards RJ (*see* Vig P et al). 2006;43:316-324
Ehara S (*see* Ikura Y et al). 2006;43:506-514
Ekbom A (*see* Stokkeland K et al). 2006;43:500-505
El Gohary LA (*see* Kamal SM et al). 2006;43:923-931 (Rapid Communication)
El Naggar A (*see* Corpechot C et al). 2006;43:1118-1124
Elias E. Hepatology highlights. 2006;43:383-384, 1175-1176
—. Liver failure and liver disease. 2006;43:S239-S241 (Highlights of the Highlights)
Embree-Ku M and Gruppuso PA. Does nucleolin bind the NF kappa B DNA binding motif? 2006;43:376-377 (Reply)
Emerson SS (*see* Combes B and Emerson SS). 2006;43:632-633 (Reply)
— (*see* Morishima C et al). 2006;43:573-580
Endou H (*see* Brandoni A et al). 2006;43:1092-1100
Engelke M, Mills K, Seitz S, Simon P, Gripon P, Schnölzer M, Urban S. Characterization of a hepatitis B and hepatitis delta virus receptor binding site. 2006;43:750-760
Erceg S (*see* Jover R et al). 2006;43:1257-1266
Erickson BM, Thompson NL, Hixson DC. Tightly regulated induction of the adhesion molecule Necl-5/CD155 during rat liver regeneration and acute liver injury. 2006;43:325–334
Esser K (*see* Untergasser A et al). 2006;43:539-547
Esteban A (*see* Jover R et al). 2006;43:1257-1266
Evans HM, Kelly DA, McKiernan PJ, Hübscher S. Progressive histological damage in liver allografts following pediatric liver transplantation. 2006;43:1109-1117
Evans JD and Seeger C. Cardif: A protein central to innate immunity is inactivated by the HCV NS3 serine protease. 2006;43:615-617 (Hepatology Elsewhere)
Evert M (*see* Dombrowski F et al). 2006;43:857-867

F

Fabre M (*see* Zucman-Rossi J et al). 2006;43:515-524
Fabregat I (*see* Quintana-Bustamante O et al). 2006;43:108-116
Fabris C (*see* Colletta C et al). 2006;43:375-376 (Reply)
Fabris L, Cadamuro M, Fiorotto R, Roskams T, Spirlì C. Melero S, Sonzogni A, Joplin RE, Okolicsanyi L, Strazzabosco M. Effects of angiogenic factor overexpression by human and rodent cholangiocytes in polycystic liver diseases. 2006;43:1001-1012
Fallon MB. Hepatopulmonary syndrome: More than just a matter of tone? 2006;43:912-914 (Editorial)
Fan D (*see* Lian Z et al). 2006;43:415-424
Fang JT (*see* Tsai MH et al). 2006;43:673-681
Fang X, Zeisel MB, Wilpert J, Gissler B, Thimme R, Kreutz C, Maiwald T, Timmer J, Kern WV, Donauer J, Geyer M, Walz G, Depla E, von Weizsäcker F, Blum HE, Baumert TF. Host cell responses induced by hepatitis C virus binding. 2006;43:1326-1336
Farrell GC and Larter CZ. Nonalcoholic fatty liver disease: From steatosis to cirrhosis. 2006;43:S99-S112
— (*see* Yu J et al). 2006;43:134-143, 826-836
Faruki H (*see* Wilson LE et al). 2006;43:788-795
Fasani P (*see* Sangiovanni A et al). 2006;43:1303-1310
Fausto N, Campbell JS, Riehle KJ. Liver regeneration. 2006;43:S45-S53
Fehr J (*see* Kamal SM et al). 2006;43:923-931 (Rapid Communication)
Feitelson MA (*see* Lian Z et al). 2006;43:415-424
Feld JJ and Liang TJ. Hepatitis C — Identifying patients with progressive liver injury. 2006;43:S194-S206
Felipo V (*see* García-Ayllón MS et al). 2006;43:444-453
— (*see* Jover R et al). 2006;43:1257-1266
Feng A (*see* Patel K et al). 2006;43:241-249
Feng S (*see* Sekine S et al). 2006;43:817-825
Ferenci P (*see* Jensen DM et al). 2006;43:954-960, 1410 (Correction)
Ferrari C (*see* Kennedy PTF et al). 2006;43:602-611
Filipowicz M (*see* Duong FHT et al). 2006;43:796-806
Fiorotto R (*see* Fabris L et al). 2006;43:1001-1012
Fisher RA (*see* Sanyal AJ et al). 2006;43:682-689
Fisicaro P (*see* Kennedy PTF et al). 2006;43:602-611
Flaschka C (*see* Dombrowski F et al). 2006;43:857-867
Fleury H (*see* Benhamou Y et al). 2006;43:548-555
Floreani A, Carderi I, Variola A, Rizzotto ER, Nicol J, Bergasa NV. A novel multidrug-resistance protein 2 gene mutation identifies a subgroup of patients with primary biliary cirrhosis and pruritus. 2006;43:1152-1154 (Concise Communication)
Fomina N (*see* Huang Y et al). 2006;43:81-90
Fontana RJ (*see* Larson AM et al). 2006;43:882 (Reply)
Forbes SJ (*see* Vig P et al). 2006;43:316-324
Forns X (*see* Blasco A et al). 2006;43:492-499
— (*see* Martínez-Bauer E et al). 2006;43:72-80
Fouassier L (*see* Demeilliers C et al). 2006;43:1125-1134
Foucher J (*see* Castera L et al). 2006;43:373-374 (Correspondence)
Francavilla A (*see* Castellaneta A et al). 2006;43:807-816
Francavilla R (*see* Castellaneta A et al). 2006;43:807-816
Franchimont D (*see* Gustot T et al). 2006;43:989-1000
Frédéric C (*see* Saadoun D et al). 2006;43:1337-1345
Frick D. Step-by-step progress toward understanding the hepatitis C virus RNA helicase. 2006;43:1392-1395 (Hepatology *Elsewhere*)
Friedman SL and Bansal MB. Reversal of hepatic fibrosis — Fact or fantasy? 2006;43:S82-S88
— (*see* Zhan SS et al). 2006;43:435-443
Fryer J (*see* Buchman AL et al). 2006;43:9-19 (Perspectives in Clinical Hepatology)
Fujii T, Nomoto S, Koshikawa K, Yatabe Y, Teshigawara O, Mori T, Inoue S, Takeda S, Nakao A. Overexpression of pituitary tumor transforming gene 1 in HCC is associated with angiogenesis and poor prognosis. 2006;43:1267-1275
Fukushima H (*see* Ikura Y et al). 2006;43:506-514
Fung L (*see* Levy GA et al). 2006;43:581-591

G

Galcerán J (*see* García-Ayllón MS et al). 2006;43:444-453
Gambino R (*see* Cassader M et al). 2006;43:1169-1170 (Correspondence)
Gao B (*see* Li B et al). 2006;43:1211-1219
Gao T (*see* Kneteman NM et al). 2006;43:1346-1353
García-Ayllón MS, Silveyra MX, Candela A, Compañ A, Clària J, Jover R, Pérez-Mateo M, Felipo V, Martínez S, Galcerán J, Sáez-Valero J. Changes in liver and plasma acetylcholinesterase in rats with cirrhosis induced by bile duct ligation. 2006;43:444-453
García-Ayllón MS (*see* Jover R et al). 2006;43:1257-1266

García-Pagán JC (*see* Blasco A et al). 2006; 43:492-499
— (*see* Hernández-Guerra M et al). 2006; 43:27-33, 485-491
— (*see* Mínguez B et al). 2006;43:707-714
— (*see* Turnes J et al). 2006;43:34-41
García-Valdecasas JC (*see* Blasco A et al). 2006;43:492-499
Gardener SD (*see* Sokal EM et al). 2006; 43:225-232
Gatta A (*see* Bortolotti F et al). 2006;43: 556-562
Gelbmann CM (*see* Wiegand J et al). 2006; 43:250-256
Geller DA (*see* Kaizu T et al). 2006;43: 464-473
Geourjon C (*see* Kuiken C et al). 2006;43: 1157-1165 (Special Article)
German HEP-NET Acute HCV Study Group (*see* Wiegand J et al). 2006;43: 25-256
Gershwin ME (*see* Lan RY et al). 2006;43: 729-737
— (*see* Wesierska-Gadek J et al). 2006;43: 1135-1144
Geyer M (*see* Fang X et al). 2006;43:1326-1336
Ghanekar A (*see* Levy GA et al). 2006;43: 581-591
Ghanta RK (*see* Mullen KD et al). 2006; 43:1155-1156 (Hepatology *Elsewhere*)
Ghany MG (*see* Perumalswami P et al). 2006;43:780-787
Giannelli F (*see* Giannini C et al). 2006;43: 1166-1167 (Correspondence)
Giannini C, Giannelli F, Zignego AL. Association between mixed cryoglobulinemia, translocation (14; 18), and persistence of occult HCV lymphoid infection after treatment. 2006;43:1166-1167 (Correspondence)
Gilabert R (*see* Blasco A et al). 2006;43: 492-499
Girona E (*see* Jover R et al). 2006;43:1257-1266
Gissler B (*see* Fang X et al). 2006;43:1326-1336
Gistau C (*see* Gómez FP et al). 2006;43: 1084-1091
Go PMNYH (*see* Venneman NG et al). 2006;43:1276-1283
Gómez FP, Barberà JA, Roca J, Burgos F, Gistau C, Rodríguez-Roisin R. Effects of nebulized N^G-nitro-L-arginine methyl ester in patients with hepatopulmonary syndrome. 2006; 43:1084-1091
Gong P and Cederbaum AI. Nrf2 is increased by CYP2E1 in rodent liver and HepG2 cells and protects against oxidative stress caused by CYP2E1. 2006;43:144-153
Gonzalez FJ. Role of β-catenin in the adult liver. 2006;43:650-653 (Editorial)
Gorczynski R (*see* Levy GA et al). 2006;43: 581-591
Gores GJ (*see* Anan A et al). 2006;43:335-344
— (*see* Kim WR et al). 2006;43:345-351
— (*see* Malhi H et al). 2006;43:S31-S44
Gotteland M (*see* Reyes H et al). 2006;43: 715-722
Grace M (*see* Talal AH et al). 2006;43:943-953
Graf R (*see* Hoekstra H et al). 2006;43: 1022-1031
Grando D (*see* Kuiken C et al). 2006;43: 1157-1165 (Special Article)
Greeve I (*see* Bonvin M et al). 2006;43: 1364-1374
Greeve J (*see* Bonvin M et al). 2006;43: 1364-1374
Gregor M (*see* Pathil A et al). 2006;43:425-434
Gressner AM (*see* Wiercinska E et al). 2006;43:1032-1041
Gretch DR. (*see* Morishima C et al). 2006; 43:573-580
Gripon P (*see* Engelke M et al). 2006;43: 750-760
Grisham JW (*see* Thorgeirsson SS and Grisham JW). 2006;43:2-8 (Science Frontier)
— (*see* Thorgeirsson SS et al). 2006;43: S145-S150
Groszmann RJ (*see* Iwakiri Y and Groszmann RJ). 2006;43:S121-S131
Gruppuso PA (*see* Embree-Ku M and Gruppuso PA). 2006;43:376-377 (Reply)
Guerra B (*see* Lanford RE et al). 2006;43: 961-972
Guettier C (*see* Zucman-Rossi J et al). 2006;43:515-524
Guido M (*see* Bortolotti F et al). 2006;43: 556-562
Gunawan B (*see* Liu ZX et al). 2006;43: 1220-1230
Günther S and Hass M. What is really ongoing during occult HBV reactivation? 2006;43:195-196 (Reply)
Gupta N (*see* Ding X et al). 2006;43:173-181
Gupta RK (*see* Kale RA et al). 2006;43: 698-706
Gustot T, Lemmers A, Moreno C, Nagy N, Quertinmont E, Nicaise C, Franchimont D, Louis H, Devière J, Le Moine O. Differential liver sensitization to Toll-like receptor pathways in mice with alcoholic fatty liver. 2006;43:989-1000
Gutiérrez A (*see* Jover R et al). 2006;43: 1257-1266
Guy CS, Wang J, Michalak TI. Hepatocytes as cytotoxic effector cells can induce cell death by CD95 ligand-mediated pathway. 2006;43: 1231-1240

H

Hadzic N, Quaglia A, Mieli-Vergani G. Hepatocellular carcinoma in a 12-year-old child with PiZZ α1-antitrypsin deficiency. 2006;43:194 (Correspondence)
Hadziyannis SJ (*see* Jensen DM et al). 2006;43:954-960, 1410 (Correction)
Hagey L (*see* Mennone A et al). 2006;43: 1013-1021
Hailfinger S, Jaworski M, Braeuning A, Buchmann A, Schwarz M. Zonal gene expression in murine liver: Lessons from tumors. 2006;43:407-414
Hall P (*see* Yu J et al). 2006;43:826-836
Halsted C (*see* Zhan SS et al). 2006;43: 435-443
Hamzavi J (*see* Wiercinska E et al). 2006; 43:1032-1041
Han D (*see* Liu ZX et al). 2006;43:1220-1230
Han JY (*see* Jang JW et al). 2006;43:233-240
— (*see* Lee HS et al). 2006;43:982-988
Hanschen M (*see* Khandoga A et al). 2006; 43:306-315
Harrison SA. Correlation between insulin resistance and hepatitis C viral load. 2006;43:1168 (Correspondence)
— (*see* Charlton MR et al). 2006;43:1177-1186 (Perspectives in Clinical Hepatology)
Harry K (*see* Mennone A et al). 2006;43: 1013-1021
Hasan KM (*see* Kale RA et al). 2006;43: 698-706
Hashash A (*see* Kneteman NM et al). 2006; 43:1346-1353
Hashimoto N (*see* Iwasaki Y et al). 2006; 43:54-63
Hass M (*see* Günther S and Hass M). 2006; 43:195-196 (Reply)
Häussinger D. Low grade cerebral edema and the pathogenesis of hepatic encephalopathy in cirrhosis. 2006;43: 1187-1190 (Editorial)
He Q (*see* Kamal SM et al). 2006;43:771-779
He W (*see* Levy GA et al). 2006;43:581-591
Hebrok M (*see* Sekine S et al). 2006;43: 817-825
Heim MH (*see* Duong FHT et al). 2006; 43:796-806
Heller T (*see* Perumalswami P et al). 2006; 43:780-787
Hernández I (*see* Reyes H et al). 2006;43: 715-722
Hernández-Guerra M, García-Pagán JC, Turnes J, Bellot P, Deulofeu R, Abraldes JG, Bosch J. Ascorbic acid improves the intrahepatic endothelial dysfunction of patients with cirrhosis and portal hypertension. 2006;43: 485-491

—, López E, Bellot P, Piera C, Turnes J, Abraldes JG, Bosch J, García-Pagán JC. Systemic hemodynamics, vasoactive systems, and plasma volume in patients with severe Budd-Chiari syndrome. 2006;43:27-33
— (*see* Turnes J et al). 2006;43:34-41
Herrmann U (*see* Wasmuth HE et al). 2006;43:738-741 (Concise Communication)
Heuman D (*see* Sanyal AJ et al). 2006;43:682-689
Hewavitharana AK (*see* Lee S et al). 2006;43:1241-1247
Hickling TP (*see* Tarr AW et al). 2006;43:592-601
Hitchman E (*see* Wesierska-Gadek J et al). 2006;43:1135-1144
Hixson DC (*see* Erickson BM et al). 2006;43:325-334
Ho YP (*see* Tsai MH et al). 2006;43:673-681
Hoekstra H, Porte RJ, Tian Y, Jochum W, Stieger B, Moritz W, Slooff MJH, Graf R, Clavien PA. Bile salt toxicity aggravataes cold ischemic injury of bile ducts after liver transplantation in Mdr2+/— mice. 2006;43:1022-1031
Hoffman RS (*see* Holubek WJ et al). 2006;43:881 (Correspondence)
Hofmann AF and Huet PM. Nasobiliary drainage for cholestatic pruritus. 2006;43:1170-1171 (Correspondence)
Holt AP, Stamataki Z, Adams DH. Attenuated liver fibrosis in the absence of B cells. 2006;43:868-871 (Hepatology *Elsewhere*)
Holubek WJ, Kalman S, Hoffman RS. Acetaminophen-induced acute liver failure: Results of a United States multicenter prospective study. 2006;43:881 (Correspondence)
Hoofnagle JH and Miller ME. Progress on the action plan for liver disease research. 2006;43:890 (News from the NIH)
— and Sokol RJ. Neonatal screening for biliary atresia. 2006;43:646 (This Month from the NIH)
— (*see* Perumalswami P et al). 2006;43:780-787
Hösel M (*see* Untergasser A et al). 2006;43:539-547
Hou JY (*see* Yu J et al). 2006;43:826–836
Hou MC (*see* Tan PC et al). 2006;43:690-697, 1410 (Correction)
Housset C (*see* Demeilliers C et al). 2006;43:1125-1134
Houwen RHJ (*see* Stapelbroek JM et al). 2006;43:51-53 (Concise Communication)
Hsi B (*see* Kneteman NM et al). 2006;43:1346-1353
Hsiao TJ (*see* Liu CJ et al). 2006;43:742-749
Hsieh MS (*see* Lai MS et al). 2006;43:1295-1302
Hsieh TY (*see* Liu CJ et al). 2006;43:742-749
Hu JT (*see* Liu CJ et al). 2006;43:742-749
Huang Y, Chen XC, Konduri M, Fomina N, Lu J, Jin L, Kolykhalov A, Tan SL. Mechanistic link between the anti-HCV effect of interferon gamma and control of viral replication by a Ras-MAPK signaling cascade. 2006;43:81-90
Hübscher S (*see* Evans HM et al). 2006;43:1109-1117
Huet PM (*see* Hofmann AF and Huet PM). 2006;43:1170-1171 (Correspondence)
Hughes DE (*see* Yoshida Y et al). 2006;43:276-286
Hultcrantz R (*see* Stokkeland K et al). 2006;43:500-505
Huo TI, Lee SD, Wu JC. Hepatitis after arterial embolization for hepatocellular carcinoma: Viral reactivation or ischemia? 2006;43:1400-1401 (Correspondence)
Hussain M (*see* Talal AH et al). 2006;43:943-953

I

Ikeda A (*see* Kaizu T et al). 2006;43:464-473
Ikeda H (*see* Iwasaki Y et al). 2006;43:54-63
Ikura Y, Ohsawa M, Suekane T, Fukushima H, Itabe H, Jomura H, Nishiguchi S, Inoue T, Naruko T, Ehara S, Kawada N, Arakawa T, Ueda M. Localization of oxidized phosphatidylcholine in nonalcoholic fatty liver disease: Impact on disease progression. 2006;43:506-514
Im DS (*see* Jung CR et al). 2006;43:1042-1052
Inderbitzin D (*see* Bonvin M et al). 2006;43:1364-1374
Inoue S (*see* Fujii T et al). 2006;43:1267-1275
Inoue T (*see* Ikura Y et al). 2006;43:506-514
Insausti R (*see* Jover R et al). 2006;43:1257-1266
Invernizzi P (*see* Wesierska-Gadek J et al). 2006;43:1135-1144
Ioannou GN, Weiss NS, Boyko EJ, Mozaffarian D, Lee SP. Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. 2006;43:1145-1151
Ip E (*see* Yu J et al). 2006;43:826-836
Ip WK (*see* Chong WP et al). 2006;43:199 (Correction)
Ippolito S (*see* Mani AR et al). 2006;43:847-856
Ishiyama K, Ohdan H, Ohira M, Mitsuta H, Arihiro K, Asahara T. Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans. 2006;43:362-372
Itabe H (*see* Ikura Y et al). 2006;43:506-514
Iwakiri Y and Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: From the patient to the molecule. 2006;43:S121-S131
Iwasaki Y, Ikeda H, Araki Y, Osawa T, Kita K, Ando M, Shimoe T, Takaguchi K, Hashimoto N, Kobatake T, Tomita M, Kawaguchi M, Kobashi H, Sakaguchi K, Shiratori Y. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. 2006;43:54–63
Iyer K (*see* Buchman AL et al). 2006;43:9-19 (Perspectives in Clinical Hepatology)

J

Jacob M (*see* Natarajan SK et al). 2006;43:1248-1257
Jacquemin E (*see* Demeilliers C et al). 2006;43:1125-1134
Jaeckel E (*see* Wiegand J et al). 2006;43:250-256
Jaeschke H. How relevant are neutrophils for acetaminophen hepatotoxicity? 2006;43:1191-1194 (Editorial)
Jahan A (*see* Li T et al). 2006;43:1202-1210
Jang JW, Choi JY, Bae SH, Yoon SK, Chang UI, Kim CW, Cho SH, Han JY, Lee YS. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemolipiodolization. 2006;43:233-240
Jang YJ (*see* Jung CR et al). 2006;43:1042-1052
Jaworski M (*see* Hailfinger S et al). 2006;43:407-414
Jeannot E (*see* Zucman-Rossi J et al). 2006;43:515-524
Jefferson J (*see* Mazzone A et al). 2006;43:287-296
Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, Ferenci P, Ackrill AM, Willems B. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40kd)/ribavirin therapy. 2006;43:954-960, 1410 (Correction)
—. Outcomes, effectiveness, tolerability, and direct costs of prophylactic variceal treatments. 2006;43:197-198 (Correspondence)
Jiang JX (*see* Zhan SS et al). 2006;43:435-443
Jin L (*see* Huang Y et al). 2006;43:81-90

Jin X, Zimmers TA, Perez EA, Pierce RH, Zhang Z, Koniaris LG. Paradoxical effects of short- and long-term interleukin-6 exposure on liver injury and repair. 2006;43:474-484
Jirón MI (*see* Reyes H et al). 2006;43:715-722
Jo EC (*see* Lee K et al). 2006;43:1063-1073
Jochum W (*see* Hoekstra H et al). 2006;43:1022-1031
Johnson PJ (*see* Yeo W and Johnson PJ). 2006;43:209-220 (Concise Review in Mechanisms of Disease)
Jomura H (*see* Ikura Y et al). 2006;43:506-514
Jonas MM (*see* Sokal EM et al). 2006;43:225-232
Jones DEJ, Bhala N, Newton JL. Reflections on therapeutic trials in primary biliary cirrhosis: A quality of life oriented counter-view. 2006;43:633 (Correspondence)
Joplin RE (*see* Fabris L et al). 2006;43:1001-1012
Jover R, Rodrigo R, Felipo V, Insausti R, Sáez-Valero J, García-Ayllón MS, Suárez I, Candela A, Compañ A, Esteban A, Cauli O, Ausó E, Rodríguez E, Gutiérrez A, Girona E, Erceg S, Berbel P, Pérez-Mateo M. Brain edema and inflammatory activation in bile duct ligated rats with diet-induced hyperammonemia: A model of hepatic encephalopathy in cirrhosis. 2006;43:1257-1266
— (*see* García-Ayllón MS et al). 2006;43:444-453
Jung CR, Yoo J, Jang YJ, Kim S, Chu IS, Yeom YI, Choi JY, Im DS. Adenovirus-mediated transfer of siRNA against PTTG1 inhibits liver cancer cell growth *in vitro* and *in vivo*. 2006;43:1042–1052
Jung SW (*see* Lee YS et al). 2006;43:1385-1391

K

Kaiser S (*see* Toan NG et al). 2006;43:1375-1384
Kaizu T, Ikeda A, Nakao A, Takahashi Y, Tsung A, Kohmoto J, Toyokawa H, Shao L, Bucher BT, Tomiyama K, Nalesnik MA, Murase N, Geller DA. Donor graft adenoviral iNOS gene transfer ameliorates rat liver transplant preservation injury and improves survival. 2006;43:464-473
Kale RA, Gupta RK, Saraswat VA, Hasan KM, Trivedi R, Mishra AM, Ranjan P, Pandey CM, Narayana PA. Demonstration of interstitial cerebral edema with diffusion tensor MR imaging in type C hepatic encephalopathy. 2006;43:698-706
Kallinowski B (*see* Wiegand J et al). 2006;43:250-256
Kalman S (*see* Holubek WJ et al). 2006;43:881 (Correspondence)
Kamal SM, Naggar KE, Chen J, Fehr J, Moneim AA, Khalifa KE, El Gohary LA, Ramy AH, Madwar MA, Rasenack J, Afdhal NH. Duration of peginterferon therapy in acute hepatitis C: A randomized trial. 2006;43:923-931 (Rapid Communication)
—, Turner B, He Q, Rasenack J, Bianchi L, Al Tawil A, Nooman A, Massoud M, Koziel MJ, Afdhal NH. Progression of fibrosis in hepatitis C with and without schistosomiasis: Correlation with serum markers of fibrosis. 2006;43:771-779
Kamoun WS, Karaa A, Kresge N, Merkel SM, Korneszczuk K, Clemens MG. LPS inhibits endothelin-1–induced endothelial NOS activation in hepatic sinusoidal cells through a negative feedback involving caveolin-1. 2006;43:182-190
Kandolf R (*see* Toan NG et al). 2006;43:1375-1384
Kaneko S (*see* Mizukoshi E et al). 2006;43:1284-1294
Kang G (*see* Natarajan SK et al). 2006;43:837-846
Kao JH and Chen DS. Local ablation vs. resection for the treatment of hepatocellular carcinoma. 2006;43:373 (Correspondence)
— (*see* Liu CJ et al). 2006;43:742-749
Kaplan M (Bonis PA and Kaplan M). 2006;43:632 (Correspondence)
Kaplowitz N. Hepatology Highlights. 2006;43:207-208, 887-889
—. Liver biology and pathobiology. 2006;43:S235-S238 (Highlights of the Highlights)
— (*see* Liu ZX et al). 2006;43:1220-1230
Karaa A (*see* Kamoun WS et al). 2006;43:182-190
Katlama C (*see* Benhamou Y et al). 2006;43:548-555
Kauffmann W (*see* Wiegand J et al). 2006;43:250-256
Kaul A (*see* Paeshuyse J et al). 2006;43:761-770
Kawabe T (*see* Teratani T et al). 2006;43:1101-1108
Kawada N (*see* Ikura Y et al). 2006;43:506-514
Kawaguchi M (*see* Iwasaki Y et al). 2006;43:54-63
Kay A (*see* Chemin I et al). 2006;43:195 (Correspondence)
Keiding S, Sørensen M, Bender D, Munk OL, Ott P, Vilstrup H. Brain metabolism of ^{13}N-ammonia during acute hepatic encephalopathy in cirrhosis measured by positron emission tomography. 2006;43:42-50
Kelleher D (*see* Neumann-Haefelin C et al). 2006;43:563-572
Kelly DA (*see* Evans HM et al). 2006;43:1109-1117
— (*see* Sokal EM et al). 2006;43:225-232
Kennedy PTF, Urbani S, Moses RA, Amadei B, Fisicaro P, Lloyd J, Maini MK, Dusheiko G, Ferrari C, Bertoletti A. The influence of T cell cross-reactivity on HCV-peptide specific human T cell response. 2006;43:602-611
Keogh A (*see* Bonvin M et al). 2006;43:1364-1374
Keppeler H (*see* Wasmuth HE et al). 2006;43:738-741 (Concise Communication)
Kerfoot S, D'Mell C, Nguyen H, Ajuebor M, Kubes P, Le T, Swain MG. Systemic effects of TNF-α secreted by circulating monocytes and fatigue in cirrhosis. 2006;43:1399 (Reply)
Kerfoot SM, D'Mello C, Nguyen H, Ajuebor MN, Kubes P, Le T, Swain MG. TNF-α–secreting monocytes are recruited into the brain of cholestatic mice. 2006;43:154-162
Kern WV (*see* Fang X et al). 2006;43:1326-1336
Kessler JS (*see* Khandoga A et al). 2006;43:306-315
Keulemans YCA (*see* Venneman NG et al). 2006;43:1276-1283
Kew M (*see* Lian Z et al). 2006;43:415-424
Khalifa KE (*see* Kamal SM et al). 2006;43:923-931 (Rapid Communication)
Khandoga A, Hanschen M, Kessler JS, Krombach F. CD4$^+$ T cells contribute to postischemic liver injury in mice by interacting with sinusoidal endothelium and platelets. 2006;43:306-315
Killinger T (*see* Neumann-Haefelin C et al). 2006;43:563-572
Kim CW (*see* Jang JW et al). 2006;43:233-240
Kim IM (*see* Yoshida Y et al). 2006;43:276-286
Kim KM (*see* Lee YS et al). 2006;43:1385-1391
Kim S (*see* Jung CR et al). 2006;43:1042-1052
Kim SO (*see* Lee YS et al). 2006;43:1385-1391
Kim WR, Therneau TM, Benson JT, Kremers WK, Rosen CB, Gores GJ, Dickson ER. Deaths on the liver transplantation waiting list: An analysis of competing risks. 2006;43:345-351
Kim YG (*see* Lee K et al). 2006;43:1063-1073
Kirk GD (*see* Wilson LE et al). 2006;43:788-795
Kirsch R (*see* Yu J et al). 2006;43:826-836
Kita K (*see* Iwasaki Y et al). 2006;43:54-63

Kiyosawa K (*see* Umemura T et al). 2006; 43:91-99
Klein A, Amigo L, Retamal MJ, Morales MG, Miquel JF, Rigotti A, Zanlungo S. NPC2 is expressed in human and murine liver and secreted into bile: Potential implications for body cholesterol homeostasis. 2006;43:126-133
Kleiner DE (*see* Perumalswami P et al). 2006;43:780-787
Klenerman P (*see* Neumann-Haefelin C et al). 2006;43:563-572
Kline J (*see* Kneteman NM et al). 2006;43: 1346-1353
Klomp LWJ (*see* Stapelbroek JM et al). 2006;43:51-53 (Concise Communication)
Klotz L (*see* Dombrowski F et al). 2006;43: 857-867
Kneteman NM, Weiner AJ, O'Connell J, Collett M, Gao T, Aukerman L, Kovelsky R, Ni ZJ, Hashash A, Kline J, Hsi B, Schiller D, Douglas D, Tyrrell DLJ, Mercer DF. Anti-HCV therapies in chimeric *scid*-Alb/uPA mice parallel outcomes in human clinical application. 2006;43:1346-1353
Knight B (*see* Lim R et al). 2006;43:1074-1083
Knisely AS , (*see* Stapelbroek JM et al). 2006;43:51-53 (Concise Communication)
Kobashi H (*see* Iwasaki Y et al). 2006;43: 54-63
Kobatake T (*see* Iwasaki Y et al). 2006;43: 54-63
Koeberlein B (*see* Toan NG et al). 2006;43: 1375-1384
Kofman AV (*see* Quintana-Bustamante O et al). 2006;43:108-116
Kohmoto J (*see* Kaizu T et al). 2006;43: 464-473
Kolanus W (*see* Untergasser A et al). 2006; 43:539-547
Kolykhalov A (*see* Huang Y et al). 2006;43: 81-90
Kondo Y (*see* Teratani T et al). 2006;43: 1101-1108
Konduri M (*see* Huang Y et al). 2006;43: 81-90
Koniaris LG (*see* Jin X et al). 2006;43:474-484
Korneszczuk K (*see* Kamoun WS et al). 2006;43:182-190
Koscik C (*see* Levy GA et al). 2006;43:581-591
Koshikawa K (*see* Fujii T et al). 2006;43: 1267-1275
Kovelsky R (*see* Kneteman NM et al). 2006;43:1346-1353
Koziel MJ. NK cells: Natural born killers in the conflict between humans and HCV. 2006;43:395-397 (Editorial)
— (*see* Kamal SM et al). 2006;43:771-779
Koziol J (*see* Patel K et al). 2006;43:241-249
Kremers WK (*see* Kim WR et al). 2006;43: 345-351
Kremsner PG (*see* Toan NG et al). 2006; 43:1375-1384
Kresge N (*see* Kamoun WS et al). 2006;43: 182-190
Kreutz C (*see* Fang X et al). 2006;43:1326-1336
Krombach F (*see* Khandoga A et al). 2006; 43:306-315
Kubes P (*see* Kerfoot S et al). 2006;43:1399 (Reply)
— (*see* Kerfoot SM et al). 2006;43:154-162
Kubota S (*see* Nagaya M et al). 2006;43: 1053-1062
Kuiken C, Mizokami M, Deleage G, Yusim K, Penin F, Shin-I T, Charavay C, Tao N, Crisan D, Grando D, Dalwani A, Geourjon C, Agrawal A, Combet C. Hepatitis C databases, principles and utility to researchers. 2006;43:1157-1165 (Special Article)
Kuzushima K (*see* Mizukoshi E et al). 2006;43:1284-1294

L

Lackner C, Struber G, Bankuti C, Bauer B, Stauber RE. Noninvasive diagnosis of cirrhosis in chronic hepatitis C based on standard laboratory tests. 2006;43: 378-379 (Correspondence)
Lai CL (*see* Chong WP et al). 2006;43:199 (Correction)
Lai MS, Hsieh MS, Chiu YH, Chen THH. Type 2 diabetes and hepatocellular carcinoma: A cohort study in high prevalence area of hepatitis virus infection. 2006;43:1295-1302
Lai MY (*see* Liu CJ et al). 2006;43:742-749
Lainé F, Bendavid C, Morcet J, Perrin M, Massart C, Deugnier Y. Reassessment of the algorithm for prediction of liver fibrosis in patients with features of the metabolic syndrome. 2006;43:377-378 (Correspondence)
Lakkis FG (*see* Starzl TE and Lakkis FG). 2006;43:S151-S163
Lammert F (*see* Wasmuth HE et al). 2006; 43:738–741 (Concise Communication)
Lan BYA (*see* Sekine S et al). 2006;43:817–825
Lan RY, Cheng C, Lian ZX, Tsuneyama K, Yang GX, Moritoki Y, Chuang YH, Nakamura T, Saito S, Shimoda S, Tanaka A, Bowlus CL, Takano Y, Ansari AA, Coppel RL, Gershwin ME. Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis. 2006;43: 729-737
Lanford RE, Guerra B, Lee H, Chavez D, Braksy KM, Bigger CB. Genomic response to interferon-α in chimpanzees: Implications of rapid downregulation for hepatitis C kinetics. 2006;43:961–972
Langenkamp A (*see* Untergasser A et al). 2006;43:539-547
Larson AM, Fontana RJ, Davern TJ, Lee WM. King's criteria, APACHE II, and SOFA scores in acute liver failure. 2006;43:882 (Reply)
Larter CZ (*see* Farrell GC and Larter CZ). 2006;43:S99-S112
LaRusso N (*see* Masyuk T and LaRusso N). 2006;43:906-908 (Editorial)
LaRusso NF (*see* Masyuk AI and LaRusso NF). 2006;43:S75-S81
— (*see* Mazzone A et al). 2006;43:287-296
Lau YL (*see* Chong WP et al). 2006;43:199 (Correction)
Lauer UM (*see* Pathil A et al). 2006;43: 425-434
Lauletta G (*see* Sansonno D et al). 2006;43: 1167-1168 (Reply)
Laurent C (*see* Zucman-Rossi J et al). 2006; 43:515-524
Laurent-Puig P (*see* Zucman-Rossi J et al). 2006;43:515-524
Lazaridis KN (*see* Talwalkar JA and Lazaridis KN). 2006;43:398-400 (Editorial)
Lazzeroni LC (*see* Strnad P et al). 2006;43: 1354-1363
Le Moine O (*see* Gustot T et al). 2006;43: 989-1000
Le T (*see* Kerfoot S et al). 2006;43:1399 (Reply)
— (*see* Kerfoot SM et al). 2006;43:154-162
Le Teuff G (*see* Benhamou Y et al). 2006; 43:548-555
Leandro G (*see* Cholongitas EB et al). 2006;43:881 (Correspondence)
Lebeck L (*see* Patel K et al). 2006;43:241-249
Lebrec D (*see* Moreau R and Lebrec D). 2006;43:385-394 (Perspectives in Clinical Hepatology)
Leclercq I (*see* Yu J et al). 2006;43:826-836
Lee FY (*see* Tan PC et al). 2006;43:690-697, 1410 (Correction)
Lee H (*see* Lanford RE et al). 2006;43:961-972
Lee HC (*see* Lee YS et al). 2006;43:1385-1391
Lee HS, Chung YH, Lee KS, Byun KS, Paik SW, Han JY, Yoo K, Yoo HW, Lee JH, Yoo BC. A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B. 2006;43:982-988
Lee JH (*see* Lee HS et al). 2006;43:982-988
Lee JS (*see* Thorgeirsson SS et al). 2006;43: S145-S150
Lee K, Yun ST, Kim YG, Yoon Y, Jo EC. Adeno-associated virus-mediated expression of apolipoprotein (a) kringles suppresses hepatocellular

carcinoma growth in mice. 2006;43:1063-1073
Lee KS (*see* Lee HS et al). 2006;43:982-988
Lee S, Dawson PA, Hewavitharana AK, Shaw PN, Markovich D. Disruption of NaS1 sulfate transport function in mice leads to enhanced acetaminophen-induced hepatotoxicity. 2006;43:1241-1247
Lee SD (*see* Huo TI et al). 2006;43:1400-1401 (Correspondence)
— (*see* Tan PC et al). 2006;43:690-697, 1410 (Correction)
Lee SP (*see* Ioannou GN et al). 2006;43:1145-1151
Lee WM (*see* Larson AM et al). 2006;43:882 (Reply)
Lee YS, Suh DJ, Lim YS, Jung SW, Kim KM, Lee HC, Chung YH, Lee YS, Yoo W, Kim SO. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. 2006;43:1385-1391
— (*see* Jang JW et al). 2006;43:233-240
— (*see* Lee YS et al). 2006;43:1385-1391
Lefkowitch JH (*see* Schattenberg JM et al). 2006;43:163-172
Lehner F (*see* Volkmann X et al). 2006;43:1311-1316
Lehnert H (*see* Dombrowski F et al). 2006;43:857-867
Lemasters JJ (*see* Malhi H et al). 2006;43:S31-S44
Lemmers A (*see* Gustot T et al). 2006;43:989-1000
— (*see* Martin A and Lemon SM). 2006;43:S164-S172
Leteurtre E (*see* Zucman-Rossi J et al). 2006;43:515-524
Levy A (*see* Levy GA et al). 2006;43:581-591
Levy GA, Adamson G, Phillips MJ, Scrocchi LA, Fung L, Biessels P, Ng NF, Ghanekar A, Rowe A, Ma MX, Levy A, Koscik C, He W, Gorczynski R, Brookes S, Woods C, McGilvray ID, Bell D. Targeted delivery of ribavirin improves outcome of murine viral fulminant hepatitis via enhanced anti-viral activity. 2006;43:581-591
Li B, Sun R, Wei H, Gao B, Tian Z. Interleukin-15 prevents concanavalin A-induced liver injury in mice via NKT cell-dependent mechanism. 2006;43:1211-1219
Li L (*see* Lian Z et al). 2006;43:415-424
Li M (*see* Callender GG et al). 2006;43:973-981
Li T, Jahan A, Chiang JYL. Bile acids and cytokines inhibit the human cholesterol 7α-hydroxylase gene via the JNK/c-Jun pathway in human liver cells. 2006;43:1202-1210
Li X (*see* Lian Z et al). 2006;43:415-424
Lian Z, Liu J, Li L, Li X, Clayton M, Wu MC, Wang HY, Arbuthnot P, Kew M, Fan D, Feitelson MA. Enhanced cell survival of Hep3B cells by the hepatitis B x antigen effector, URG11, is associated with upregulation of β-catenin. 2006;43:415-424
Lian ZX (*see* Lan RY et al). 2006;43:729-737
Liang TJ (*see* Feld JJ and Liang TJ). 2006;43:S194-S206
— (*see* Perumalswami P et al). 2006;43:780-787
Liao LY (*see* Liu CJ et al). 2006;43:742-749
Libra M (*see* Sansonno D et al). 2006;43:1167-1168 (Reply)
Licata A (*see* Craxì A and Licata A). 2006;43:221-224 (Editorial)
Lien JM (*see* Tsai MH et al). 2006;43:673-681
Lienau TC (*see* Strnad P et al). 2006;43:1354-1363
Lim A (*see* Cobbold JFL et al). 2006;43:1401-1402 (Correspondence)
Lim R, Knight B, Patel K, McHutchison JG, Yeoh GC, Olynyk JK. Antiproliferative effects of interferon alpha on hepatic progenitor cells *in vitro* and *in vivo*. 2006;43:1074-1083
Lim YS (*see* Lee YS et al). 2006;43:1385-1391
Lin CL (*see* Liu CJ et al). 2006;43:742-749
Lin HC (*see* Tan PC et al). 2006;43:690-697, 1410 (Correction)
Lin S (*see* Ding X et al). 2006;43:173-181
Lin W (*see* Yu J et al). 2006;43:134-143
Lindenbach BD (*see* von Hahn T et al). 2006;43:932-942
Lissen E (*see* Sterling RK et al). 2006;43:1317-1325
Little NR (*see* Sokal EM et al). 2006;43:225-232
Liu CJ, Lai MY, Chao YC, Liao LY, Yang SS, Hsiao TJ, Hsieh TY, Lin CL, Hu JT, Chen CL, Chen PJ, Kao JH, Chen DS. Interferon α-2b with and without ribavirin in the treatment of hepatitis B e antigen–positive chronic hepatitis B: A randomized study. 2006;43:742-749
Liu J (*see* Lian Z et al). 2006;43:415-424
Liu NJ (*see* Tsai MH et al). 2006;43:673-681
Liu TT (*see* Tan PC et al). 2006;43:690-697, 1410 (Correction)
Liu ZX, Han D, Gunawan B, Kaplowitz N. Neutrophil depletion protects against murine acetaminophen hepatotoxicity. 2006;43:1220-1230
Lloyd J (*see* Kennedy PTF et al). 2006;43:602-611
Lok ASF. Noninvasive diagnosis of cirrhosis in chronic hepatitis C based on standard laboratory tests. 2006;43:379 (Reply)
— (*see* Yim HJ and Lok ASF). 2006;43:S173-S181
Lomri NE (*see* Demeilliers C et al). 2006;43:1125-1134
López E (*see* Hernández-Guerra M et al). 2006;43:27-33
Louis H (*see* Gustot T et al). 2006;43:989-1000
— (*see* Moreno C et al). 2006;43:879-880 (Reply)
Lu J (*see* Huang Y et al). 2006;43:81-90
Luketic VA (*see* Sanyal AJ et al). 2006;43:682-689
Lutchman G (*see* Perumalswami P et al). 2006;43:780-787
Lyons GE (*see* Callender GG et al). 2006;43:973-981

M

Ma MX (*see* Levy GA et al). 2006;43:581-591
Madwar MA (*see* Kamal SM et al). 2006;43:923-931 (Rapid Communication)
Maina AM (*see* Raimondo G et al). 2006;43:100-107
Maini MK (*see* Kennedy PTF et al). 2006;43:602-611
Maiwald T (*see* Fang X et al). 2006;43:1326-1336
Malfertheiner P (*see* Yu J et al). 2006;43:134-143
Malhi H, Gores GJ, Lemasters JJ. Apoptosis and necrosis in the liver: A tale of two deaths? 2006;43:S31-S44
Mandac JC, Chaudhry S, Sherman KE, Tomer Y. The clinical and physiological spectrum of interferon-alpha induced thyroiditis: Toward a new classification. 2006;43:661-672 (Perspectives in Clinical Hepatology)
Mani AR, Ippolito S, Ollosson R, Moore KP. Nitration of cardiac proteins is associated with abnormal cardiac chronotropic responses in rats with biliary cirrhosis. 2006;43:847-856
Manini M (*see* Sangiovanni A et al). 2006;43:1303-1310
Mannherz HG (*see* Napirei M et al). 2006;43:297-305
Manns MP and Vogel A. Autoimmune hepatitis, from mechanisms to therapy. 2006;43:S132–S144
— (*see* Volkmann X et al). 2006;43:1311-1316
— (*see* Wiegand J et al). 2006;43:250-256
Manolakopoulos S (*see* Triantos C et al). 2006;43:196-197 (Correspondence)
Marcellin P (*see* Corpechot C et al). 2006;43:1118-1124
— (*see* Jensen DM et al). 2006;43:954-960, 1410 (Correction)
— (*see* Saadoun D et al). 2006;43:1337-1345
Marchesini G (*see* Bugianesi E and Marchesini G). 2006;43:1168-1169 (Reply)

Margeridon S (*see* Chemin I et al). 2006; 43:195 (Correspondence)
Margiotta M (*see* Castellaneta A et al). 2006;43:807-816
Markatou M (*see* Talal AH et al). 2006;43: 943-953
Markovich D (*see* Lee S et al). 2006;43: 1241-1247
Martin A and Lemon SM. Hepatitis A virus: From discovery to vaccines. 2006;43:S164-S172
Martínez S (*see* García-Ayllón MS et al). 2006;43:444-453
Martínez-Bauer E, Crespo J, Romero-Gómez M, Moreno-Otero R, Solá R, Tesei N, Pons F, Forns X, Sánchez-Tapias JM. Development and validation of two models for early prediction of response to therapy in genotype 1 chronic hepatitis C. 2006; 43:72-80
Marukawa Y (*see* Mizukoshi E et al). 2006; 43:1284-1294
Mascagni P (*see* Pathil A et al). 2006;43: 425-434
Massart C (*see* Lainé F et al). 2006;43:377-378 (Correspondence)
Massoud M (*see* Kamal SM et al). 2006;43: 771-779
Masyuk AI and LaRusso NF. Aquaporins in the hepatobiliary system. 2006;43: S75-S81
Masyuk T and LaRusso N. Polycystic liver disease: New insights into disease pathogenesis. 2006;43:906-908 (Editorial)
Mauss S and Puoti M. CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice — Clinical implications for CCR5 inhibition as antiretroviral therapy. 2006;43:879 (Correspondence)
Mazzone A, Tietz P, Jefferson J, Pagano R, LaRusso NF. Isolation and characterization of lipid microdomains from apical and basolateral plasma membranes of rat hepatocytes. 2006;43:287-296
McClure CP (*see* Tarr AW et al). 2006;43: 592-601
McGilvray ID (*see* Levy GA et al). 2006; 43:581-591
McHutchison JG (*see* Lim R et al). 2006; 43:1074-1083
—(*see* Patel K et al). 2006;43:241-249
McKeating JA (*see* von Hahn T et al). 2006;43:932-942
McKee MD (*see* Callender GG et al). 2006;43:973-981
McKiernan PJ (*see* Evans HM et al). 2006; 43:1109-1117
McKiernan S (*see* Neumann-Haefelin C et al). 2006;43:563-572
Medina JF (*see* Banales JM et al). 2006;43: 266-275
Mehta S (*see* Wilson LE et al). 2006;43: 788-795
Melero S (*see* Fabris L et al). 2006;43: 1001-1012
Mellottee L (*see* Zucman-Rossi J et al). 2006;43:515-524
Mennone A, Soroka CJ, Cai SY, Harry K, Adachi M, Hagey L, Schuetz JD, Boyer JL. Mrp4-/- mice have an impaired cytoprotective response in obstructive cholestasis. 2006;43:1013-1021
Menthena A (*see* Shafritz DA et al). 2006; 43:S89-S98
Mercer DF (*see* Kneteman NM et al). 2006;43:1346-1353
Mergey M (*see* Demeilliers C et al). 2006; 43:1125-1134
Merkel SM (*see* Kamoun WS et al). 2006; 43:182-190
Mertens PR (*see* Wiercinska E et al). 2006; 43:1032-1041
Messinger D (*see* Sterling RK et al). 2006; 43:1317-1325
Michalak S (*see* Zucman-Rossi J et al). 2006;43:515-524
Michalak TI (*see* Guy CS et al). 2006;43: 1231-1240
Mieli-Vergani G (*see* Hadzic N et al). 2006;43:194 (Correspondence)
Miller ME (*see* Hoofnagle JH and Miller ME). 2006;43:890 (News from the NIH)
Mills AS (*see* Sanyal AJ et al). 2006;43:682-689
Mills K (*see* Engelke M et al). 2006;43: 750-760
Mine N (*see* Teratani T et al). 2006;43: 1101-1108
Mínguez B, García-Pagán JC, Bosch J, Turnes J, Alonso J, Rovira A, Córdoba J. Noncirrhotic portal vein thrombosis exhibits neuropsychological and MR changes consistent with minimal hepatic encephalopathy. 2006;43:707-714
Minola E (*see* Cammà C et al). 2006;43: 64-71
Miquel JF (*see* Arrese M et al). 2006;43: 191-193 (Hepatology *Elsewhere*)
— (*see* Klein A et al). 2006;43:126-133
Miquel R (*see* Blasco A et al). 2006;43:492-499
Mishra AM (*see* Kale RA et al). 2006;43: 698-706
Mitaka T (*see* Nagaya M et al). 2006;43: 1053-1062
Mitsuta H (*see* Ishiyama K et al). 2006;43: 362-372
Mizerski J (*see* Sokal EM et al). 2006;43: 225-232
Mizokami M (*see* Kuiken C et al). 2006;43: 1157-1165 (Special Article)
Mizukoshi E, Nakamoto Y, Marukawa Y, Arai K, Yamashita T, Tsuji H, Kuzushima K, Takiguchi M, Kaneko S. Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma. 2006;43: 1284-1294
Mondelli MU (*see* Cammà C et al). 2006; 43:64-71
Moneim AA (*see* Kamal SM et al). 2006; 43:923-931 (Rapid Communication)
Monga SPS. Hepatic adenomas: Presumed innocent until proven to be beta-catenin mutated. 2006;43:401-404 (Editorial)
Montaner J (*see* Sterling RK et al). 2006; 43:1317-1325
Montrone M (*see* Sansonno D et al). 2006; 43:1167-1168 (Reply)
Moore KP (*see* Mani AR et al). 2006;43: 847-856
Moore T (*see* Callender GG et al). 2006; 43:973-981
Morabito A (*see* Sangiovanni A et al). 2006; 43:1303-1310
Morales MG (*see* Klein A et al). 2006;43: 126-133
Morcet J (*see* Lainé F et al). 2006;43:377-378 (Correspondence)
Moreau R and Lebrec D. The use of vasoconstrictors in patients with cirrhosis: Type 1 HRS and beyond. 2006;43:385–394 (Perspectives in Clinical Hepatology)
Moreno C, Devière J, Louis H. CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice — Clinical implications for CCR5 inhibition as antiretroviral therapy. 2006;43:879-880 (Reply)
— (*see* Gustot T et al). 2006;43:989-1000
Moreno-Otero R (*see* Martínez-Bauer E et al). 2006;43:72-80
Morgan TR (*see* Jensen DM et al). 2006; 43:954-960, 1410 (Correction)
Mori T (*see* Fujii T et al). 2006;43:1267-1275
Moriondo M (*see* Bortolotti F et al). 2006; 43:556-562
Morishima C, Paschal DM, Wang CC, Yoshihara CS, Wood BL, Yeo AET, Emerson SS, Shuhart MC, Gretch DR. Decreased NK cell frequency in chronic hepatitis C does not affect *ex vivo* cytolytic killing. 2006;43:573-580
Moritoki Y (*see* Lan RY et al). 2006;43: 729-737
Moritz W (*see* Hoekstra H et al). 2006;43: 1022-1031
Morsica G (*see* Bortolotti F et al). 2006;43: 556-562
Moses RA (*see* Kennedy PTF et al). 2006; 43:602-611
Mozaffarian D (*see* Ioannou GN et al). 2006;43:1145-1151
Mrani S (*see* Chemin I et al). 2006;43:195 (Correspondence)
Mullen KD, Ghanta RK, Putka BS. Prevention of first overt episode of hepatic encephalopathy after TIPS:

No easy task. 2006;43:1155-1156 (Hepatology *Elsewhere*)
Munk OL (*see* Keiding S et al). 2006;43: 42-50
Muñoz L (*see* Albillos A et al). 2006;43: 1399 (Correspondence)
Munteanu M (*see* Poynard T et al). 2006; 43:374-375 (Correspondence)
Murase N (*see* Kaizu T et al). 2006;43:464-473
Musso G (*see* Cassader M et al). 2006;43: 1169-1170 (Correspondence)

N

Nagaya M, Kubota S, Suzuki N, Akashi K, Mitaka T. Thermoreversible gelation polymer induces the emergence of hepatic stem cells in the partially injured rat liver. 2006;43:1053-1062
Naggar KE (*see* Kamal SM et al). 2006;43: 923-931 (Rapid Communication)
Nagy N (*see* Gustot T et al). 2006;43:989-1000
Nahmias Y, Casali M, Barbe L, Berthiaume F, Yarmush ML. Liver endothelial cells promote LDL-R expression and the uptake of HCV-like particles in primary rat and human hepatocytes. 2006;43:257-265
Nakamoto Y (*see* Mizukoshi E et al). 2006; 43:1284-1294
Nakamura T (*see* Lan RY et al). 2006;43: 729-737
Nakao A (*see* Fujii T et al). 2006;43:1267-1275
— (*see* Kaizu T et al). 2006;43:464-473
Nalesnik MA (*see* Kaizu T et al). 2006;43: 464-473
Napirei M, Basnakian AG, Apostolov EO, Mannherz HG. Deoxyribonuclease 1 aggravates acetaminophen-induced liver necrosis in male CD-1 mice. 2006;43:297-305
Narayana PA (*see* Kale RA et al). 2006;43: 698-706
Naruko T (*see* Ikura Y et al). 2006;43:506-514
Natarajan SK, Basivireddy J, Ramachandran A, Thomas S, Ramamoorthy P, Pulimood AB, Jacob M, Balasubramanian K. Renal damage in experimentally induced cirrhosis in rats: Role of oxygen free radicals. 2006;43:1248-1257
—, Ramamoorthy P, Thomas S, Basivireddy J, Kang G, Ramachandran A, Pulimood AB, Balasubramanian KA. Intestinal mucosal alterations in rats with carbon tetrachloride-induced cirrhosis: Changes in glycosylation and luminal bacteria. 2006;43:837-846
Navasa M (*see* Blasco A et al). 2006;43: 492-499
Nazarova N (*see* Neumann-Haefelin C et al). 2006;43:563-572
Nelson K (*see* Wilson LE et al). 2006;43: 788-795
Nelson M (*see* Sterling RK et al). 2006;43: 1317-1325
Neumann-Haefelin C, McKiernan S, Ward S, Viazov S, Spangenberg HC, Killinger T, Baumert TF, Nazarova N, Sheridan I, Pybus O, von Weizsäcker F, Roggendorf M, Kelleher D, Klenerman P, Blum HF, Thimme R. Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution. 2006;43:563-572
Newton JL (*see* Jones DEJ et al). 2006;43: 633 (Correspondence)
Neyts J (*see* Paeshuyse J et al). 2006;43: 761-770
Ng NF (*see* Levy GA et al). 2006;43:581-591
Ngo Y (*see* Poynard T et al). 2006;43:374-375 (Correspondence)
Nguyen H (*see* Kerfoot S et al). 2006;43: 1399 (Reply)
— (*see* Kerfoot SM et al). 2006;43:154 162
Ni ZJ (*see* Kneteman NM et al). 2006;43: 1346-1353
Nicaise C (*see* Gustot T et al). 2006;43: 989-1000
Nicol J (*see* Floreani A et al). 2006;43: 1152-1154 (Concise Communication)
Nierhoff D (*see* Shafritz DA et al). 2006; 43:S89-S98
Nieto M (*see* Albillos A et al). 2006;43: 1399 (Correspondence)
Nishiguchi S (*see* Ikura Y et al). 2006;43: 506-514
Nishimura MI (*see* Callender GG et al). 2006;43:973-981
Nomoto S (*see* Fujii T et al). 2006;43: 1267-1275
Nooman A (*see* Kamal SM et al). 2006;43: 771-779
Norris S (*see* Patel K et al). 2006;43:241-249
Noventa F (*see* Bortolotti F et al). 2006;43: 556-562

O

Obi S (*see* Teratani T et al). 2006;43:1101-1108
O'Connell J (*see* Kneteman NM et al). 2006;43:1346-1353
Odin JA (*see* Ala A et al). 2006;43:525-531
Oertel M (*see* Shafritz DA et al). 2006;43: S89-S98
Ohdan H (*see* Ishiyama K et al). 2006;43: 362-372
Ohira M (*see* Ishiyama K et al). 2006;43: 362-372
Ohsawa M (*see* Ikura Y et al). 2006;43: 506-514
Okolicsanyi L (*see* Fabris L et al). 2006;43: 1001-1012
Oliva R (*see* Turnes J et al). 2006;43:34-41
Ollosson R (*see* Mani AR et al). 2006;43: 847-856
Olynyk JK (*see* Lim R et al). 2006;43: 1074-1083
Omary MB (*see* Strnad P et al). 2006;43: 1354-1363
Omata M (*see* Teratani T et al). 2006;43: 1101-1108
Osawa T (*see* Iwasaki Y et al). 2006;43:54-63
Ott P (*see* Keiding S et al). 2006;43:42-50
Owsianka AM (*see* Tarr AW et al). 2006; 43:592-601

P

Paeshuyse J, Kaul A, De Clercq E, Rosenwirth B, Dumont JM, Scalfaro P, Bartenschlager R, Neyts J. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication *in vitro*. 2006;43:761-770
Pagano G (*see* Cassader M et al). 2006;43: 1169-1170 (Correspondence)
Pagano R (*see* Mazzone A et al). 2006;43: 287-296
Paik SW (*see* Lee HS et al). 2006;43:982-988
Palma J (*see* Reyes H et al). 2006;43:715-722
Pandey CM (*see* Kale RA et al). 2006;43: 698-706
Paradis V (*see* Zucman-Rossi J et al). 2006; 43:515-524
Park Y (*see* Perumalswami P et al). 2006; 43:780-787
Partensky C (*see* Zucman-Rossi J et al). 2006;43:515-524
Paschal DM (*see* Morishima C et al). 2006; 43:573-580
Patch D (*see* Cholongitas EB et al). 2006; 43:881 (Correspondence)
Patel AH (*see* Tarr AW et al). 2006;43: 592-601
Patel K, Norris S, Lebeck L, Feng A, Clare M, Pianko S, Portmann B, Blatt LM, Koziol J, Conrad A, McHutchison JG. HLA class I allelic diversity and progression of fibrosis in patients with chronic hepatitis C. 2006;43:241-249
— (*see* Lim R et al). 2006;43:1074-1083
Patel N (*see* Cobbold JFL et al). 2006;43: 1401-1402 (Correspondence)
Pathil A, Armeanu S, Venturelli S, Mascagni P, Weiss TS, Gregor M, Lauer UM, Bitzer M. HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL. 2006;43:425-434
Paulson M (*see* von Hahn T et al). 2006; 43:932-942

Pawlotsky JM. Therapy of hepatitis C: From empiricism to eradication. 2006;43:S207-S220
Paye F (*see* Demeilliers C et al). 2006;43: 1125-1134
Pellegrin I (*see* Benhamou Y et al). 2006; 43:548-555
Peng YS (*see* Tsai MH et al). 2006;43:673-681
Penin F (*see* Kuiken C et al). 2006;43: 1157-1165 (Special Article)
Penner E (*see* Wesierska-Gadek J et al). 2006;43:1135-1144
Pera N (*see* Yu J et al). 2006;43:826-836
Perelson AS (*see* Talal AH et al). 2006;43: 943-953
Perez EA (*see* Jin X et al). 2006;43:474-484
Pérez-Mateo M (*see* García-Ayllón MS et al). 2006;43:444-453
— (*see* Jover R et al). 2006;43:1257-1266
Perrillo RP. Therapy of hepatitis B — Viral suppression or eradication? 2006;43: S182-S193
Perrin M (*see* Lainé F et al). 2006;43:377-378 (Correspondence)
Perumalswami P, Kleiner DE, Lutchman G, Heller T, Borg B, Park Y, Liang TJ, Hoofnagle JH, Ghany MG. Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection. 2006;43:780-787
Phillips MJ (*see* Levy GA et al). 2006;43: 581-591
Pianko S (*see* Patel K et al). 2006;43:241-249
Picena JC (*see* Brandoni A et al). 2006;43: 1092-1100
Piera C (*see* Hernández-Guerra M et al). 2006;43:27-33
Pierce RH (*see* Jin X et al). 2006;43:474-484
Pietschmann T (*see* Tarr AW et al). 2006; 43:592-601
Piette JC (*see* Saadoun D et al). 2006;43: 1337-1345
Piketty C (*see* Benhamou Y et al). 2006;43: 548-555
Pinzello G (*see* Cammà C et al). 2006;43: 64-71
Pirisi M (*see* Colletta C et al). 2006;43: 375-376 (Reply)
Pizzolanti G (*see* Cammà C et al). 2006;43: 64-71
Pockros PJ (*see* Charlton MR et al). 2006; 43:1177-1186 (Perspectives in Clinical Hepatology)
— (*see* Jensen DM et al). 2006;43:954-960, 1410 (Correction)
Podda M (*see* Wesierska-Gadek J et al). 2006;43:1135-1144
Pons F (*see* Martínez-Bauer E et al). 2006; 43:72-80
Pontisso P (*see* Raimondo G et al). 2006; 43:100-107
Poon TP (*see* Chong WP et al). 2006;43: 199 (Correction)
Porte RJ (*see* Hoekstra H et al). 2006;43: 1022-1031
Portmann B (*see* Patel K et al). 2006;43: 241-249
Poujol-Robert A (*see* Corpechot C et al). 2006;43:1118-1124
Poupon R (*see* Corpechot C et al). 2006; 43:1118-1124
Powers KA (*see* Talal AH et al). 2006;43: 943-953
Poynard T, Munteanu M, Ngo Y, Torres M, Benhamou Y, Thabut D, Ratziu V. Diagnostic value of FibroTest with normal serum aminotransferases. 2006;43:374-375 (Correspondence)
Prati GM (*see* Sangiovanni A et al). 2006; 43:1303-1310
Prieto J (*see* Banales JM et al). 2006;43: 266-275
Protzer U (*see* Untergasser A et al). 2006; 43:539-547
Pulimood AB (*see* Natarajan SK et al). 2006;43:837-846, 1248-1257
PUMPS Group (*see* Combes B and PUMPS Group). 2006;43:634 (Reply)
Puoti M (Mauss S and Puoti M). 2006;43: 879 (Correspondence)
Purohit V and Brenner DA. Mechanisms of alcohol-induced hepatic fibrosis: A summary of the Ron Thurman symposium. 2006;43:872-878 (Special Article)
Pusl T (*see* Beuers U and Pusl T). 2006;43: 647-649 (Editorial)
Putka BS (*see* Mullen KD et al). 2006;43: 1155-1156 (Hepatology *Elsewhere*)
Pybus O (*see* Neumann-Haefelin C et al). 2006;43:563-572

Q

Qiao L (*see* Yu J et al). 2006;43:134-143
Quaglia A (*see* Hadzic N et al). 2006;43: 194 (Correspondence)
Quasdorff M (*see* Untergasser A et al). 2006;43:539-547
Quehenberger O (*see* von Hahn T et al). 2006;43:932-942
Quertinmont E (*see* Gustot T et al). 2006; 43:989-1000
Quintana-Bustamante O, Alvarez-Barrientos A, Kofman AV, Fabregat I, Bueren JA, Theise ND, Segovia JC. Hematopoietic mobilization in mice increases the presence of bone marrow–derived hepatocytes via *in vivo* cell fusion. 2006;43:108-116

R

Racanelli V and Rehermann B. The liver as an immunological organ. 2006;43: S54-S62
Rai R (*see* Wilson LE et al). 2006;43:788-795
Raimondo G, Brunetto MR, Pontisso P, Smedile A, Maina AM, Saitta C, Squadrito G, Tono N, Associazione Italiana Studio Fegato (AISF) Cooperative Group. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus–coinfected patients. 2006;43:100—107
Ramachandran A (*see* Natarajan SK et al). 2006;43:837-846, 1248-1257
Ramamoorthy P (*see* Natarajan SK et al). 2006;43:837846, 1248-1257
Ramy AH (*see* Kamal SM et al). 2006;43: 923-931 (Rapid Communication)
Ranjan P (*see* Kale RA et al). 2006;43:698-706
Rasenack J (*see* Kamal SM et al). 2006;43: 771-779, 923-931 (Rapid Communication)
Ratziu V (*see* Poynard T et al). 2006;43: 374-375 (Correspondence)
Rausa FM III (*see* Yoshida Y et al). 2006; 43:276-286
Rebouissou S (*see* Zucman-Rossi J et al). 2006;43:515-524
Rebucci C (*see* Cammà C et al). 2006;43: 64-71
Reddy KR (*see* Jensen DM et al). 2006;43: 954-960, 1410 (Correction)
Rehermann B (*see* Racanelli V and Rehermann B). 2006;43:S54-S62
— (*see* Shiina M and Rehermann B). 2006; 43:1395-1398 (Hepatology *Elsewhere*)
Resche-Rigon M (*see* Saadoun D et al). 2006;43:1337-1345
Retamal MJ (*see* Klein A et al). 2006;43: 126-133
Reuben A. First do no harm. 2006;43: S243-S249 (Landmarks in Hepatology)
—. Seeing purple. 2006;43:1403-1409 (Landmarks in Hepatology)
—. True, true . . . but are they related? 2006;43:635-639 (Landmarks in Hepatology)
Reyes H, Zapata R, Hernández I, Gotteland M, Sandoval L, Jirón MI, Palma J, Almuna R, Silva JJ. Is a leaky gut involved in the pathogenesis of intrahepatic cholestasis of pregnancy? 2006;43:715-722
Ribeiro RM (*see* Talal AH et al). 2006;43: 943-953
Rice CM (*see* von Hahn T et al). 2006;43: 932-942
Riehle KJ (*see* Fausto N et al). 2006;43: S45-S53
Rigoli RM (*see* Schattenberg JM et al). 2006;43:163-172
Rigotti A (*see* Klein A et al). 2006;43:126-133
Riikonen S (*see* Ropponen A et al). 2006; 43:723-728
Rimola A (*see* Blasco A et al). 2006;43:492-499

Rizzotto ER (*see* Floreani A et al). 2006;43:1152-1154 (Concise Communication)
Roca J (*see* Gómez FP et al). 2006;43:1084-1091
Röcken C (*see* Yu J et al). 2006;43:134-143
Rockey DC and Bissell DM. Magnetic resonance and ultrasound techniques for the evaluation of hepatic fibrosis. 2006;43:1402 (Reply)
Rockey DC and Bissell DM. Noninvasive measures of liver fibrosis. 2006;43:S113-S120
Rodrigo R (*see* Jover R et al). 2006;43:1257-1266
Rodríguez E (*see* Jover R et al). 2006;43:1257-1266
Rodríguez-Ortigosa CM (*see* Banales JM et al). 2006;43:266-275
Rodríguez-Roisin R (*see* Gómez FP et al). 2006;43:1084-1091
Roggendorf M (*see* Neumann-Haefelin C et al). 2006;43:563-572
Romeo R (*see* Sangiovanni A et al). 2006;43:1303-1310
Romero-Gómez M (*see* Martínez-Bauer E et al). 2006;43:72-80
Ronchi G (*see* Sangiovanni A et al). 2006;43:1303-1310
Ropponen A, Sund R, Riikonen S, Ylikorkala O, Aittomäki K. Intrahepatic cholestasis of pregnancy as an indicator of liver and biliary diseases: A population-based study. 2006;43:723-728
Rosen CB (*see* Kim WR et al). 2006;43:345-351
Rosen HR (*see* Callender GG et al). 2006;43:973-981
Rosenwirth B (*see* Paeshuyse J et al). 2006;43:761-770
Roskams T (*see* Fabris L et al). 2006;43:1001-1012
Roszkowski JJ (*see* Callender GG et al). 2006;43:973-981
Rovira A (*see* Mínguez B et al). 2006;43:707-714
Rowe A (*see* Levy GA et al). 2006;43:581-591
Rozenbaum W (*see* Benhamou Y et al). 2006;43:548-555
Rumi M (*see* Cammà C et al). 2006;43:64-71
Russo FP (*see* Vig P et al). 2006;43:316-324

S

Saadoun D, Asselah T, Resche-Rigon M, Frédéric C, Bedossa P, Valla D, Piette JC, Marcellin P, Cacoub P. Cryoglobulinemia is associated with steatosis and fibrosis in chronic hepatitis C. 2006;43:1337-1345
Sáez E (*see* Banales JM et al). 2006;43:266-275
Sáez-Valero J (*see* García-Ayllón MS et al). 2006;43:444-453
— (*see* Jover R et al). 2006;43:1257-1266
Said HM (*see* Wiercinska E et al). 2006;43:1032-1041
Saito S (*see* Lan RY et al). 2006;43:729-737
Saitta C (*see* Raimondo G et al). 2006;43:100-107
Sakaguchi K (*see* Iwasaki Y et al). 2006;43:54-63
Sánchez-Tapias JM (*see* Martínez-Bauer E et al). 2006;43:72-80
Sandoval L (*see* Reyes H et al). 2006;43:715-722
Sangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M, Del Ninno E, Morabito A, Colombo M. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. 2006;43:1303-1310
Sansonno D, Tucci FA, De Re V, Lauletta G, Montrone M, Libra M, Dammacco F. Association between mixed cryoglobulinemia, translocation (14;18), and persistence of occult HCV lymphoid infection after treatment. 2006;43:1167-1168 (Reply)
Santos M (*see* Zintzaras E et al). 2006;43:352-361
Sanyal AJ, Banas C, Sargeant C, Luketic VA, Sterling RK, Stravitz RT, Shiffman ML, Heuman D, Coterrell A, Fisher RA, Contos MJ, Mills AS. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. 2006;43:682-689
Saraswat VA (*see* Kale RA et al). 2006;43:698-706
Sargeant C (*see* Sanyal AJ et al). 2006;43:682-689
Sato S (*see* Teratani T et al). 2006;43:1101-1108
Saxena NK (*see* Ding X et al). 2006;43:173-181
Scalfaro P (*see* Paeshuyse J et al). 2006;43:761-770
Schartman J and Weinstein J. Intermittent disconjugate gaze: A novel finding in nonalcoholic steatohepatitis. 2006;43:882-883 (Correspondence)
Schattenberg JM, Singh R, Wang Y, Lefkowitch JH, Rigoli RM, Scherer PE, Czaja MJ. JNK1 but not JNK2 promotes the development of steatohepatitis in mice. 2006;43:163-172
Schechterly C (*see* Umemura T et al). 2006;43:91-99
Schenker S, Bissell DM, Blei AT. *Hepatology* over the years. 2006;43:S6-S12
Scherer PE (*see* Schattenberg JM et al). 2006;43:163-172
Schiano TD (*see* Ala A et al). 2006;43:525-531
Schiller D (*see* Kneteman NM et al). 2006;43:1346-1353
Schirin-Sokhan R (*see* Wasmuth HE et al). 2006;43:738-741 (Concise Communication)
Schnölzer M (*see* Engelke M et al). 2006;43:750-760
Schuetz JD (*see* Mennone A et al). 2006;43:1013-1021
Schulz C (*see* Dombrowski F et al). 2006;43:857-867
Schulze-Osthoff K (*see* Volkmann X et al). 2006;43:1311-1316
Schuppan D (*see* Strnad P et al). 2006;43:1354-1363
Schwartz TP (*see* Stapelbroek JM et al). 2006;43:51-53 (Concise Communication)
Schwarz KB (*see* Sokal EM et al). 2006;43:225-232
Schwarz M (*see* Hailfinger S et al). 2006;43:407-414
Scoazec JY (*see* Zucman-Rossi J et al). 2006;43:515-524
Scrocchi LA (*see* Levy GA et al). 2006;43:581-591
Seeff LB (*see* Watkins PB and Seeff LB). 2006;43:618-631 (Special Article)
Seeger C (*see* Evans JD and Seeger C). 2006;43:615-617 (Hepatology Elsewhere)
Segovia JC (*see* Quintana-Bustamante O et al). 2006;43:108-116
Seitz S (*see* Engelke M et al). 2006;43:750-760
Sekine S, Lan BYA, Bedolli M, Feng S, Hebrok M. Liver-specific loss of β-catenin blocks glutamine synthesis pathway activity and cytochrome P450 expression in mice. 2006;43:817-825
Selmi C (*see* Wesierska-Gadek J et al). 2006;43:1135-1144
Sesha J (*see* Yu J et al). 2006;43:826-836
Shafritz DA, Oertel M, Menthena A, Nierhoff D, Dabeva MD. Liver stem cells and prospects for liver reconstitution by transplanted cells. 2006;43:S89-S98
Shah VH (*see* Anan A et al). 2006;43:335-344
Shao L (*see* Kaizu T et al). 2006;43:464-473
Shaw PN (*see* Lee S et al). 2006;43:1241-1247
Shaw S (*see* Cholongitas EB et al). 2006;43:881 (Correspondence)
Sheridan I (*see* Neumann-Haefelin C et al). 2006;43:563-572
Sherman KE (*see* Mandac JC et al). 2006;43:661-672 (Perspectives in Clinical Hepatology)
Shiffman ML (*see* Sanyal AJ et al). 2006;43:682-689

Shih JWK (*see* Umemura T et al). 2006;43:91-99
Shiina M and Rehermann B. Hepatitis C vaccines: Inducing and challenging memory T cells. 2006;43:1395-1398 (Hepatology *Elsewhere*)
Shiina S (*see* Teratani T et al). 2006;43:1101-1108
Shimoda S (*see* Lan RY et al). 2006;43:729-737
Shimoe T (*see* Iwasaki Y et al). 2006;43:54-63
Shin-I T (*see* Kuiken C et al). 2006;43:1157-1165 (Special Article)
Shiratori Y (*see* Iwasaki Y et al). 2006;43:54-63
Shuhart MC (*see* Morishima C et al). 2006;43:573-580
Silva JJ (*see* Reyes H et al). 2006;43:715-722
Silveyra MX (*see* García-Ayllón MS et al). 2006;43:444-453
Simon P (*see* Engelke M et al). 2006;43:750-760
Singh R (*see* Schattenberg JM et al). 2006;43:163-172
Slooff MJH (*see* Hoekstra H et al). 2006;43:1022-1031
Smedile A (*see* Raimondo G et al). 2006;43:100-107
Smirne C (*see* Colletta C et al). 2006;43:375-376 (Reply)
Sokal EM, Kelly DA, Mizerski J, Badia IB, Areias JA, Schwarz KB, Vegnente A, Little NR, Gardener SD, Jonas MM. Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B. 2006;43:225-232
Sokol RJ (*see* Hoofnagle JH and Sokol RJ). 2006;43:646 (This Month from the NIH)
Solá R (*see* Martínez-Bauer E et al). 2006;43:72-80
Sola R (*see* Sterling RK et al). 2006;43:1317-1325
Sommer P (*see* Bonvin M et al). 2006;43:1364-1374
Song KH and Chiang JYL. Glucagon and cAMP inhibit cholesterol 7α-hydroxylase (CYP7A1) gene expression in human hepatocytes: Discordant regulation of bile acid synthesis and gluconeogenesis. 2006;43:117-125
Song LH (*see* Toan NG et al). 2006;43:1375-1384
Sonzogni A (*see* Fabris L et al). 2006;43:1001-1012
Sørensen M (*see* Keiding S et al). 2006;43:42-50
Soroka CJ (*see* Mennone A et al). 2006;43:1013-1021
Spangenberg HC (*see* Neumann-Haefelin C et al). 2006;43:563-572
Spirlì C (*see* Fabris L et al). 2006;43:1001-1012
Spoler C (*see* Wilson LE et al). 2006;43:788-795
Squadrito G (*see* Raimondo G et al). 2006;43:100-107
Stanca CM (*see* Ala A et al). 2006;43:525-531
Stapelbroek JM, van Erpecum KJ, Klomp LWJ, Venneman NG, Schwartz TP, van Berge Henegouwen GP, Devlin J, van Nieuwkerk CMJ, Knisely AS, Houwen RHJ. Nasobiliary drainage induces long-lasting remission in benign recurrent intrahepatic cholestasis. 2006;43:51-53 (Concise Communication)
Starzl TE and Lakkis FG. The unfinished legacy of liver transplantation: Emphasis on immunology. 2006;43:S151-S163
Stauber RE (*see* Lackner C et al). 2006;43:378-379 (Correspondence)
Stefanidis I (*see* Zintzaras E et al). 2006;43:352-361
Sterling RK, Lissen E, Clumeck N, Sola R, Cassia Correa M, Montaner J, Sulkowski M, Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M, APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. 2006;43:1317-1325
— (*see* Sanyal AJ et al). 2006;43:682-689
Stickel F (*see* Strnad P et al). 2006;43:1354-1363
Stieger B (*see* Hoekstra H et al). 2006;43:1022-1031
Stokkeland K, Brandt L, Ekbom A, Hultcrantz R. Improved prognosis for patients hospitalized with esophageal varices in Sweden 1969-2002. 2006;43:500-505
Stravitz RT (*see* Sanyal AJ et al). 2006;43:682-689
Strazzabosco M (*see* Fabris L et al). 2006;43:1001-1012
Strickland GT. Liver disease in Egypt: Hepatitis C superseded schistosomiasis as a result of iatrogenic and biological factors. 2006;43:915-922 (Perspectives in Clinical Hepatology)
Strnad P, Lienau TC, Tao GZ, Lazzeroni LC, Stickel F, Schuppan D, Omary MB. Keratin variants associate with progression of fibrosis during chronic hepatitis C infection. 2006;43:1354-1363
Stroka D (*see* Bonvin M et al). 2006;43:1364-1374
Struber G (*see* Lackner C et al). 2006;43:378-379 (Correspondence)
Suárez I (*see* Jover R et al). 2006;43:1257-1266
Suekane T (*see* Ikura Y et al). 2006;43:506-514
Suh DJ (*see* Lee YS et al). 2006;43:1385-1391
Sulkowski M (*see* Sterling RK et al). 2006;43:1317-1325
Sun R (*see* Li B et al). 2006;43:1220-1219
Sund R (*see* Ropponen A et al). 2006;43:723-728
Suzuki N (*see* Nagaya M et al). 2006;43:1053-1062
Swain MG (*see* Kerfoot S et al). 2006;43:1399-1400 (Reply)
— (*see* Kerfoot SM et al). 2006;43:154-162

T

Tadrous PJ (*see* Vig P et al). 2006;43:316-324
Takaguchi K (*see* Iwasaki Y et al). 2006;43:54-63
Takahashi Y (*see* Kaizu T et al). 2006;43:464-473
Takano Y (*see* Lan RY et al). 2006;43:729-737
Takeda S (*see* Fujii T et al). 2006;43:1267-1275
Takiguchi M (*see* Mizukoshi E et al). 2006;43:1284-1294
Talal AH, Ribeiro RM, Powers KA, Grace M, Cullen C, Hussain M, Markatou M, Perelson AS. Pharmacodynamics of PEG-IFNα differentiate HIV/HCV coinfected sustained virological responders from nonresponders. 2006;43:943-953
Talwalkar JA and Lazaridis KN. Polluting the pathogenesis of primary biliary cirrhosis. 2006;43:398-400 (Editorial)
Tan PC, Hou MC, Lin HC, Liu TT, Lee FY, Chang FY, Lee SD. A randomized trial of endoscopic treatment of acute gastric variceal hemorrhage: N-butyl-2-cyanoacrylate injection versus band ligation. 2006;43:690-697, 1410 (Correction)
Tan SL (*see* Huang Y et al). 2006;43:81-90
Tan Y (*see* Yoshida Y et al). 2006;43:276-286
Tanaka A (*see* Lan RY et al). 2006;43:729-737
Tao GZ (*see* Strnad P et al). 2006;43:1354-1363
Tao N (*see* Kuiken C et al). 2006;43:1157-1165 (Special Article)
Tappertzhofen B (*see* Untergasser A et al). 2006;43:539-547
Tarr AW, Owsianka AM, Timms JM, McClure CP, Brown RJP, Hickling TP, Pietschmann T, Bartenschlager R, Patel AH, Ball JK. Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. 2006;43:592-601
Tateishi R (*see* Teratani T et al). 2006;43:1101-1108

Taylor-Robinson SD (*see* Cobbold JFL et al). 2006;43:1401-1402 (Correspondence)
TECOVIR Study Group (*see* Benhamou Y et al). 2006;43:548-555
ten Dijke P (*see* Wiercinska E et al). 2006; 43:1032-1041
Teratani T, Yoshida H, Shiina S, Obi S, Sato S, Tateishi R, Mine N, Kondo Y, Kawabe T, Omata M. Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations. 2006;43:1101-1108
Tesei N (*see* Martínez-Bauer E et al). 2006; 43:72-80
Teshigawara O (*see* Fujii T et al). 2006;43: 1267-1275
Thabut D (*see* Poynard T et al). 2006;43: 374-375 (Correspondence)
Theise ND (*see* Quintana-Bustamante O et al). 2006;43:108-116
Therneau TM (*see* Kim WR et al). 2006; 43:345-351
Thimme R (*see* Fang X et al). 2006;43: 1326-1336
— (*see* Neumann-Haefelin C et al). 2006; 43:563-572
Thomas DL. Growing importance of liver disease in HIV-infected persons. 2006;43:S221-S229
— (*see* Sterling RK et al). 2006;43:1317-1325
— (*see* Wilson LE et al). 2006;43:788-795
Thomas HC (*see* Cobbold JFL et al). 2006; 43:1401-1402 (Correspondence)
— (*see* Vig P et al). 2006;43:316-324
Thomas S (*see* Natarajan SK et al). 2006; 43:837-846, 1248-1257
Thompson NL (*see* Erickson BM et al). 2006;43:325-334
Thomson AW (*see* Castellaneta A et al). 2006;43:807-816
Thorgeirsson SS, Lee JS, Grisham JW. Functional genomics of hepatocellular carcinoma. 2006;43:S145-S150
—and Grisham JW. Hematopoietic cells as hepatocyte stem cells: A critical review of the evidence. 2006;43:2-8 (Science Frontier)
Thorikay M (*see* Wiercinska E et al). 2006; 43:1032-1041
Tian Y (*see* Hoekstra H et al). 2006;43: 1022-1031
Tian Z (*see* Li B et al). 2006;43:1211-1219
Tietz P (*see* Mazzone A et al). 2006;43: 287-296
Timmer J (*see* Fang X et al). 2006;43:1326-1336
Timms JM (*see* Tarr AW et al). 2006;43: 592-601
To YF (*see* Chong WP et al). 2006;43:199 (Correction)
Toan NG, Song LH, Kremsner PG, Duy DN, Binh VQ, Koeberlein B, Kaiser S, Kandolf R, Torresi J, Bock CT. Impact of the hepatitis B virus genotype and genotype mixtures on the course of liver disease in Vietnam. 2006;43:1375-1384
Tomer Y (*see* Mandac JC et al). 2006;43: 661-672 (Perspectives in Clinical Hepatology)
Tomita M (*see* Iwasaki Y et al). 2006;43: 54-63
Tomiyama K (*see* Kaizu T et al). 2006;43: 464-473
Toniutto P (*see* Colletta C et al). 2006;43: 375-376 (Reply)
Tono N (*see* Raimondo G et al). 2006;43: 100-107
Torbenson M (*see* Wilson LE et al). 2006; 43:788-795
Torok NJ (*see* Zhan SS et al). 2006;43: 435-443
Torres AM (*see* Brandoni A et al). 2006;43: 1092-1100
Torres M (*see* Poynard T et al). 2006;43: 374-375 (Correspondence)
Torresi J (*see* Toan NG et al). 2006;43: 1375-1384
Torriani FJ (*see* Sterling RK et al). 2006; 43:1317-1325
Toyokawa H (*see* Kaizu T et al). 2006;43: 464-473
Tran Van Nhieu J (*see* Zucman-Rossi J et al). 2006;43:515-524
Trépo C (*see* Chemin I et al). 2006;43:195 (Correspondence)
Triantos C, Vlachogiannakos J, Manolakopoulos S, Burroughs A, Avgernos A. Is banding ligation for primary prevention of variceal bleeding as effective as beta-blockers, and is it safe? 2006;43:196-197 (Correspondence)
Trimoulet P (*see* Benhamou Y et al). 2006; 43:548-555
Trivedi R (*see* Kale RA et al). 2006;43:698-706
Troiani L (*see* Castellaneta A et al). 2006; 43:807-816
Trylesinski A (*see* Benhamou Y et al). 2006; 43:548-555
Tsai MH, Peng YS, Chen YC, Liu NJ, Ho YP, Fang JT, Lien JM, Yang C, Chen PC, Wu CS. Adrenal insufficiency in patients with cirrhosis, severe sepsis and septic shock. 2006;43:673-681
Tsuji H (*see* Mizukoshi E et al). 2006;43: 1284-1294
Tsuneyama K (*see* Lan RY et al). 2006;43: 729-737
Tsung A (*see* Kaizu T et al). 2006;43:464-473
Tucci FA (*see* Sansonno D et al). 2006;43: 1167-1168 (Reply)
Turner B (*see* Kamal SM et al). 2006;43: 771-779
Turnes J, Hernández-Guerra M, Abraldes JG, Bellot P, Oliva R, García-Pagán JC, Bosch J. Influence of beta-2 adrenergic receptor gene polymorphism on the hemodynamic response to propranolol in patients with cirrhosis. 2006;43:34-41
— (*see* Hernández-Guerra M et al). 2006; 43:27-33, 485-491
— (*see* Mínguez B et al). 2006;43:707-714
Tyrrell DLJ (*see* Kneteman NM et al). 2006;43:1346-1353

U

Úbeda M (*see* Albillos A et al). 2006;43: 1399 (Correspondence)
Ueda M (*see* Ikura Y et al). 2006;43:506-514
Umemura T, Wang RYH, Schechterly C, Shih JWK, Kiyosawa K, Alter HJ. Quantitative analysis of anti–hepatitis C virus antibody–secreting B cells in patients with chronic hepatitis C. 2006;43:91-99
Untergasser A, Zedler U, Langenkamp A, Hösel M, Quasdorff M, Esser K, Dienes HP, Tappertzhofen B, Kolanus W, Protzer U. Dendritic cells take up viral antigens but do not support the early steps of hepatitis B virus infection. 2006;43:539-547
Urban S (*see* Engelke M et al). 2006;43: 750-760
Urbani S (*see* Kennedy PTF et al). 2006; 43:602-611
Urbinelli R (*see* Benhamou Y et al). 2006; 43:548-555
Uriarte I (*see* Banales JM et al). 2006;43: 266-275

V

Valla D (*see* Saadoun D et al). 2006;43: 1337-1345
van Berge-Henegouwen GP (*see* Stapelbroek JM et al). 2006;43:51-53 (Concise Communication)
— (*see* Venneman NG et al). 2006;43: 1276-1283
van Erpecum KJ (*see* Stapelbroek JM et al). 2006;43:51-53 (Concise Communication)
— (*see* Venneman NG et al). 2006;43: 1276-1283
van Leeuwen DJ and Bernat JL. Ethical, Social and legal implications of genetic testing in liver disease. 2006; 43:1195-1201 (Sounding Board).
van Nieuwkerk CMJ (*see* Stapelbroek JM et al). 2006;43:51-53 (Concise Communication)
Varbu V (*see* Demeilliers C et al). 2006;43: 1125-1134
Variola A (*see* Floreani A et al). 2006;43: 1152-1154 (Concise Communication)
Vartanian JP (*see* Bonvin M et al). 2006; 43:1364-1374
Vegnente A (*see* Sokal EM et al). 2006;43: 225-232

Venneman NG, Besselink MGH, Keulemans YCA, van Berge-Henegouwen GP, Boermeester MA, Broeders IAMJ, Go PMNYH, van Erpecum KJ. Ursodeoxycholic acid exerts no beneficial effects in patients with symptomatic gallstones awaiting cholecystectomy. 2006;43:1276-1283
— (*see* Stapelbroek JM et al). 2006;43:51-53 (Concise Communication)
Venturelli S (*see* Pathil A et al). 2006;43:425-434
Viazov S (*see* Neumann-Haefelin C et al). 2006;43:563-572
Vidal F (*see* Zintzaras E et al). 2006;43:352-361
Vig P, Russo FP, Edwards RJ, Tadrous PJ, Wright NA, Thomas HC, Alison MR, Forbes SJ. The sources of parenchymal regeneration after chronic hepatocellular liver injury in mice. 2006;43:316-324
Villar SR (*see* Brandoni A et al). 2006;43:1092-1100
Vilstrup H (*see* Keiding S et al). 2006;43:42-50
Vinci M (*see* Cammà C et al). 2006;43:64-71
Vlachogiannakos J (*see* Triantos C et al). 2006;43:196-197 (Correspondence)
Vogel A (*see* Manns MP and Vogel A). 2006;43:S132-S144
Volkmann X, Cornberg M, Wedemeyer H, Lehner F, Manns MP, Schulze-Osthoff K, Bantel H. Caspase activation is required for antiviral treatment response in chronic hepatitis C virus infection. 2006;43:1311-1316
von Hahn T, Lindenbach BD, Boullier A, Quehenberger O, Paulson M, Rice CM, McKeatiing JA. Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells. 2006;43:932–942
von Netzer B (*see* Dombrowski F et al). 2006;43:857-867
von Weizsäcker F (*see* Fang X et al). 2006;43:1326-1336
— (*see* Neumann-Haefelin C et al). 2006;43:563-572

W

Wain-Hobson W (*see* Bonvin M et al). 2006;43:1364-1374
Walz G (*see* Fang X et al). 2006;43:1326-1336
Wands JR (*see* Branda M and Wands JR). 2006;43:891-902 (Science Frontier)
Wang CC (*see* Morishima C et al). 2006;43:573-580
Wang HY (*see* Lian Z et al). 2006;43:415-424
Wang J (*see* Guy CS et al). 2006;43:1231-1240
Wang RYH (*see* Umemura T et al). 2006;43:91-99
Wang Y (*see* Schattenberg JM et al). 2006;43:163-172
Ward S (*see* Neumann-Haefelin C et al). 2006;43:563-572
Wasmuth HE, Keppeler H, Herrmann U, Schirin-Sokhan R, Barker M, Lammert F. Coinheritance of Gilbert syndrome–associated *UGT1A1* mutation increases gallstone risk in cystic fibrosis. 2006;43:738–741 (Concise Communication)
Watkins PB and Seeff LB. Drug-induced liver injury: Summary of a single topic clinical research conference. 2006;43:618-631 (Special Article)
Wedemeyer H (*see* Volkmann X et al). 2006;43:1311-1316
— (*see* Wiegand J et al). 2006;43:250-256
Wei H (*see* Li B et al). 2006;43:1211-1219
Weiner AJ (*see* Kneteman NM et al). 2006;43:1346-1353
Weinstein J (*see* Schartman J and Weinstein J). 2006;43:882-883 (Correspondence)
Weiss NS (*see* Ioannou GN et al). 2006;43:1145-1151
Weiss TS (*see* Pathil A et al). 2006;43:425-434
Wendum D (*see* Corpechot C et al). 2006;43:1118-1124
— (*see* Zucman-Rossi J et al). 2006;43:515-524
Werneburg NW (*see* Anan A et al). 2006;43:335-344
Wesierska-Gadek J, Penner E, Battezzati PM, Selmi C, Zuin M, Hitchman E, Worman HJ, Gershwin ME, Podda M, Invernizzi P. Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. 2006;43:1135-1144
Whitington PF. Fetal and infantile hemochromatosis. 2006;43:654-660 (Concise Review in Mechanisms of Disease)
Wickert L (*see* Wiercinska E et al). 2006;43:1032-1041
Wiegand J, Buggisch P, Boecher W, Zeuzem S, Gelbmann CM, Berg T, Kauffmann W, Kallinowski B, Cornberg M, Jaeckel E, Wedemeyer H, Manns MP, German HEP-NET Acute HCV Study Group. Early monotherapy with pegylated interferon alpha-2 for acute hepatitis C infection: The HEP-NET Acute-HCV-II Study. 2006;43:250-256
Wiercinska E, Wickert L, Denecke B, Said HM, Hamzavi J, Gressner AM, Thorikay M, ten Dijke P, Mertens PR, Breitkopf K, Dooley S. Id1 is a critical mediator in TGF-β–induced transdifferentiation of rat hepatic stellate cells. 2006;43:1032-1041
Willems B (*see* Jensen DM et al). 2006;43:954-960, 1410 (Correction)
Wilpert J (*see* Fang X et al). 2006;43:1326-1336
Wilson LE, Torbenson M, Astemborski J, Faruki H, Spoler C, Rai R, Mehta S, Kirk GD, Nelson K, Afdhal N, Thomas DL. Progression of liver fibrosis among injection drug users with chronic hepatitis C. 2006;43:788-795
Wong WHS (*see* Chong WP et al). 2006;43:199 (Correction)
Wood BL (*see* Morishima C et al). 2006;43:573-580
Woods C (*see* Levy GA et al). 2006;43:581-591
Worman HJ (*see* Wesierska-Gadek J et al). 2006;43:1135-1144
Wright NA (*see* Vig P et al). 2006;43:316-324
Wu CS (*see* Tsai MH et al). 2006;43:673-681
Wu J (*see* Zhan SS et al). 2006;43:435-443
Wu JC (*see* Huo TI et al). 2006;43:1400-1401 (Correspondence)
Wu MC (*see* Lian Z et al). 2006;43:415-424
Wylezinska M (*see* Cobbold JFL et al). 2006;43:1401-1402 (Correspondence)

Y

Yamashita T (*see* Mizukoshi E et al). 2006;43:1284-1294
Yang C (*see* Tsai MH et al). 2006;43:673-681
Yang GX (*see* Lan RY et al). 2006;43:729-737
Yang SS (*see* Liu CJ et al). 2006;43:742-749
Yarmush ML (*see* Nahmias Y et al). 2006;43:257-265
Yatabe Y (*see* Fujii T et al). 2006;43:1267-1275
Yeo AET (*see* Morishima C et al). 2006;43:573-580
Yeo W and Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. 2006;43:209-220 (Concise Review in Mechanisms of Disease)
Yeoh GC (*see* Lim R et al). 2006;43:1074-1083
Yeom YI (*see* Jung CR et al). 2006;43:1042-1052
Yim HJ and Lok ASF. Natural history of chronic hepatitis B virus infection: What we knew in 1981 and what we know in 2005. 2006;43:S173-S181
Ylikorkala O (*see* Ropponen A et al). 2006;43:723-728
Yoo BC (*see* Lee HS et al). 2006;43:982-988
Yoo HW (*see* Lee HS et al). 2006;43:982-988
Yoo J (*see* Jung CR et al). 2006;43:1042-1052
Yoo K (*see* Lee HS et al). 2006;43:982-988

Yoo W (*see* Lee YS et al). 2006;43:1385-1391
Yoon SK (*see* Jang JW et al). 2006;43:233-240
Yoon Y (*see* Lee K et al). 2006;43:1063-1073
Yoshida H (*see* Teratani T et al). 2006;43:1101-1108
Yoshida Y, Hughes DE, Rausa FM III, Kim IM, Tan Y, Darlington GJ, Costa RH. C/EBPα and HNF6 protein complex formation stimulates HNF6-dependent transcription by CBP coactivator recruitment in HepG2 cells. 2006;43:276-286
Yoshihara CS (*see* Morishima C et al). 2006;43:573-580
Yu J, Ip E, dela Peña A, Hou JY, Sesha J, Pera N, Hall P, Kirsch R, Leclercq I, Farrell GC. COX-2 induction in mice with experimental nutritional steatohepatitis: Role as pro-inflammatory mediator. 2006;43:826-836
—, Qiao L, Zimmermann L, Ebert MPA, Zhang H, Lin W, Röcken C, Malfertheiner P, Farrell GC. Troglitazone inhibits tumor growth in hepatocellular carcinoma *in vitro* and *in vivo*. 2006;43:134-143
Yuen MF (*see* Chong WP et al). 2006;43:199 (Correction)
Yun ST (*see* Lee K et al). 2006;43:1063-1073
Yusim K (*see* Kuiken C et al). 2006;43:1157-1165 (Special Article)

Z

Zafrani ES (*see* Zucman-Rossi J et al). 2006;43:515-524
Zanlungo S (*see* Klein A et al). 2006;43:126-133
Zapata R (*see* Reyes H et al). 2006;43:715-722
Zedler U (*see* Untergasser A et al). 2006;43:539-547
Zeisel MB (*see* Fang X et al). 2006;43:1326-1336
Zern MA (*see* Zhan SS et al). 2006;43:435-443
Zeuzem S (*see* Wiegand J et al). 2006;43:250-256
Zhan SS, Jiang JX, Wu J, Halsted C, Friedman SL, Zern MA, Torok NJ. Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis *in vivo*. 2006;43:435-443
Zhang H (*see* Yu J et al). 2006;43:134-143
Zhang Z (*see* Jin X et al). 2006;43:474-484
Zignego AL (*see* Giannini C et al). 2006;43:1166-1167 (Correspondence)
Zimmermann L (*see* Yu J et al). 2006;43:134-143
Zimmers TA (*see* Jin X et al). 2006;43:474-484
Zintzaras E, Stefanidis I, Santos M, Vidal F. Do alcohol-metabolizing enzyme gene polymorphisms increase the risk of alcoholism and alcoholic liver disease? 2006;43:352-361
Ziol M (*see* Corpechot C et al). 2006;43:1118-1124
Zucman-Rossi J, Jeannot E, Tran Van Nhieu J, Scoazec JY, Guettier C, Rebouissou S, Bacq Y, Leteurtre E, Paradis V, Michalak S, Wendum D, Chiche L, Fabre M, Mellottee L, Laurent C, Partensky C, Castaing D, Zafrani ES, Laurent-Puig P, Balabaud C, Bioulac-Sage P. Genotype-phenotype correlation in hepatocellular adenoma: New classification and relationship with HCC. 2006;43:515-524
Zuin M (*see* Wesierska-Gadek J et al). 2006;43:1135-1144
Zwingmann C and Bilodeau M. Metabolic insights into the hepatoprotective role of *N*-acetylcysteine in mouse liver. 2006;43:454-463

Subject Index to Volume 43*

A

Ablation therapy
Local ablation vs. resection for the treatment of hepatocellular carcinoma (Kao and Chen). 2006; 43:373 (Correspondence)

Acetaminophen
Acetaminophen-induced acute liver failure: Results of a United States multicenter prospective study (Holubek et al). 2006;43:881 (Correspondence)
Deoxyribonuclease 1 aggravates acetaminophen-induced liver necrosis in male CD-1 mice (Napirei et al). 2006;43:297-305
Disruption of NaS1 sulfate transport function in mice leads to enhanced acetaminophen-induced hepatotoxicity (Lee et al). 2006;43: 1241-1247
Hepatology Highlights (Kaplowitz). 2006;43:207-208
How relevant are neutrophils for acetaminophen hepatotoxicity? (Jaeschke). 2006;43:1191-1194 (Editorial)
King's criteria, APACHE II, and SOFA scores in acute liver failure (Cholongitas et al). 2006;43:881 (Correspondence)
Neutrophil depletion protects against murine acetaminophen hepatotoxicity (Liu et al). 2006;43: 1220-1230

Acetylcholinesterase
Changes in liver and plasma acetylcholinesterase in rats with cirrhosis induced by bile duct ligation (García-Ayllón et al). 2006; 43:444-453

***N*-Acetylcysteine**
Metabolic insights into the hepatoprotective role of *N*-acetylcysteine in mouse liver (Zwingmann and Bilodeau). 2006; 43:454-463

Acute biliary obstruction
Expression of rat renal cortical OAT1 and OAT3 in response to acute biliary obstruction (Brandoni et al). 2006;43:1092-1100

Acute gastric variceal hemorrhage
A randomized trial of endoscopic treatment of acute gastric variceal hemorrhage: N-butyl-2-cyanoacrylate injection versus band ligation (Tan et al). 2006;43:690-697, 1410 (Correction)

Acute hepatic encephalopathy
Brain metabolism of ^{13}N-ammonia during acute hepatic encephalopathy in cirrhosis measured by positron emission tomography (Keiding et al). 2006;43:42-50

Acute hepatitis C
Acute hepatitis C: In search of the optimal approach to cure (Craxì and Licata). 2006;43:221-224 (Editorial)
Duration of peginterferon therapy in acute hepatitis C: A randomized trial (Kamal et al). 2006;43:923-931 (Rapid Communication)
Early monotherapy with pegylated interferon alpha-2 for acute hepatitis C infection: The HEP-NET Acute-HCV-II Study (Wiegand et al). 2006;43:250-256

Acute liver injury
Tightly regulated induction of the adhesion molecule Necl-5/CD155 during rat liver regeneration and acute liver injury (Erickson et al). 2006;43:325-334

Acute Physiology and Chronic Health Evaluation (APACHE II)
King's criteria, APACHE II, and SOFA scores in acute liver failure (Cholongitas et al). 2006;43:881 (Correspondence)
King's criteria, APACHE II, and SOFA scores in acute liver failure (Larson et al). 2006;43:882 (Reply)

Adefovir
Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy (Lee et al). 2006;43:1385-1391

Adeno-associated virus
Adeno-associated virus-mediated expression of apolipoprotein (a) kringles suppresses hepatocellular carcinoma growth in mice (Lee et al). 2006;43:1063-1073

Adenoma
Genotype-phenotype correlation in hepatocellular adenoma: New classification and relationship with HCC (Zucman-Rossi et al). 2006; 43:515-524
Hepatic adenomas: Presumed innocent until proven to be beta-catenin mutated (Monga). 2006;43:401-404 (Editorial)
Hepatology Highlights (Elias). 2006;43: 383-384

Adenosine triphosphate gene ATP8B1
Altered hepatobiliary gene expressions in PFIC1: ATP8B1 gene defect is associated with CFTR downregulation (Demeilliers et al). 2006;43:1125-1134

Adenosylmethionine
Adenosylmethionine and betaine correct hepatitis C virus induced inhibition of interferon signaling *in vitro* (Duong et al). 2006;43:796-806

Adenovirus
Adenovirus-mediated transfer of siRNA against PTTG1 inhibits liver cancer cell growth *in vitro* and *in vivo* (Jung et al). 2006;43:1042-1052

Adrenal insufficiency
Adrenal insufficiency in patients with cirrhosis, severe sepsis and septic shock (Tsai et al). 2006;43:673-681
Hepatology Highlights (Elias). 2006;43: 1175-1176

Adrenergic receptors
Influence of beta-2 adrenergic receptor gene polymorphism on the hemodynamic response to propranolol in patients with cirrhosis (Turnes et al). 2006;43:34-41

Alcohol
Alcohol and oxidative liver injury (Dey and Cederbaum). 2006;43:S63-S74
Hepatology Highlights (Elias). 2006;43: 383-384
Hepatology Highlights (Kaplowitz). 2006;43:207-208, 887-889

Alcohol dehydrogenase
Do alcohol-metabolizing enzyme gene polymorphisms increase the risk of alcoholism and alcoholic liver disease? (Zintzaras et al). 2006;43: 352-361

Alcoholic liver disease
Differential liver sensitization to Toll-like receptor pathways in mice with alcoholic fatty liver (Gustot et al). 2006;43:989-1000
Do alcohol-metabolizing enzyme gene polymorphisms increase the risk of alcoholism and alcoholic liver disease? (Zintzaras et al). 2006;43: 352-361
Hepatology Highlights (Elias). 2006;43: 383-384

Alcohol-induced hepatic fibrosis
Mechanisms of alcohol-induced hepatic fibrosis: A summary of the Ron Thurman symposium (Purohit and Brenner). 2006;43:872-878 (Special Article)

Alcoholism
Do alcohol-metabolizing enzyme gene polymorphisms increase the risk of

**January, 1-206; February 207-382; Supplement to February S1-S250; March, 383-642; April 643-886; May, 887-1174; June, 1175-1450.*

alcoholism and alcoholic liver disease? (Zintzaras et al). 2006;43: 352-361
Hepatology Highlights (Elias). 2006;43: 383-384

Ammonia
Brain metabolism of ^{13}N-ammonia during acute hepatic encephalopathy in cirrhosis measured by positron emission tomography (Keiding et al). 2006;43:42-50
Hepatology Highlights (Elias). 2006;43: 383-384

Angiogenesis
Overexpression of pituitary tumor transforming gene 1 in HCC is associated with angiogenesis and poor prognosis (Fujii et al). 2006; 43:1267-1275

Angiogenic factors
Effects of angiogenic factor overexpression by human and rodent cholangiocytes in polycystic liver diseases (Fabris et al). 2006;43: 1001-1012

Animal models
Adeno-associated virus-mediated expression of apolipoprotein (a) kringles suppresses hepatocellular carcinoma growth in mice (Lee et al). 2006;43:1063-1073
Anti-HCV therapies in chimeric *scid*-Alb/uPA mice parallel outcomes in human clinical application (Kneteman et al). 2006;43:1346-1353
Antiproliferative effects of interferon alpha on hepatic progenitor cells in vitro and in vivo (Lim et al). 2006; 43:1074-1083
Bicarbonate-rich choleresis induced by secretin in normal rat is taurocholate-dependent and involves AE2 anion exchanger (Banales et al). 2006;43:266-275
Bile salt toxicity aggravatae cold ischemic injury of bile ducts after liver transplantation in Mdr2+/- mice (Hoekstra et al). 2006;43: 1022-1031
Brain edema and inflammatory activation in bile duct ligated rats with diet-induced hyperammonemia: A model of hepatic encephalopathy in cirrhosis (Jover et al). 2006;43:1257-1266
CD4$^+$ T cells contribute to postischemic liver injury in mice by interacting with sinusoidal endothelium and platelets (Khandoga et al). 2006;43: 306-315
Changes in liver and plasma acetylcholinesterase in rats with cirrhosis induced by bile duct ligation (García-Ayllón et al). 2006; 43:444-453
Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33 (Tarr et al). 2006;43:592-601
COX-2 induction in mice with experimental nutritional steatohepatitis: Role as pro-inflammatory mediator (Yu et al). 2006;43:826-836
Deoxyribonuclease 1 aggravates acetaminophen-induced liver necrosis in male CD-1 mice (Napirei et al). 2006;43:297-305
Differential liver sensitization to Toll-like receptor pathways in mice with alcoholic fatty liver (Gustot et al). 2006;43:989-1000
Disruption of NaS1 sulfate transport function in mice leads to enhanced acetaminophen-induced hepatotoxicity (Lee et al). 2006;43: 1241-1247
Donor graft adenoviral iNOS gene transfer ameliorates rat liver transplant preservation injury and improves survival (Kaizu et al). 2006;43:464-473
Effects of angiogenic factor overexpression by human and rodent cholangiocytes in polycystic liver diseases (Fabris et al). 2006;43: 1001-1012
Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in *ob/ob* mice (Ding et al). 2006;43:173-181
Expression of rat renal cortical OAT1 and OAT3 in response to acute biliary obstruction (Brandoni et al). 2006;43:1092-1100
Functional modification of CD11c+ liver dendritic cells during liver regeneration after partial hepatectomy in mice (Castellaneta et al). 2006;43:807-816
Genomic response to interferon-α in chimpanzees: Implications of rapid downregulation for hepatitis C kinetics (Lanford et al). 2006;43: 961-972
Hematopoietic mobilization in mice increases the presence of bone marrow–derived hepatocytes via *in vivo* cell fusion (Quintana-Bustamante et al). 2006;43:108-116
Hepatocellular neoplasms after intrahepatic transplantation of ovarian fragments into ovariectomized rats (Dombrowski et al). 2006;43:857-867
Id1 is a critical mediator in TGF-β–induced transdifferentiation of rat hepatic stellate cells (Wiercinska et al). 2006;43:1032-1041
Interleukin-15 prevents concanavalin A-induced liver injury in mice via NKT cell-dependent mechanism (Li et al). 2006;43:1211-1219
Intestinal mucosal alterations in rats with carbon tetrachloride-induced cirrhosis: Changes in glycosylation and luminal bacteria (Natarajan et al). 2006;43:837-846
Isolation and characterization of lipid microdomains from apical and basolateral plasma membranes of rat hepatocytes (Mazzone et al). 2006; 43:287-296
JNK1 but not JNK2 promotes the development of steatohepatitis in mice (Schattenberg et al). 2006;43: 163-172
Liver endothelial cells promote LDL-R expression and the uptake of HCV-like particles in primary rat and human hepatocytes (Nahmias et al). 2006;43:257-265
Liver-specific loss of β-catenin blocks glutamine synthesis pathway activity and cytochrome P450 expression in mice (Sekine et al). 2006;43:817-825
Metabolic insights into the hepatoprotective role of *N*-acetylcysteine in mouse liver (Zwingmann and Bilodeau). 2006; 43:454-463
Mrp4−/− mice have an impaired cytoprotective response in obstructive cholestasis (Mennone et al). 2006;43:1013-1021
Neutrophil depletion protects against murine acetaminophen hepatotoxicity (Liu et al). 2006;43: 1220-1230
Nitration of cardiac proteins is associated with abnormal cardiac chronotropic responses in rats with biliary cirrhosis (Mani et al). 2006;43:847-856
NPC2 is expressed in human and murine liver and secreted into bile: Potential implications for body cholesterol homeostasis (Klein et al). 2006;43: 126-133
Nrf2 is increased by CYP2E1 in rodent liver and HepG2 cells and protects against oxidative stress caused by CYP2E1 (Gong and Cederbaum). 2006;43:144-153
Renal damage in experimentally induced cirrhosis in rats: Role of oxygen free radicals (Natarajan et al). 2006;43: 1248-1257
The sources of parenchymal regeneration after chronic hepatocellular liver injury in mice (Vig et al). 2006;43: 316-324
Targeted delivery of ribavirin improves outcome of murine viral fulminant hepatitis via enhanced anti-viral activity (Levy et al). 2006;43:581-591
Thermoreversible gelation polymer induces the emergence of hepatic

stem cells in the partially injured rat liver (Nagaya et al). 2006;43:1053-1062
Tightly regulated induction of the adhesion molecule Necl-5/CD155 during rat liver regeneration and acute liver injury (Erickson et al). 2006;43:325-334
TNF-α–secreting monocytes are recruited into the brain of cholestatic mice (Kerfoot et al). 2006;43:154-162
Zonal gene expression in murine liver: Lessons from tumors (Hailfinger et al). 2006;43:407-414

Anion exchanger AE2
Bicarbonate-rich choleresis induced by secretin in normal rat is taurocholate-dependent and involves AE2 anion exchanger (Banales et al). 2006;43:266-275

Antiretroviral therapy
CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice — Clinical implications for CCR5 inhibition as antiretroviral therapy (Mauss and Puoti). 2006;43:879 (Correspondence)
CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice — Clinical implications for CCR5 inhibition as antiretroviral therapy (Moreno et al). 2006;43:879-880 (Reply)

Antiviral therapy
Anti-HCV therapies in chimeric *scid*-Alb/uPA mice parallel outcomes in human clinical application (Kneteman et al). 2006;43:1346-1353
Caspase activation is required for antiviral treatment response in chronic hepatitis C virus infection (Volkmann et al). 2006;43:1311-1316
Tailoring antiviral therapy in hepatitis C (Davis). 2006;43:909-911 (Editorial)
Targeted delivery of ribavirin improves outcome of murine viral fulminant hepatitis via enhanced anti-viral activity (Levy et al). 2006;43:581-591
Therapy of hepatitis B — Viral suppression or eradication? (Perrillo). 2006;43:S182-S193
Therapy of hepatitis C: From empiricism to eradication (Pawlotsky). 2006;43:S207-S220

AP33
Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33 (Tarr et al). 2006;43:592-601

APACHE II (Acute Physiology and Chronic Health Evaluation)
King's criteria, APACHE II, and SOFA scores in acute liver failure (Cholongitas et al). 2006;43:881 (Correspondence)
King's criteria, APACHE II, and SOFA scores in acute liver failure (Larson et al). 2006;43:882 (Reply)

APOBEC3
Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication (Bonvin et al). 2006;43:1364-1374

Apolipoprotein (a) kringles
Adeno-associated virus-mediated expression of apolipoprotein (a) kringles suppresses hepatocellular carcinoma growth in mice (Lee et al). 2006;43:1063-1073

Apoptosis
Apoptosis and necrosis in the liver: A tale of two deaths? (Malhi et al). 2006;43:S31-S44
Hepatology Highlights (Kaplowitz). 2006;43:207-208
Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo (Zhan et al). 2006;43:435-443
Proteasome inhibition induces hepatic stellate cell apoptosis (Anan et al). 2006;43:335-344

Aquaporins
Aquaporins in the hepatobiliary system (Masyuk and LaRusso). 2006;43:S75-S81

Arterial embolization
Hepatitis after arterial embolization for hepatocellular carcinoma: Viral reactivation or ischemia? (Huo et al). 2006;43:1400-1401 (Correspondence)

Ascorbic acid
Ascorbic acid improves the intrahepatic endothelial dysfunction of patients with cirrhosis and portal hypertension (Hernández-Guerra et al). 2006;43:485-491

Autoimmune hepatitis
Autoimmune hepatitis, from mechanisms to therapy (Manns and Vogel). 2006;43:S132-S144
Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly (Czaja and Carpenter). 2006;43:532-538
Hepatology Highlights (Elias). 2006;43:383-384

B

B cells
Attenuated liver fibrosis in the absence of B cells (Holt et al). 2006;43:868-871 (Hepatology *Elsewhere*)
Quantitative analysis of anti–hepatitis C virus antibody–secreting B cells in patients with chronic hepatitis C (Umemura et al). 2006;43:91-99

Banding ligation
Is banding ligation for primary prevention of variceal bleeding as effective as beta-blockers, and is it safe? (Triantos et al). 2006;43:196-197 (Correspondence)

Beta-2 adrenergic receptor gene (β_2-AR)
Influence of beta-2 adrenergic receptor gene polymorphism on the hemodynamic response to propranolol in patients with cirrhosis (Turnes et al). 2006;43:34-41

Betaine
Adenosylmethionine and betaine correct hepatitis C virus induced inhibition of interferon signaling *in vitro* (Duong et al). 2006;43:796-806

Bicarbonate
Bicarbonate-rich choleresis induced by secretin in normal rat is taurocholate-dependent and involves AE2 anion exchanger (Banales et al). 2006;43:266-275

Bile acid synthesis
βKlotho: A new kid on the bile acid biosynthesis block (Arrese et al). 2006;43:191-193 (Hepatology *Elsewhere*)
Glucagon and cAMP inhibit cholesterol 7α-hydroxylase (CYP7A1) gene expression in human hepatocytes: Discordant regulation of bile acid synthesis and gluconeogenesis (Song and Chiang). 2006;43:117-125

Bile acids
Bile acids and cytokines inhibit the human cholesterol 7α-hydroxylase gene via the JNK/c-Jun pathway in human liver cells (Li et al). 2006;43:1202-1210

Bile duct ligation
Brain edema and inflammatory activation in bile duct ligated rats with diet-induced hyperammonemia: A model of hepatic encephalopathy in cirrhosis (Jover et al). 2006;43:1257-1266
Changes in liver and plasma acetylcholinesterase in rats with cirrhosis induced by bile duct ligation (García-Ayllón et al). 2006;43:444-453
Hepatology Highlights (Kaplowitz). 2006;43:207-208, 887-889

Bile salt toxicity
Bile salt toxicity aggravatae cold ischemic injury of bile ducts after liver transplantation in Mdr2+/− mice (Hoekstra et al). 2006;43:1022-1031

Biliary atresia
Neonatal screening for biliary atresia

(Hoofnagle and Sokol). 2006;43: 646 (This Month from the NIH)

Biliary cirrhosis
Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC (Corpechot et al). 2006; 43:1118-1124
Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis (Wesierska-Gadek et al). 2006;43:1135-1144
Increased prevalence of primary biliary cirrhosis near Superfund toxic waste sites (Ala et al). 2006;43:525-531
Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis (Lan et al). 2006;43:729-737
Methotrexate for treatment of primary biliary cirrhosis (Bonis and Kaplan). 2006;43:632 (Correspondence)
Methotrexate for treatment of primary biliary cirrhosis (Combes and Emerson). 2006;43:632-633 (Reply)
Nitration of cardiac proteins is associated with abnormal cardiac chronotropic responses in rats with biliary cirrhosis (Mani et al). 2006;43:847-856
A novel multidrug-resistance protein 2 gene mutation identifies a subgroup of patients with primary biliary cirrhosis and pruritus (Floreani et al). 2006;43:1152-1154 (Concise Communication)
Polluting the pathogenesis of primary biliary cirrhosis (Talwalkar and Lazaridis). 2006;43:398-400 (Editorial)
Reflections on therapeutic trials in primary biliary cirrhosis: A quality of life oriented counter-view (Jones et al). 2006;43:633 (Correspondence)

Biliary fibrosis
Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC (Corpechot et al). 2006; 43:1118-1124

Biliary obstruction, acute
Expression of rat renal cortical OAT1 and OAT3 in response to acute biliary obstruction (Brandoni et al). 2006;43:1092-1100

Bone marrow-derived hepatocytes
Hematopoietic mobilization in mice increases the presence of bone marrow–derived hepatocytes via in vivo cell fusion (Quintana-Bustamante et al). 2006;43:108-116

Brain edema
Brain edema and inflammatory activation in bile duct ligated rats with diet-induced hyperammonemia: A model of hepatic encephalopathy in cirrhosis (Jover et al). 2006;43:1257-1266

Budd-Chiari syndrome
Systemic hemodynamics, vasoactive systems, and plasma volume in patients with severe Budd-Chiari syndrome (Hernández-Guerra et al). 2006;43:27-33

C

Cardiac proteins
Nitration of cardiac proteins is associated with abnormal cardiac chronotropic responses in rats with biliary cirrhosis (Mani et al). 2006;43:847-856

Cardif
Cardif: A protein central to innate immunity is inactivated by the HCV NS3 serine protease (Evans and Seeger). 2006;43:615-617 (Hepatology Elsewhere)

Caspase
Caspase activation is required for antiviral treatment response in chronic hepatitis C virus infection (Volkmann et al). 2006;43:1311-1316

β-catenin
Enhanced cell survival of Hep3B cells by the hepatitis B x antigen effector, URG11, is associated with upregulation of β-catenin (Lian et al). 2006;43:415-424
Hepatic adenomas: Presumed innocent until proven to be beta-catenin mutated (Monga). 2006;43:401-404 (Editorial)
Liver-specific loss of β-catenin blocks glutamine synthesis pathway activity and cytochrome P450 expression in mice (Sekine et al). 2006;43:817-825
Role of β-catenin in the adult liver (Gonzalez). 2006;43:650-653 (Editorial)

Caveolin-1
LPS inhibits endothelin-1–induced endothelial NOS activation in hepatic sinusoidal cells through a negative feedback involving caveolin-1 (Kamoun et al). 2006;43: 182-190

CCAAT/enhancer-binding protein α (C/EBPα)
C/EBPα and HNF6 protein complex formation stimulates HNF6-dependent transcription by CBP coactivator recruitment in HepG2 cells (Yoshida et al). 2006;43:276-286

CD-1
Deoxyribonuclease 1 aggravates acetaminophen-induced liver necrosis in male CD-1 mice (Napirei et al). 2006;43:297-305
Hepatology Highlights (Kaplowitz). 2006;43:207-208

CD4
$CD4^+$ T cells contribute to postischemic liver injury in mice by interacting with sinusoidal endothelium and platelets (Khandoga et al). 2006;43: 306-315

CD8
Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution (Neumann-Haefelin et al). 2006;43:563-572

CD11c
Functional modification of CD11c+ liver dendritic cells during liver regeneration after partial hepatectomy in mice (Castellaneta et al). 2006;43:807-816

CD95 ligand
Hepatocytes as cytotoxic effector cells can induce cell death by CD95 ligand-mediated pathway (Guy et al). 2006;43:1231-1240

CD155
Tightly regulated induction of the adhesion molecule Necl-5/CD155 during rat liver regeneration and acute liver injury (Erickson et al). 2006;43:325-334

Cell differentiation
Id1 is a critical mediator in TGF-β–induced transdifferentiation of rat hepatic stellate cells (Wiercinska et al). 2006;43:1032-1041

Cell growth
Adenovirus-mediated transfer of siRNA against PTTG1 inhibits liver cancer cell growth *in vitro* and *in vivo* (Jung et al). 2006;43:1042-1052

Cell proliferation
Antiproliferative effects of interferon alpha on hepatic progenitor cells *in vitro* and *in vivo* (Lim et al). 2006; 43:1074-1083

Cerebral edema
Brain edema and inflammatory activation in bile duct ligated rats with diet-induced hyperammonemia: A model of hepatic encephalopathy in cirrhosis (Jover et al). 2006;43:1257-1266
Demonstration of interstitial cerebral edema with diffusion tensor MR imaging in type C hepatic encephalopathy (Kale et al). 2006; 43:698-706
Low grade cerebral edema and the pathogenesis of hepatic encephalopathy in cirrhosis (Häussinger). 2006;43:1187-1190 (Editorial)

Chemo-lipiodolization
A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-

lipiodolization (Jang et al). 2006;43:233-240

Children
Chronic hepatitis B in children after e antigen seroclearance: Final report of a 29-year longitudinal study (Bortolotti et al). 2006;43:556-562
Hepatocellular carcinoma in a 12-year-old child with PiZZ α1-antitrypsin deficiency (Hadzic et al). 2006;43:194 (Correspondence)
Hepatology Highlights (Elias). 2006;43:1175-1176
Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B (Sokal et al). 2006;43:225-232

Cholangiocytes
Effects of angiogenic factor overexpression by human and rodent cholangiocytes in polycystic liver diseases (Fabris et al). 2006;43:1001-1012

Cholangitis, sclerosing
Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC (Corpechot et al). 2006;43:1118-1124

Cholecystectomy
Ursodeoxycholic acid exerts no beneficial effects in patients with symptomatic gallstones awaiting cholecystectomy (Venneman et al). 2006;43:1276-1283

Choleresis
Bicarbonate-rich choleresis induced by secretin in normal rat is taurocholate-dependent and involves AE2 anion exchanger (Banales et al). 2006;43:266-275

Cholestasis
Hepatology Highlights (Kaplowitz). 2006;43:207-208
TNF-α–secreting monocytes are recruited into the brain of cholestatic mice (Kerfoot et al). 2006;43:154-162

Cholestasis, chronic
Sickness behaviors in chronic cholestasis: An immune-mediated process? (Aspinall and Adams). 2006;43:20-23 (Editorial)

Cholestasis, intrahepatic
Altered hepatobiliary gene expressions in PFIC1: ATP8B1 gene defect is associated with CFTR downregulation (Demeilliers et al). 2006;43:1125-1134
Hepatology Highlights (Elias). 2006;43:383-384, 1175-1176
Intrahepatic cholestasis of pregnancy — A heterogeneous group of pregnancy-related disorders? (Beuers and Pusl). 2006;43:647-649 (Editorial)
Intrahepatic cholestasis of pregnancy as an indicator of liver and biliary diseases: A population-based study (Ropponen et al). 2006;43:723-728
Is a leaky gut involved in the pathogenesis of intrahepatic cholestasis of pregnancy? (Reyes et al). 2006;43:715-722

Cholestasis, obstructive
Mrp4−/− mice have an impaired cytoprotective response in obstructive cholestasis (Mennone et al). 2006;43:1013-1021

Cholestatic pruritus
Nasobiliary drainage for cholestatic pruritus (Hofmann and Huet). 2006;43:1170-1171 (Correspondence)

Cholesterol
NPC2 is expressed in human and murine liver and secreted into bile: Potential implications for body cholesterol homeostasis (Klein et al). 2006;43:126-133

Cholesterol 7α-hydroxylase
Bile acids and cytokines inhibit the human cholesterol 7α-hydroxylase gene via the JNK/c-Jun pathway in human liver cells (Li et al). 2006;43:1202-1210
Glucagon and cAMP inhibit cholesterol 7α-hydroxylase (CYP7A1) gene expression in human hepatocytes: Discordant regulation of bile acid synthesis and gluconeogenesis (Song and Chiang). 2006;43:117-125

Chromosomal translocation t(14;18)
Association between mixed cryoglobulinemia, translocation (14;18), and persistence of occult HCV lymphoid infection after treatment (Giannini et al). 2006;43:1166-1167 (Correspondence)
Association between mixed cryoglobulinemia, translocation (14;18), and persistence of occult HCV lymphoid infection after treatment (Sansonno et al). 2006;43:1167-1168 (Reply)

Chronic cholestasis
Sickness behaviors in chronic cholestasis: An immune-mediated process? (Aspinall and Adams). 2006;43:20-23 (Editorial)

Chronic hepatitis B
A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B (Lee et al). 2006;43:982-988
Chronic hepatitis B in children after e antigen seroclearance: Final report of a 29-year longitudinal study (Bortolotti et al). 2006;43:556-562
Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy (Lee et al). 2006;43:1385-1391
Interferon α-2b with and without ribavirin in the treatment of hepatitis B e antigen–positive chronic hepatitis B: A randomized study (Liu et al). 2006;43:742-749
Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B (Sokal et al). 2006;43:225-232
Mannose-binding lectin in chronic hepatitis B virus infection (Chong et al). 2006;43:199 (Correction)
Natural history of chronic hepatitis B virus infection: What we knew in 1981 and what we know in 2005 (Yim and Lok). 2006;43:S173-S181
Therapy of hepatitis B — Viral suppression or eradication? (Perrillo). 2006;43:S182-S193

Chronic hepatitis C
Caspase activation is required for antiviral treatment response in chronic hepatitis C virus infection (Volkmann et al). 2006;43:1311-1316
Cryoglobulinemia is associated with steatosis and fibrosis in chronic hepatitis C (Saadoun et al). 2006;43:1337-1345
Decreased NK cell frequency in chronic hepatitis C does not affect *ex vivo* cytolytic killing (Morishima et al). 2006;43:573-580
Development and validation of two models for early prediction of response to therapy in genotype 1 chronic hepatitis C (Martínez-Bauer et al). 2006;43:72-80
HLA class I allelic diversity and progression of fibrosis in patients with chronic hepatitis C (Patel et al). 2006;43:241-249
Impact of obesity on treatment of chronic hepatitis C (Charlton et al). 2006;43:1177-1186 (Perspectives in Clinical Hepatology)
Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C (Cammà et al). 2006;43:64-71
Keratin variants associate with progression of fibrosis during chronic hepatitis C infection (Strnad et al). 2006;43:1354-1363
Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C (Iwasaki et al). 2006;43:54-63
Noninvasive diagnosis of cirrhosis in chronic hepatitis C based on standard laboratory tests (Lackner et al). 2006;43:378-379 (Correspondence)
Progression of liver fibrosis among injection drug users with chronic hepatitis C (Wilson et al). 2006;43:788-795
Quantitative analysis of anti–hepatitis C

virus antibody–secreting B cells in patients with chronic hepatitis C (Umemura et al). 2006;43:91-99
Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection (Perumalswami et al). 2006;43:780-787
Therapy of hepatitis C: From empiricism to eradication (Pawlotsky). 2006;43: S207-S220

Chronic liver disease
The hyperdynamic circulation of chronic liver diseases: From the patient to the molecule (Iwakiri and Groszmann). 2006;43:S121-S131

Chronotropic response
Nitration of cardiac proteins is associated with abnormal cardiac chronotropic responses in rats with biliary cirrhosis (Mani et al). 2006;43:847-856

Circulation, hyperdynamic
The hyperdynamic circulation of chronic liver diseases: From the patient to the molecule (Iwakiri and Groszmann). 2006;43:S121-S131

Cirrhosis. *See also* Biliary cirrhosis
Adrenal insufficiency in patients with cirrhosis, severe sepsis and septic shock (Tsai et al). 2006;43:673-681
Ascorbic acid improves the intrahepatic endothelial dysfunction of patients with cirrhosis and portal hypertension (Hernández-Guerra et al). 2006;43:485-491
Brain edema and inflammatory activation in bile duct ligated rats with diet-induced hyperammonemia: A model of hepatic encephalopathy in cirrhosis (Jover et al). 2006;43:1257-1266
Brain metabolism of ^{13}N-ammonia during acute hepatic encephalopathy in cirrhosis measured by positron emission tomography (Keiding et al). 2006;43:42-50
Changes in liver and plasma acetylcholinesterase in rats with cirrhosis induced by bile duct ligation (García-Ayllón et al). 2006; 43:444-453
Hepatology Highlights (Elias). 2006;43: 1175-1176
Influence of beta-2 adrenergic receptor gene polymorphism on the hemodynamic response to propranolol in patients with cirrhosis (Turnes et al). 2006;43:34-41
Intestinal mucosal alterations in rats with carbon tetrachloride-induced cirrhosis: Changes in glycosylation and luminal bacteria (Natarajan et al). 2006;43:837-846
Low grade cerebral edema and the pathogenesis of hepatic encephalopathy in cirrhosis (Häussinger). 2006;43:1187-1190 (Editorial)
Nonalcoholic fatty liver disease: From steatosis to cirrhosis (Farrell and Larter). 2006;43:S99-S112
Noninvasive diagnosis of cirrhosis in chronic hepatitis C based on standard laboratory tests (Lackner et al). 2006;43:378-379 (Correspondence)
Renal damage in experimentally induced cirrhosis in rats: Role of oxygen free radicals (Natarajan et al). 2006;43: 1248-1257
Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C (Sanyal et al). 2006;43:682-689
Systemic effects of TNF-α secreted by circulating monocytes and fatigue in cirrhosis (Albillos et al). 2006;43: 1399 (Correspondence)
Systemic effects of TNF-α secreted by circulating monocytes and fatigue in cirrhosis (Kerfoot et al). 2006;43: 1399-1400 (Reply)
The use of vasoconstrictors in patients with cirrhosis: Type 1 HRS and beyond (Moreau and Lebrec). 2006; 43:385-394 (Perspectives in Clinical Hepatology)

Cirrhosis, compensated
The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients (Sangiovanni et al). 2006;43:1303-1310

c-Jun N-terminal kinase
Bile acids and cytokines inhibit the human cholesterol 7α-hydroxylase gene via the JNK/c-Jun pathway in human liver cells (Li et al). 2006;43: 1202-1210

Clevudine
A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B (Lee et al). 2006;43:982-988

Cold ischemic injury
Bile salt toxicity aggravataes cold ischemic injury of bile ducts after liver transplantation in Mdr2+/− mice (Hoekstra et al). 2006;43: 1022-1031

Concanavalin A
Interleukin-15 prevents concanavalin A-induced liver injury in mice via NKT cell-dependent mechanism (Li et al). 2006;43:1211-1219

Coronary heart disease
Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States (Ioannou et al). 2006;43: 1145-1151

CREB binding protein
C/EBPα and HNF6 protein complex formation stimulates HNF6-dependent transcription by CBP coactivator recruitment in HepG2 cells (Yoshida et al). 2006;43:276-286

Cryoglobulinemia
Association between mixed cryoglobulinemia, translocation (14; 18), and persistence of occult HCV lymphoid infection after treatment (Giannini et al). 2006;43:1166-1167 (Correspondence)
Association between mixed cryoglobulinemia, translocation (14; 18), and persistence of occult HCV lymphoid infection after treatment (Sansonno et al). 2006;43:1167-1168 (Reply)
Cryoglobulinemia is associated with steatosis and fibrosis in chronic hepatitis C (Saadoun et al). 2006; 43:1337-1345

Cyclic adenosine monophosphate (cAMP)
Glucagon and cAMP inhibit cholesterol 7α-hydroxylase (CYP7A1) gene expression in human hepatocytes: Discordant regulation of bile acid synthesis and gluconeogenesis (Song and Chiang). 2006;43:117-125

Cyclic AMP response element binding protein
C/EBPα and HNF6 protein complex formation stimulates HNF6-dependent transcription by CBP coactivator recruitment in HepG2 cells (Yoshida et al). 2006;43:276-286

Cyclooxygenase 2
COX-2 induction in mice with experimental nutritional steatohepatitis: Role as pro-inflammatory mediator (Yu et al). 2006;43:826-836

Cyclosporin DEBIO-025
The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro (Paeshuyse et al). 2006;43:761-770

Cyclosporin-A
Hepatology Highlights (Alter). 2006;43: 643-645

Cystic fibrosis
Coinheritance of Gilbert syndrome–associated *UGT1A1* mutation increases gallstone risk in cystic fibrosis (Wasmuth et al). 2006;43: 738-741 (Concise Communication)

Cystic fibrosis transmembrane conductance regulator (CFTR)
Altered hepatobiliary gene expressions in PFIC1: ATP8B1 gene defect is associated with CFTR downregulation (Demeilliers et al). 2006;43:1125-1134

Cytochrome P450
Liver-specific loss of β-catenin blocks glutamine synthesis pathway activity

and cytochrome P450 expression in mice (Sekine et al). 2006;43:817-825

Cytochrome P450 2E1
Do alcohol-metabolizing enzyme gene polymorphisms increase the risk of alcoholism and alcoholic liver disease? (Zintzaras et al). 2006;43:352-361
Nrf2 is increased by CYP2E1 in rodent liver and HepG2 cells and protects against oxidative stress caused by CYP2E1 (Gong and Cederbaum). 2006;43:144-153

Cytochrome P450 7A1
Glucagon and cAMP inhibit cholesterol 7α-hydroxylase (CYP7A1) gene expression in human hepatocytes: Discordant regulation of bile acid synthesis and gluconeogenesis (Song and Chiang). 2006;43:117-125

Cytotoxic T lymphocytes
Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma (Mizukoshi et al). 2006;43:1284-1294

Cytotoxicity
Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans (Ishiyama et al). 2006;43:362-372

D

Databases
Hepatitis C databases, principles and utility to researchers (Kuiken et al). 2006;43:1157-1165 (Special Article)

DEBIO-025
The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro (Paeshuyse et al). 2006;43:761-770

Dendritic cells
Dendritic cells take up viral antigens but do not support the early steps of hepatitis B virus infection (Untergasser et al). 2006;43:539-547
Functional modification of CD11c+ liver dendritic cells during liver regeneration after partial hepatectomy in mice (Castellaneta et al). 2006;43:807-816

Deoxyribonuclease 1
Deoxyribonuclease 1 aggravates acetaminophen-induced liver necrosis in male CD-1 mice (Napirei et al). 2006;43:297-305
Hepatology Highlights (Kaplowitz). 2006;43:207-208

Diabetes, type 2
Type 2 diabetes and hepatocellular carcinoma: A cohort study in high prevalence area of hepatitis virus infection (Lai et al). 2006;43:1295-1302

Diet-induced hyperammonemia
Brain edema and inflammatory activation in bile duct ligated rats with diet-induced hyperammonemia: A model of hepatic encephalopathy in cirrhosis (Jover et al). 2006;43:1257-1267

Diffusion-weighted imaging
Demonstration of interstitial cerebral edema with diffusion tensor MR imaging in type C hepatic encephalopathy (Kale et al). 2006;43:698-706

E

Egypt
Liver disease in Egypt: Hepatitis C superseded schistosomiasis as a result of iatrogenic and biological factors (Strickland). 2006;43:915-922 (Perspectives in Clinical Hepatology)

Elastography, transient
Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC (Corpechot et al). 2006;43:1118-1124

Elderly
Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly (Czaja and Carpenter). 2006;43:532-538

Endoscopy
Endoscopy critics vs. endoscopy enthusiasts for primary prophylaxis of variceal bleeding (de Franchis). 2006;43:24-26 (Editorial)
A randomized trial of endoscopic treatment of acute gastric variceal hemorrhage: N-butyl-2-cyanoacrylate injection versus band ligation (Tan et al). 2006;43:690-697, 1410 (Correction)

Endothelial cells
Liver endothelial cells promote LDL-R expression and the uptake of HCV-like particles in primary rat and human hepatocytes (Nahmias et al). 2006;43:257-265

Endothelial dysfunction
Ascorbic acid improves the intrahepatic endothelial dysfunction of patients with cirrhosis and portal hypertension (Hernández-Guerra et al). 2006;43:485-491

Endothelin-1
LPS inhibits endothelin-1–induced endothelial NOS activation in hepatic sinusoidal cells through a negative feedback involving caveolin-1 (Kamoun et al). 2006;43:182-190

Eppinger, Hans
First do no harm (Reuben). 2006;43:S243-S249 (Landmarks in Hepatology)

Esophageal varices
Improved prognosis for patients hospitalized with esophageal varices in Sweden 1969-2002 (Stokkeland et al). 2006;43:500-505

Ethics
Ethical, Social and legal implications of genetic testing in liver disease (van Leeuwen and Bernat). 2006;43:1195-1201 (Sounding Board)
First do no harm (Reuben). 2006;43:S243-S249 (Landmarks in Hepatology)

European hepatitis C virus database
Hepatitis C databases, principles and utility to researchers (Kuiken et al). 2006;43:1157-1165 (Special Article)

Exendin-4
Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice (Ding et al). 2006;43:173-181

F

Familial intrahepatic cholestasis, progressive
Altered hepatobiliary gene expressions in PFIC1: ATP8B1 gene defect is associated with CFTR downregulation (Demeilliers et al). 2006;43:1125-1134
Hepatology Highlights (Elias). 2006;43:1175-1176

Familial intrahepatic cholestasis 1 (FIC1)
Altered hepatobiliary gene expressions in PFIC1: ATP8B1 gene defect is associated with CFTR downregulation (Demeilliers et al). 2006;43:1125-1134
Hepatology Highlights (Elias). 2006;43:1175-1176

FasL
Hepatocytes as cytotoxic effector cells can induce cell death by CD95 ligand-mediated pathway (Guy et al). 2006;43:1231-1240

Fetal hemochromatosis
Fetal and infantile hemochromatosis (Whitington). 2006;43:654-660 (Concise Review in Mechanisms of Disease)

FIB-4
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection (Sterling et al). 2006;43:1317-1325

FibroScan
FibroScan and FibroTest to assess liver fibrosis in HCV with normal aminotransferases (Castera et al). 2006;43:373-374 (Correspondence)

Fibrosis
Assessment of biliary fibrosis by transient

elastography in patients with PBC and PSC (Corpechot et al). 2006; 43:1118-1124
Association between postprandial LDL conjugated dienes and the severity of liver fibrosis in NASH (Cassader et al). 2006;43:1169-1170 (Correspondence)
Attenuated liver fibrosis in the absence of B cells (Holt et al). 2006;43:868-871 (Hepatology *Elsewhere*)
Cryoglobulinemia is associated with steatosis and fibrosis in chronic hepatitis C (Saadoun et al). 2006; 43:1337-1345
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection (Sterling et al). 2006;43: 1317-1325
Hepatology Highlights (Alter). 2006;43: 643-645
Hepatology Highlights (Kaplowitz). 2006;43:207-208
HLA class I allelic diversity and progression of fibrosis in patients with chronic hepatitis C (Patel et al). 2006;43:241-249
Keratin variants associate with progression of fibrosis during chronic hepatitis C infection (Strnad et al). 2006;43:1354-1363
Magnetic resonance and ultrasound techniques for the evaluation of hepatic fibrosis (Cobbold et al). 2006;43:1401-1402 (Correspondence)
Magnetic resonance and ultrasound techniques for the evaluation of hepatic fibrosis (Rockey and Bissell). 2006;43:1402 (Reply)
Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo (Zhan et al). 2006;43:435-443
Progression of fibrosis in hepatitis C with and without schistosomiasis: Correlation with serum markers of fibrosis (Kamal et al). 2006;43:771-779
Progression of liver fibrosis among injection drug users with chronic hepatitis C (Wilson et al). 2006;43: 788-795
Reassessment of the algorithm for prediction of liver fibrosis in patients with features of the metabolic syndrome (Lainé et al). 2006;43: 377-378 (Correspondence)
Reversal of hepatic fibrosis — Fact or fantasy? (Friedman and Bansal). 2006;43:S82-S88
Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection (Perumalswami et al). 2006;43:780-787

Fibrosis, alcohol-induced
Mechanisms of alcohol-induced hepatic fibrosis: A summary of the Ron Thurman symposium (Purohit and Brenner). 2006;43:872-878 (Special Article)

Fibrosis measurement
Diagnostic value of FibroTest with normal serum aminotransferases (Colletta et al). 2006;43:375-376 (Reply)
Diagnostic value of FibroTest with normal serum aminotransferases (Poynard et al). 2006;43:374-375 (Correspondence)
FibroScan and FibroTest to assess liver fibrosis in HCV with normal aminotransferases (Castera et al). 2006;43:373-374 (Correspondence)
Noninvasive measures of liver fibrosis (Rockey and Bissell). 2006;43:S113-S120

FibroTest
Diagnostic value of FibroTest with normal serum aminotransferases (Colletta et al). 2006;43:375-376 (Reply)
Diagnostic value of FibroTest with normal serum aminotransferases (Poynard et al). 2006;43:374-375 (Correspondence)
FibroScan and FibroTest to assess liver fibrosis in HCV with normal aminotransferases (Castera et al). 2006;43:373-374 (Correspondence)

Fulminant hepatitis
Targeted delivery of ribavirin improves outcome of murine viral fulminant hepatitis via enhanced anti-viral activity (Levy et al). 2006;43:581-591

G

Gallstones
Coinheritance of Gilbert syndrome–associated *UGT1A1* mutation increases gallstone risk in cystic fibrosis (Wasmuth et al). 2006;43: 738-741 (Concise Communication)
Ursodeoxycholic acid exerts no beneficial effects in patients with symptomatic gallstones awaiting cholecystectomy (Venneman et al). 2006;43:1276-1283

Gastric variceal hemorrhage, acute
A randomized trial of endoscopic treatment of acute gastric variceal hemorrhage: N-butyl-2-cyanoacrylate injection versus band ligation (Tan et al). 2006;43:690-697, 1410 (Correction)

Gaze, disconjugate
Intermittent disconjugate gaze: A novel finding in nonalcoholic steatohepatitis (Al-Osaimi and Caldwell). 2006;43:883 (Reply)
Intermittent disconjugate gaze: A novel finding in nonalcoholic steatohepatitis (Schartman and Weinstein). 2006;43:882-883 (Correspondence)

Gene expression
Altered hepatobiliary gene expressions in PFIC1: ATP8B1 gene defect is associated with CFTR downregulation (Demeilliers et al). 2006;43:1125-1134
Zonal gene expression in murine liver: Lessons from tumors (Hailfinger et al). 2006;43:407-414

Gene polymorphisms
Do alcohol-metabolizing enzyme gene polymorphisms increase the risk of alcoholism and alcoholic liver disease? (Zintzaras et al). 2006;43: 352-361
Hepatology Highlights (Elias). 2006;43: 383-384
Influence of beta-2 adrenergic receptor gene polymorphism on the hemodynamic response to propranolol in patients with cirrhosis (Turnes et al). 2006;43:34-41

Gene transfer
Adenovirus-mediated transfer of siRNA against PTTG1 inhibits liver cancer cell growth in vitro and in vivo (Jung et al). 2006;43:1042-1052
Donor graft adenoviral iNOS gene transfer ameliorates rat liver transplant preservation injury and improves survival (Kaizu et al). 2006;43:464-473

Genetic testing
Ethical, Social and legal implications of genetic testing in liver disease (van Leeuwen and Bernat). 2006;43: 1195-1201 (Sounding Board)

Genomics
Functional genomics of hepatocellular carcinoma (Thorgeirsson et al). 2006;43:S145-S150
Genomic response to interferon-α in chimpanzees: Implications of rapid downregulation for hepatitis C kinetics (Lanford et al). 2006;43: 961-972

Genotype
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40kd)/ribavirin therapy (Jensen et al). 2006;43:954-960, 1410 (Correction)
Impact of the hepatitis B virus genotype and genotype mixtures on the course of liver disease in Vietnam (Toan et al). 2006;43:1375-1384

Genotype 1 chronic hepatitis C
Development and validation of two models for early prediction of response to therapy in genotype 1

chronic hepatitis C (Martínez-Bauer et al). 2006;43:72-80
Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C (Cammà et al). 2006;43:64-71

Genotype-phenotype correlations
Genotype-phenotype correlation in hepatocellular adenoma: New classification and relationship with HCC (Zucman-Rossi et al). 2006; 43:515-524

Gilbert syndrome
Coinheritance of Gilbert syndrome–associated *UGT1A1* mutation increases gallstone risk in cystic fibrosis (Wasmuth et al). 2006;43: 738-741 (Concise Communication)

Glucagon
Glucagon and cAMP inhibit cholesterol 7α-hydroxylase (CYP7A1) gene expression in human hepatocytes: Discordant regulation of bile acid synthesis and gluconeogenesis (Song and Chiang). 2006;43:117-125

Gluconeogenesis
Glucagon and cAMP inhibit cholesterol 7α-hydroxylase (CYP7A1) gene expression in human hepatocytes: Discordant regulation of bile acid synthesis and gluconeogenesis (Song and Chiang). 2006;43:117-125

Glycosylation
Intestinal mucosal alterations in rats with carbon tetrachloride-induced cirrhosis: Changes in glycosylation and luminal bacteria (Natarajan et al). 2006;43:837-846

Granulocyte colony-stimulating factor
Hematopoietic mobilization in mice increases the presence of bone marrow–derived hepatocytes via in vivo cell fusion (Quintana-Bustamante et al). 2006;43:108-116

H

Hematopoietic cells
Hematopoietic cells as hepatocyte stem cells: A critical review of the evidence (Thorgeirsson and Grisham). 2006;43:2-8 (Science Frontier)

Hemochromatosis
Fetal and infantile hemochromatosis (Whitington). 2006;43:654-660 (Concise Review in Mechanisms of Disease)

Hemodynamics
Systemic hemodynamics, vasoactive systems, and plasma volume in patients with severe Budd-Chiari syndrome (Hernández-Guerra et al). 2006;43:27-33

Hep3B cells
Enhanced cell survival of Hep3B cells by' the hepatitis B x antigen effector, URG11, is associated with upregulation of β-catenin (Lian et al). 2006;43:415-424

Hepatectomy, partial
Functional modification of CD11c+ liver dendritic cells during liver regeneration after partial hepatectomy in mice (Castellaneta et al). 2006;43:807-816

Hepatic encephalopathy
Brain edema and inflammatory activation in bile duct ligated rats with diet-induced hyperammonemia: A model of hepatic encephalopathy in cirrhosis (Jover et al). 2006;43:1257-1266
Demonstration of interstitial cerebral edema with diffusion tensor MR imaging in type C hepatic encephalopathy (Kale et al). 2006; 43:698-706
Hepatology Highlights (Elias). 2006;43: 383-384
Low grade cerebral edema and the pathogenesis of hepatic encephalopathy in cirrhosis (Häussinger). 2006;43:1187-1190 (Editorial)
Noncirrhotic portal vein thrombosis exhibits neuropsychological and MR changes consistent with minimal hepatic encephalopathy (Mínguez et al). 2006;43:707-714
Prevention of first overt episode of hepatic encephalopathy after TIPS: No easy task (Mullen et al). 2006; 43:1155-1156 (Hepatology *Elsewhere*)

Hepatic encephalopathy, acute
Brain metabolism of ^{15}N-ammonia during acute hepatic encephalopathy in cirrhosis measured by positron emission tomography (Keiding et al). 2006;43:42-50

Hepatic venous pressure gradient
Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation (Blasco et al). 2006; 43:492-499

Hepatitis
Type 2 diabetes and hepatocellular carcinoma: A cohort study in high prevalence area of hepatitis virus infection (Lai et al). 2006;43:1295-1302

Hepatitis, autoimmune
Autoimmune hepatitis, from mechanisms to therapy (Manns and Vogel). 2006;43:S132-S144
Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly (Czaja and Carpenter). 2006;43: 532-538
Hepatology Highlights (Elias). 2006;43: 383-384

Hepatitis, fulminant
Targeted delivery of ribavirin improves outcome of murine viral fulminant hepatitis via enhanced anti-viral activity (Levy et al). 2006;43:581-591

Hepatitis A vaccine
Hepatitis A virus: From discovery to vaccines (Martin and Lemon). 2006; 43:S164-S172

Hepatitis A virus
Hepatitis A virus: From discovery to vaccines (Martin and Lemon). 2006; 43:S164-S172

Hepatitis B
Dendritic cells take up viral antigens but do not support the early steps of hepatitis B virus infection (Untergasser et al). 2006;43:539-547
Signal transduction cascades and hepatitis B and C related hepatocellular carcinoma (Branda and Wands). 2006;43:891-902 (Science Frontier)

Hepatitis B, chronic
A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B (Lee et al). 2006;43:982-988
Chronic hepatitis B in children after e antigen seroclearance: Final report of a 29-year longitudinal study (Bortolotti et al). 2006;43:556-562
Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy (Lee et al). 2006;43:1385-1391
Interferon α-2b with and without ribavirin in the treatment of hepatitis B e antigen–positive chronic hepatitis B: A randomized study (Liu et al). 2006;43:742-749
Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B (Sokal et al). 2006;43:225-232
Mannose-binding lectin in chronic hepatitis B virus infection (Chong et al). 2006;43:199 (Correction)
Natural history of chronic hepatitis B virus infection: What we knew in 1981 and what we know in 2005 (Yim and Lok). 2006;43:S173-S181
Therapy of hepatitis B — Viral suppression or eradication? (Perrillo). 2006;43:S182-S193

Hepatitis B e antigen
A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B (Lee et al). 2006;43:982-988
Chronic hepatitis B in children after e antigen seroclearance: Final report of a 29-year longitudinal study (Bortolotti et al). 2006;43:556-562
Interferon α-2b with and without

ribavirin in the treatment of hepatitis B e antigen–positive chronic hepatitis B: A randomized study (Liu et al). 2006;43:742-749
Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B (Sokal et al). 2006;43:225-232

Hepatitis B virus

Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients (Benhamou et al). 2006;43:548-555
Characterization of a hepatitis B and hepatitis delta virus receptor binding site (Engelke et al). 2006;43:750-760
Dendritic cells take up viral antigens but do not support the early steps of hepatitis B virus infection (Untergasser et al). 2006;43:539-547
Impact of the hepatitis B virus genotype and genotype mixtures on the course of liver disease in Vietnam (Toan et al). 2006;43:1375-1384
Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication (Bonvin et al). 2006;43:1364-1374
Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis virus–coinfected patients (Raimondo et al). 2006;43:100-107
Natural history of chronic hepatitis B virus infection: What we knew in 1981 and what we know in 2005 (Yim and Lok). 2006;43:S173-S181
Therapy of hepatitis B — Viral suppression or eradication? (Perrillo). 2006;43:S182-S193

Hepatitis B virus reactivation

Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy (Yeo and Johnson). 2006;43:209-220 (Concise Review in Mechanisms of Disease)
A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemolipiodolization (Jang et al). 2006;43:233-240
What is really ongoing during occult HBV reactivation? (Chemin et al). 2006;43:195 (Correspondence)
What is really ongoing during occult HBV reactivation? (Günther and Hass). 2006;43:195-196 (Reply)

Hepatitis C

Association between mixed cryoglobulinemia, translocation (14; 18), and persistence of occult HCV lymphoid infection after treatment (Giannini et al). 2006;43:1166-1167 (Correspondence)
Association between mixed cryoglobulinemia, translocation (14; 18), and persistence of occult HCV lymphoid infection after treatment (Sansonno et al). 2006;43:1167-1168 (Reply)
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection (Sterling et al). 2006;43:1317-1325
Genomic response to interferon-α in chimpanzees: Implications of rapid downregulation for hepatitis C kinetics (Lanford et al). 2006;43:961-972
Hepatitis C — Identifying patients with progressive liver injury (Feld and Liang). 2006;43:S194-S206
Hepatitis C databases, principles and utility to researchers (Kuiken et al). 2006;43:1157-1165 (Special Article)
Host cell responses induced by hepatitis C virus binding (Fang et al). 2006;43:1326-1336
Liver disease in Egypt: Hepatitis C superseded schistosomiasis as a result of iatrogenic and biological factors (Strickland). 2006;43:915-922 (Perspectives in Clinical Hepatology)
Pharmacodynamics of PEG-IFN α differentiate HIV/HCV coinfected sustained virological responders from nonresponders (Talal et al). 2006;43:943-953
Progression of fibrosis in hepatitis C with and without schistosomiasis: Correlation with serum markers of fibrosis (Kamal et al). 2006;43:771-779
Signal transduction cascades and hepatitis B and C related hepatocellular carcinoma (Branda and Wands). 2006;43:891-902 (Science Frontier)
Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C (Sanyal et al). 2006;43:682-689
Tailoring antiviral therapy in hepatitis C (Davis). 2006;43:909-911 (Editorial)
Therapy of hepatitis C: From empiricism to eradication (Pawlotsky). 2006;43:S207-S220
Viral hepatitis (Alter). 2006;43:S230-S234 (Highlights of the Highlights)

Hepatitis C, acute

Acute hepatitis C: In search of the optimal approach to cure (Craxì and Licata). 2006;43:221-224 (Editorial)
Duration of peginterferon therapy in acute hepatitis C: A randomized trial (Kamal et al). 2006;43:923-931 (Rapid Communication)
Early monotherapy with pegylated interferon alpha-2 for acute hepatitis C infection: The HEP-NET Acute-HCV-II Study (Wiegand et al). 2006;43:250-256

Hepatitis C, chronic

Caspase activation is required for antiviral treatment response in chronic hepatitis C virus infection (Volkmann et al). 2006;43:1311-1316
Cryoglobulinemia is associated with steatosis and fibrosis in chronic hepatitis C (Saadoun et al). 2006;43:1337-1345
Decreased NK cell frequency in chronic hepatitis C does not affect *ex vivo* cytolytic killing (Morishima et al). 2006;43:573-580
Development and validation of two models for early prediction of response to therapy in genotype 1 chronic hepatitis C (Martínez-Bauer et al). 2006;43:72-80
HLA class I allelic diversity and progression of fibrosis in patients with chronic hepatitis C (Patel et al). 2006;43:241-249
Impact of obesity on treatment of chronic hepatitis C (Charlton et al). 2006;43:1177-1186 (Perspectives in Clinical Hepatology)
Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C (Cammà et al). 2006;43:64-71
Keratin variants associate with progression of fibrosis during chronic hepatitis C infection (Strnad et al). 2006;43:1354-1363
Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C (Iwasaki et al). 2006;43:54-63
Noninvasive diagnosis of cirrhosis in chronic hepatitis C based on standard laboratory tests (Lackner et al). 2006;43:378-379 (Correspondence)
Progression of liver fibrosis among injection drug users with chronic hepatitis C (Wilson et al). 2006;43:788-795
Quantitative analysis of anti–hepatitis C virus antibody–secreting B cells in patients with chronic hepatitis C (Umemura et al). 2006;43:91-99
Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection (Perumalswami et al). 2006;43:780-787
Therapy of hepatitis C: From empiricism to eradication (Pawlotsky). 2006;43:S207-S220

Hepatitis C Immunology Database
Hepatitis C databases, principles and utility to researchers (Kuiken et al). 2006;43:1157-1165 (Special Article)
Hepatitis C recurrence
Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation (Blasco et al). 2006; 43:492-499
Hepatitis C vaccine
Hepatitis C vaccines: Inducing and challenging memory T cells (Shiina and Rehermann). 2006;43:1395-1398 (Hepatology *Elsewhere*)
Hepatitis C virus
Adenosylmethionine and betaine correct hepatitis C virus induced inhibition of interferon signaling in vitro (Duong et al). 2006;43:796-806
Anti-HCV therapies in chimeric *scid*-Alb/uPA mice parallel outcomes in human clinical application (Kneteman et al). 2006;43:1346-1353
Correlation between insulin resistance and hepatitis C viral load (Bugianesi and Marchesini). 2006;43:1168-1169 (Reply)
Correlation between insulin resistance and hepatitis C viral load (Harrison). 2006;43:1168 (Correspondence)
Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution (Neumann-Haefelin et al). 2006;43:563-572
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40kd)/ribavirin therapy (Jensen et al). 2006;43:954-960, 1410 (Correction)
HCV and lipoproteins: Is oxLDL an Achilles' Heel of the Trojan horse? (Dreux and Cosset). 2006;43:903-905 (Editorial)
Host cell responses induced by hepatitis C virus binding (Fang et al). 2006; 43:1326-1336
Identification of a hepatitis C virus–reactive T cell receptor that does not require CD8 for target cell recognition (Callender et al). 2006; 43:973-981
The influence of T cell cross-reactivity on HCV-peptide specific human T cell response (Kennedy et al). 2006; 43:602-611
Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus–coinfected patients (Raimondo et al). 2006;43:100-107
Mechanistic link between the anti-HCV effect of interferon gamma and control of viral replication by a Ras-MAPK signaling cascade (Huang et al). 2006;43:81-90
The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients (Sangiovanni et al). 2006;43:1303-1310
NK cells: Natural born killers in the conflict between humans and HCV (Koziel). 2006;43:395-397 (Editorial)
The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro (Paeshuyse et al). 2006;43:761-770
A novel function for a micro RNA: Negative regulators can do positive for the hepatitis C virus (Appel and Bartenschlager). 2006;43:612-615 (Hepatology Elsewhere)
Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells (von Hahn et al). 2006;43:932-942
Quantitative analysis of anti–hepatitis C virus antibody–secreting B cells in patients with chronic hepatitis C (Umemura et al). 2006;43:91-99
Step-by-step progress toward understanding the hepatitis C virus RNA helicase (Frick). 2006;43: 1392-1395 (Hepatology *Elsewhere*)
Therapy of hepatitis C: From empiricism to eradication (Pawlotsky). 2006;43: S207-S220
Viral hepatitis (Alter). 2006;43:S230-S234 (Highlights of the Highlights)
Hepatitis C virus E2
Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33 (Tarr et al). 2006;43:592-601
Hepatitis C virus NS3
Cardif: A protein central to innate immunity is inactivated by the HCV NS3 serine protease (Evans and Seeger). 2006;43:615-617 (Hepatology Elsewhere)
Hepatitis C virus-like particles
Liver endothelial cells promote LDL-R expression and the uptake of HCV-like particles in primary rat and human hepatocytes (Nahmias et al). 2006;43:257-265
Hepatitis delta virus
Characterization of a hepatitis B and hepatitis delta virus receptor binding site (Engelke et al). 2006;43:750-760
Hepatitis Virus Database (HVDB)
Hepatitis C databases, principles and utility to researchers (Kuiken et al). 2006;43:1157-1165 (Special Article)
Hepatobiliary system
Aquaporins in the hepatobiliary system (Masyuk and LaRusso). 2006;43: S75-S81
Hepatocellular adenoma
Genotype-phenotype correlation in hepatocellular adenoma: New classification and relationship with HCC (Zucman-Rossi et al). 2006; 43:515-524
Hepatocellular carcinoma
Adeno-associated virus-mediated expression of apolipoprotein (a) kringles suppresses hepatocellular carcinoma growth in mice (Lee et al). 2006;43:1063-1073
Adenovirus-mediated transfer of siRNA against PTTG1 inhibits liver cancer cell growth in vitro and in vivo (Jung et al). 2006;43:1042-1052
Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma (Mizukoshi et al). 2006; 43:1284-1294
Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans (Ishiyama et al). 2006;43:362-372
Functional genomics of hepatocellular carcinoma (Thorgeirsson et al). 2006;43:S145-S150
Genotype-phenotype correlation in hepatocellular adenoma: New classification and relationship with HCC (Zucman-Rossi et al). 2006; 43:515-524
Hepatitis after arterial embolization for hepatocellular carcinoma: Viral reactivation or ischemia? (Huo et al). 2006;43:1400-1401 (Correspondence)
Hepatocellular carcinoma in a 12-year-old child with PiZZ α1-antitrypsin deficiency (Hadzic et al). 2006;43: 194 (Correspondence)
Overexpression of pituitary tumor transforming gene 1 in HCC is associated with angiogenesis and poor prognosis (Fujii et al). 2006; 43:1267-1275
Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations (Teratani et al). 2006;43:1101-1108
A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization (Jang et al). 2006;43: 233-240
Signal transduction cascades and hepatitis B and C related hepatocellular carcinoma (Branda and Wands). 2006;43:891-902 (Science Frontier)
Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo (Yu et al). 2006;43:134-143
Type 2 diabetes and hepatocellular carcinoma: A cohort study in high

prevalence area of hepatitis virus infection (Lai et al). 2006;43:1295-1302

Hepatocellular liver injury, chronic
The sources of parenchymal regeneration after chronic hepatocellular liver injury in mice (Vig et al). 2006;43:316-324

Hepatocellular neoplasms
Hepatocellular neoplasms after intrahepatic transplantation of ovarian fragments into ovariectomized rats (Dombrowski et al). 2006;43:857-867

Hepatocyte nuclear factor 6
C/EBPα and HNF6 protein complex formation stimulates HNF6-dependent transcription by CBP coactivator recruitment in HepG2 cells (Yoshida et al). 2006;43:276-286

Hepatocyte stem cells
Hematopoietic cells as hepatocyte stem cells: A critical review of the evidence (Thorgeirsson and Grisham). 2006;43:2-8 (Science Frontier)

Hepatocytes
Apoptosis and necrosis in the liver: A tale of two deaths? (Malhi et al). 2006;43:S31-S44
Glucagon and cAMP inhibit cholesterol 7α-hydroxylase (CYP7A1) gene expression in human hepatocytes: Discordant regulation of bile acid synthesis and gluconeogenesis (Song and Chiang). 2006;43:117-125
Hematopoietic mobilization in mice increases the presence of bone marrow–derived hepatocytes via in vivo cell fusion (Quintana-Bustamante et al). 2006;43:108-116
Hepatocytes as cytotoxic effector cells can induce cell death by CD95 ligand-mediated pathway (Guy et al). 2006;43:1231-1240
Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication (Bonvin et al). 2006;43:1364-1374
Isolation and characterization of lipid microdomains from apical and basolateral plasma membranes of rat hepatocytes (Mazzone et al). 2006;43:287-296
Liver endothelial cells promote LDL-R expression and the uptake of HCV-like particles in primary rat and human hepatocytes (Nahmias et al). 2006;43:257-265

HEPATOLOGY
25 years of *HEPATOLOGY* (Blei). 2006;43:S1
An editor's look-back (Berk). 2006;43:S13-S30
HEPATOLOGY over the years (Schenker et al). 2006;43:S6-S12
Reflections on the first five years of *HEPATOLOGY*, 1981-1986 (Arias). 2006;43:S3-S4
Who reads the paper? (Blei). 2006;43:1 (Editor's Corner)

Hepatoma
HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL (Pathil et al). 2006;43:425-434
Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells (von Hahn et al). 2006;43:932-942

Hepatopulmonary syndrome
Effects of nebulized N^G-nitro-L-arginine methyl ester in patients with hepatopulmonary syndrome (Gómez et al). 2006;43:1084-1091
Hepatology Highlights (Elias). 2006;43:1175-1176
Hepatopulmonary syndrome: More than just a matter of tone? (Fallon). 2006;43:912-914 (Editorial)

Hepatorenal syndrome
The use of vasoconstrictors in patients with cirrhosis: Type 1 HRS and beyond (Moreau and Lebrec). 2006;43:385-394 (Perspectives in Clinical Hepatology)

HepG2 cells
C/EBPα and HNF6 protein complex formation stimulates HNF6-dependent transcription by CBP coactivator recruitment in HepG2 cells (Yoshida et al). 2006;43:276-286
Nrf2 is increased by CYP2E1 in rodent liver and HepG2 cells and protects against oxidative stress caused by CYP2E1 (Gong and Cederbaum). 2006;43:144-153

Histone deacetylase inhibitors
HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL (Pathil et al). 2006;43:425-434

History
First do no harm (Reuben). 2006;43:S243-S249 (Landmarks in Hepatology)
True, true . . . but are they related? (Reuben). 2006;43:635-639 (Landmarks in Hepatology)

Holocaust
First do no harm (Reuben). 2006;43:S243-S249 (Landmarks in Hepatology)

Human immunodeficiency virus infection
Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients (Benhamou et al). 2006;43:548-555
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection (Sterling et al). 2006;43:1317-1325
Growing importance of liver disease in HIV-infected persons (Thomas). 2006;43:S221-S229
Pharmacodynamics of PEG-IFN α differentiate HIV/HCV coinfected sustained virological responders from nonresponders (Talal et al). 2006;43:943-953

Human leukocyte antigen
HLA class I allelic diversity and progression of fibrosis in patients with chronic hepatitis C (Patel et al). 2006;43:241-249

Human leukocyte antigen B27
Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution (Neumann-Haefelin et al). 2006;43:563-572
Hepatology Highlights (Alter). 2006;43:643-645

Human telomerase reverse transcriptase (hTERT)
Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma (Mizukoshi et al). 2006;43:1284-1294

Hyperammonemia
Brain edema and inflammatory activation in bile duct ligated rats with diet-induced hyperammonemia: A model of hepatic encephalopathy in cirrhosis (Jover et al). 2006;43:1257-1266

Hyperdynamic circulation
The hyperdynamic circulation of chronic liver diseases: From the patient to the molecule (Iwakiri and Groszmann). 2006;43:S121-S131

I

Immunology
The liver as an immunological organ (Racanelli and Rehermann). 2006;43:S54-S62
The unfinished legacy of liver transplantation: Emphasis on immunology (Starzl and Lakkis). 2006;43:S151-S163

Infantile hemochromatosis
Fetal and infantile hemochromatosis (Whitington). 2006;43:654-660 (Concise Review in Mechanisms of Disease)

Inhibitor of differentiation 1 (Id1) gene
Id1 is a critical mediator in TGF-β–induced transdifferentiation of rat hepatic stellate cells (Wiercinska et al). 2006;43:1032-1041

Injection drug users
Progression of liver fibrosis among injection drug users with chronic

hepatitis C (Wilson et al). 2006;43: 788-795

Insulin resistance
Correlation between insulin resistance and hepatitis C viral load (Bugianesi and Marchesini). 2006;43:1168-1169 (Reply)
Correlation between insulin resistance and hepatitis C viral load (Harrison). 2006;43:1168 (Correspondence)
Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C (Cammà et al). 2006;43:64-71

Interferon
Adenosylmethionine and betaine correct hepatitis C virus induced inhibition of interferon signaling in vitro (Duong et al). 2006;43:796-806
Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication (Bonvin et al). 2006;43:1364-1374
Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C (Iwasaki et al). 2006;43:54-63

Interferon α
Antiproliferative effects of interferon alpha on hepatic progenitor cells in vitro and in vivo (Lim et al). 2006; 43:1074-1083
The clinical and physiological spectrum of interferon-alpha induced thyroiditis: Toward a new classification (Mandac et al). 2006; 43:661-672 (Perspectives in Clinical Hepatology)
Genomic response to interferon-α in chimpanzees: Implications of rapid downregulation for hepatitis C kinetics (Lanford et al). 2006;43: 961-972
Pharmacodynamics of PEG-IFN α differentiate HIV/HCV coinfected sustained virological responders from nonresponders (Talal et al). 2006;43:943-953

Interferon α-2
Early monotherapy with pegylated interferon alpha-2 for acute hepatitis C infection: The HEP-NET Acute-HCV-II Study (Wiegand et al). 2006;43:250-256

Interferon α-2a
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40kd)/ribavirin therapy (Jensen et al). 2006;43:954-960, 1410 (Correction)

Interferon α-2b
Duration of peginterferon therapy in acute hepatitis C: A randomized trial (Kamal et al). 2006;43:923-931 (Rapid Communication)
Interferon α-2b with and without ribavirin in the treatment of hepatitis B e antigen–positive chronic hepatitis B: A randomized study (Liu et al). 2006;43:742-749

Interferon gamma
Mechanistic link between the anti-HCV effect of interferon gamma and control of viral replication by a Ras-MAPK signaling cascade (Huang et al). 2006;43:81-90

Interleukin 6
Hepatology Highlights (Kaplowitz). 2006;43:887-889
Paradoxical effects of short- and long-term interleukin-6 exposure on liver injury and repair (Jin et al). 2006; 43:474-484

Interleukin 15
Interleukin-15 prevents concanavalin A-induced liver injury in mice via NKT cell-dependent mechanism (Li et al). 2006;43:1211-1219

Intestinal mucosa
Intestinal mucosal alterations in rats with carbon tetrachloride-induced cirrhosis: Changes in glycosylation and luminal bacteria (Natarajan et al). 2006;43:837-846

Intestine transplantation
Parenteral nutrition–associated liver disease and the role for isolated intestine and intestine/liver transplantation (Buchman et al). 2006;43:9-19 (Perspectives in Clinical Hepatology)

Intrahepatic cholestasis
Altered hepatobiliary gene expressions in PFIC1: ATP8B1 gene defect is associated with CFTR downregulation (Demeilliers et al). 2006;43:1125-1134
Hepatology Highlights (Elias). 2006;43: 383-384, 1175-1176
Nasobiliary drainage induces long-lasting remission in benign recurrent intrahepatic cholestasis (Stapelbroek et al). 2006;43:51-53 (Concise Communication)

Intrahepatic cholestasis of pregnancy
Intrahepatic cholestasis of pregnancy — A heterogeneous group of pregnancy-related disorders? (Beuers and Pusl). 2006;43:647-649 (Editorial)
Intrahepatic cholestasis of pregnancy as an indicator of liver and biliary diseases: A population-based study (Ropponen et al). 2006;43:723-728
Is a leaky gut involved in the pathogenesis of intrahepatic cholestasis of pregnancy? (Reyes et al). 2006;43:715-722

Intrahepatic transplantation of ovarian fragments
Hepatocellular neoplasms after intrahepatic transplantation of ovarian fragments into ovariectomized rats (Dombrowski et al). 2006;43:857-867

Ischemic injury
$CD4^+$ T cells contribute to postischemic liver injury in mice by interacting with sinusoidal endothelium and platelets (Khandoga et al). 2006;43: 306-315

Ischemic injury, cold
Bile salt toxicity aggravataes cold ischemic injury of bile ducts after liver transplantation in Mdr2+/- mice (Hoekstra et al). 2006;43: 1022-1031

ITF2357
HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL (Pathil et al). 2006;43:425-434

J

JNK
Bile acids and cytokines inhibit the human cholesterol 7α-hydroxylase gene via the JNK/c-Jun pathway in human liver cells (Li et al). 2006;43: 1202-1210
Hepatology Highlights (Kaplowitz). 2006;43:207-208
JNK1 but not JNK2 promotes the development of steatohepatitis in mice (Schattenberg et al). 2006;43: 163-172

K

Keratin
Keratin variants associate with progression of fibrosis during chronic hepatitis C infection (Strnad et al). 2006;43:1354-1363

King's criteria
King's criteria, APACHE II, and SOFA scores in acute liver failure (Cholongitas et al). 2006;43:881 (Correspondence)
King's criteria, APACHE II, and SOFA scores in acute liver failure (Larson et al). 2006;43:882 (Reply)

L

Laboratory testing
Noninvasive diagnosis of cirrhosis in chronic hepatitis C based on standard laboratory tests (Lackner et al). 2006;43:378-379 (Correspondence)

Lamivudine
Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy (Lee et al). 2006;43:1385-1391

Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B (Sokal et al). 2006;43:225-232
A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization (Jang et al). 2006;43:233-240

Legal issues
Ethical, Social and legal implications of genetic testing in liver disease (van Leeuwen and Bernat). 2006;43:1195-1201 (Sounding Board)

Lipid microdomains
Isolation and characterization of lipid microdomains from apical and basolateral plasma membranes of rat hepatocytes (Mazzone et al). 2006;43:287-296

Lipopolysaccharide
LPS inhibits endothelin-1–induced endothelial NOS activation in hepatic sinusoidal cells through a negative feedback involving caveolin-1 (Kamoun et al). 2006;43:182-190

Lipoproteins
HCV and lipoproteins: Is oxLDL an Achilles' Heel of the Trojan horse? (Dreux and Cosset). 2006;43:903-905 (Editorial)

Liver
Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans (Ishiyama et al). 2006;43:362-372
The liver as an immunological organ (Racanelli and Rehermann). 2006;43:S54-S62
Liver biology and pathobiology (Kaplowitz). 2006;43:S235-S238 (Highlights of the Highlights)

Liver disease
Ethical, Social and legal implications of genetic testing in liver disease (van Leeuwen and Bernat). 2006;43:1195-1201 (Sounding Board)
Growing importance of liver disease in HIV-infected persons (Thomas). 2006;43:S221-S229
Impact of the hepatitis B virus genotype and genotype mixtures on the course of liver disease in Vietnam (Toan et al). 2006;43:1375-1384
Intrahepatic cholestasis of pregnancy as an indicator of liver and biliary diseases: A population-based study (Ropponen et al). 2006;43:723-728
Liver disease in Egypt: Hepatitis C superseded schistosomiasis as a result of iatrogenic and biological factors (Strickland). 2006;43:915-922 (Perspectives in Clinical Hepatology)
Liver failure and liver disease (Elias). 2006;43:S239-S241 (Highlights of the Highlights)
Progress on the action plan for liver disease research (Hoofnagle and Miller). 2006;43:890 (News from the NIH)

Liver disease, alcoholic
Differential liver sensitization to Toll-like receptor pathways in mice with alcoholic fatty liver (Gustot et al). 2006;43:989-1000
Do alcohol-metabolizing enzyme gene polymorphisms increase the risk of alcoholism and alcoholic liver disease? (Zintzaras et al). 2006;43:352-361
Hepatology Highlights (Elias). 2006;43:383-384

Liver disease, chronic
The hyperdynamic circulation of chronic liver diseases: From the patient to the molecule (Iwakiri and Groszmann). 2006;43:S121-S131

Liver disease, fatty
Localization of oxidized phosphatidylcholine in nonalcoholic fatty liver disease: Impact on disease progression (Ikura et al). 2006;43:506-514
Nonalcoholic fatty liver disease: From steatosis to cirrhosis (Farrell and Larter). 2006;43:S99-S112

Liver disease, parenteral nutrition–associated
Parenteral nutrition–associated liver disease and the role for isolated intestine and intestine/liver transplantation (Buchman et al). 2006;43:9-19 (Perspectives in Clinical Hepatology)

Liver disease, polycystic
Effects of angiogenic factor overexpression by human and rodent cholangiocytes in polycystic liver diseases (Fabris et al). 2006;43:1001-1012
Polycystic liver disease: New insights into disease pathogenesis (Masyuk and LaRusso). 2006;43:906-908 (Editorial)

Liver failure, acute
Acetaminophen-induced acute liver failure: Results of a United States multicenter prospective study (Holubek et al). 2006;43:881 (Correspondence)
King's criteria, APACHE II, and SOFA scores in acute liver failure (Cholongitas et al). 2006;43:881 (Correspondence)
King's criteria, APACHE II, and SOFA scores in acute liver failure (Larson et al). 2006;43:882 (Reply)

Liver injury
Interleukin-15 prevents concanavalin A-induced liver injury in mice via NKT cell-dependent mechanism (Li et al). 2006;43:1211-1219
Paradoxical effects of short- and long-term interleukin-6 exposure on liver injury and repair (Jin et al). 2006;43:474-484
Thermoreversible gelation polymer induces the emergence of hepatic stem cells in the partially injured rat liver (Nagaya et al). 2006;43:1053-1062

Liver injury, acute
Tightly regulated induction of the adhesion molecule Necl-5/CD155 during rat liver regeneration and acute liver injury (Erickson et al). 2006;43:325-334

Liver injury, chronic
The sources of parenchymal regeneration after chronic hepatocellular liver injury in mice (Vig et al). 2006;43:316-324

Liver injury, drug-induced
Drug-induced liver injury: Summary of a single topic clinical research conference (Watkins and Seeff). 2006;43:618-631 (Special Article)

Liver injury, oxidative
Alcohol and oxidative liver injury (Dey and Cederbaum). 2006;43:S63-S74

Liver injury, postischemic
$CD4^+$ T cells contribute to postischemic liver injury in mice by interacting with sinusoidal endothelium and platelets (Khandoga et al). 2006;43:306-315

Liver injury, progressive
Hepatitis C — Identifying patients with progressive liver injury (Feld and Liang). 2006;43:S194-S206

Liver regeneration
Functional modification of CD11c+ liver dendritic cells during liver regeneration after partial hepatectomy in mice (Castellaneta et al). 2006;43:807-816
Liver regeneration (Fausto et al). 2006;43:S45-S53
The sources of parenchymal regeneration after chronic hepatocellular liver injury in mice (Vig et al). 2006;43:316-324
Tightly regulated induction of the adhesion molecule Necl-5/CD155 during rat liver regeneration and acute liver injury (Erickson et al). 2006;43:325-334

Liver stiffness measurement
Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC (Corpechot et al). 2006;43:1118-1124

Liver transplantation
Bile salt toxicity aggravatae cold ischemic injury of bile ducts after liver transplantation in Mdr2+/−

mice (Hoekstra et al). 2006;43: 1022-1031
Donor graft adenoviral iNOS gene transfer ameliorates rat liver transplant preservation injury and improves survival (Kaizu et al). 2006;43:464-473
Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation (Blasco et al). 2006; 43:492-499
Hepatology Highlights (Elias). 2006;43: 1175-1176
Hepatology Highlights (Kaplowitz). 2006;43:887-889
The unfinished legacy of liver transplantation: Emphasis on immunology (Starzl and Lakkis). 2006;43:S151-S163

Liver transplantation, pediatric
Progressive histological damage in liver allografts following pediatric liver transplantation (Evans et al). 2006; 43:1109-1117

Liver transplantation waiting lists
Deaths on the liver transplantation waiting list: An analysis of competing risks (Kim et al). 2006; 43:345-351

Liver tumors
Zonal gene expression in murine liver: Lessons from tumors (Hailfinger et al). 2006;43:407-414

Low-density lipoprotein
Association between postprandial LDL conjugated dienes and the severity of liver fibrosis in NASH (Cassader et al). 2006;43:1169-1170 (Correspondence)
Liver endothelial cells promote LDL-R expression and the uptake of HCV-like particles in primary rat and human hepatocytes (Nahmias et al). 2006;43:257-265

Low-density lipoprotein, oxidized (oxLDL)
HCV and lipoproteins: Is oxLDL an Achilles' Heel of the Trojan horse? (Dreux and Cosset). 2006;43:903-905 (Editorial)
Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells (von Hahn et al). 2006;43:932-942

Low-density lipoprotein receptor
Liver endothelial cells promote LDL-R expression and the uptake of HCV-like particles in primary rat and human hepatocytes (Nahmias et al). 2006;43:257-265

M

Magnetization transfer
Demonstration of interstitial cerebral edema with diffusion tensor MR imaging in type C hepatic encephalopathy (Kale et al). 2006; 43:698-706

Mannose-binding lectin
Mannose-binding lectin in chronic hepatitis B virus infection (Chong et al). 2006;43:199 (Correction)

Memory T cells
Hepatitis C vaccines: Inducing and challenging memory T cells (Shiina and Rehermann). 2006;43:1395-1398 (Hepatology *Elsewhere*)

Methotrexate
Methotrexate for treatment of primary biliary cirrhosis (Bonis and Kaplan). 2006;43:632 (Correspondence)
Methotrexate for treatment of primary biliary cirrhosis (Combes and Emerson). 2006;43:632-633 (Reply)

MicroRNAs (miRNAs)
A novel function for a micro RNA: Negative regulators can do positive for the hepatitis C virus (Appel and Bartenschlager). 2006;43:612-615 (Hepatology Elsewhere)

Monocytes
Hepatology Highlights (Kaplowitz). 2006;43:207-208
Systemic effects of TNF-α secreted by circulating monocytes and fatigue in cirrhosis (Albillos et al). 2006;43: 1399 (Correspondence)
Systemic effects of TNF-α secreted by circulating monocytes and fatigue in cirrhosis (Kerfoot et al). 2006;43: 1399-1400 (Reply)
TNF-α–secreting monocytes are recruited into the brain of cholestatic mice (Kerfoot et al). 2006;43:154-162

Multidrug resistance
Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy (Lee et al). 2006;43:1385-1391

Multidrug resistance 2
Bile salt toxicity aggravatae cold ischemic injury of bile ducts after liver transplantation in Mdr2+/− mice (Hoekstra et al). 2006;43: 1022-1031

Multidrug resistance-protein 2
A novel multidrug-resistance protein 2 gene mutation identifies a subgroup of patients with primary biliary cirrhosis and pruritus (Floreani et al). 2006;43:1152-1154 (Concise Communication)

Multidrug resistance-protein 4
Hepatology Highlights (Kaplowitz). 2006;43:887-889
Mrp4−/− mice have an impaired cytoprotective response in obstructive cholestasis (Mennone et al). 2006;43:1013-1021

Mutations
Coinheritance of Gilbert syndrome–associated *UGTIA1* mutation increases gallstone risk in cystic fibrosis (Wasmuth et al). 2006;43: 738-741 (Concise Communication)
Hepatic adenomas: Presumed innocent until proven to be beta-catenin mutated (Monga). 2006;43:401-404 (Editorial)
A novel multidrug-resistance protein 2 gene mutation identifies a subgroup of patients with primary biliary cirrhosis and pruritus (Floreani et al). 2006;43:1152-1154 (Concise Communication)

N

NADPH oxidase
Hepatology Highlights (Kaplowitz). 2006;43:887-889
Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo (Zhan et al). 2006;43:435-443

NaS1 sulfate transporter
Disruption of NaS1 sulfate transport function in mice leads to enhanced acetaminophen-induced hepatotoxicity (Lee et al). 2006;43: 1241-1247

Nasobiliary drainage
Nasobiliary drainage for cholestatic pruritus (Hofmann and Huet). 2006;43:1170-1171 (Correspondence)
Nasobiliary drainage induces long-lasting remission in benign recurrent intrahepatic cholestasis (Stapelbroek et al). 2006;43:51-53 (Concise Communication)

National Institutes of Health (NIH)
Mechanisms of alcohol-induced hepatic fibrosis: A summary of the Ron Thurman symposium (Purohit and Brenner). 2006;43:872-878 (Special Article)
Neonatal screening for biliary atresia (Hoofnagle and Sokol). 2006;43: 646 (This Month from the NIH)
Progress on the action plan for liver disease research (Hoofnagle and Miller). 2006;43:890 (News from the NIH)

Natural killer cells
Decreased NK cell frequency in chronic hepatitis C does not affect *ex vivo* cytolytic killing (Morishima et al). 2006;43:573-580
Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans (Ishiyama et al). 2006;43:362-372
NK cells: Natural born killers in the

conflict between humans and HCV (Koziel). 2006;43:395-397 (Editorial)

Natural killer T cells
Interleukin-15 prevents concanavalin A-induced liver injury in mice via NKT cell-dependent mechanism (Li et al). 2006;43:1211-1219

N-butyl-2-cyanoacrylate
A randomized trial of endoscopic treatment of acute gastric variceal hemorrhage: N-butyl-2-cyanoacrylate injection versus band ligation (Tan et al). 2006;43:690-697, 1410 (Correction)

Necl-5/CD155
Tightly regulated induction of the adhesion molecule Necl-5/CD155 during rat liver regeneration and acute liver injury (Erickson et al). 2006;43:325-334

Necrosis
Apoptosis and necrosis in the liver: A tale of two deaths? (Malhi et al). 2006;43:S31-S44
Deoxyribonuclease 1 aggravates acetaminophen-induced liver necrosis in male CD-1 mice (Napirei et al). 2006;43:297-305
Hepatology Highlights (Kaplowitz). 2006;43:207-208

Neonatal screening
Neonatal screening for biliary atresia (Hoofnagle and Sokol). 2006;43:646 (This Month from the NIH)

Neuropsychology
Noncirrhotic portal vein thrombosis exhibits neuropsychological and MR changes consistent with minimal hepatic encephalopathy (Mínguez et al). 2006;43:707-714

Neutrophils
How relevant are neutrophils for acetaminophen hepatotoxicity? (Jaeschke). 2006;43:1191-1194 (Editorial)
Neutrophil depletion protects against murine acetaminophen hepatotoxicity (Liu et al). 2006;43:1220-1230

Niemann-Pick type C 2 gene (NPC2)
NPC2 is expressed in human and murine liver and secreted into bile: Potential implications for body cholesterol homeostasis (Klein et al). 2006;43:126-133

Nitration
Nitration of cardiac proteins is associated with abnormal cardiac chronotropic responses in rats with biliary cirrhosis (Mani et al). 2006;43:847-856

Nitric oxide synthase
Hepatology Highlights (Elias). 2006;43:1175-1176
LPS inhibits endothelin-1–induced endothelial NOS activation in hepatic sinusoidal cells through a negative feedback involving caveolin-1 (Kamoun et al). 2006;43:182-190

Nitric oxide synthase, inducible (iNOS)
Donor graft adenoviral iNOS gene transfer ameliorates rat liver transplant preservation injury and improves survival (Kaizu et al). 2006;43:464-473

N^G-Nitro-L-arginine methyl ester (L-NAME)
Effects of nebulized N^G-nitro-L-arginine methyl ester in patients with hepatopulmonary syndrome (Gómez et al). 2006;43:1084-1091

Nonalcoholic fatty liver disease
Localization of oxidized phosphatidylcholine in nonalcoholic fatty liver disease: Impact on disease progression (Ikura et al). 2006;43:506-514
Nonalcoholic fatty liver disease: From steatosis to cirrhosis (Farrell and Larter). 2006;43:S99-S112

Nonalcoholic steatohepatitis
Association between postprandial LDL conjugated dienes and the severity of liver fibrosis in NASH (Cassader et al). 2006;43:1169-1170 (Correspondence)
Hepatology Highlights (Elias). 2006;43:1175-1176
Intermittent disconjugate gaze: A novel finding in nonalcoholic steatohepatitis (Al-Osaimi and Caldwell). 2006;43:883 (Reply)
Intermittent disconjugate gaze: A novel finding in nonalcoholic steatohepatitis (Schartman and Weinstein). 2006;43:882-883 (Correspondence)
Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C (Sanyal et al). 2006;43:682-689

Nuclear factor erythroid 2-related factor 2 (Nrf2)
Nrf2 is increased by CYP2E1 in rodent liver and HepG2 cells and protects against oxidative stress caused by CYP2E1 (Gong and Cederbaum). 2006;43:144-153

Nuclear factor-κB
Does nucleolin bind the NF kappa B DNA binding motif? (Bernstein). 2006;43:376 (Correspondence)
Does nucleolin bind the NF kappa B DNA binding motif? (Embree-Ku and Gruppuso). 2006;43:376-377 (Reply)

Nucleolin
Does nucleolin bind the NF kappa B DNA binding motif? (Bernstein). 2006;43:376 (Correspondence)
Does nucleolin bind the NF kappa B DNA binding motif? (Embree-Ku and Gruppuso). 2006;43:376-377 (Reply)

Nutritional steatohepatitis, experimental
COX-2 induction in mice with experimental nutritional steatohepatitis: Role as pro-inflammatory mediator (Yu et al). 2006;43:826-836

O

Obesity
Hepatology Highlights (Kaplowitz). 2006;43:207-208
Impact of obesity on treatment of chronic hepatitis C (Charlton et al). 2006;43:1177-1186 (Perspectives in Clinical Hepatology)

Obstruction, biliary
Expression of rat renal cortical OAT1 and OAT3 in response to acute biliary obstruction (Brandoni et al). 2006;43:1092-1100

Obstructive cholestasis
Mrp4-/- mice have an impaired cytoprotective response in obstructive cholestasis (Mennone et al). 2006;43:1013-1021

Organ allocation
Deaths on the liver transplantation waiting list: An analysis of competing risks (Kim et al). 2006;43:345-351

Organic anion transporter 1
Expression of rat renal cortical OAT1 and OAT3 in response to acute biliary obstruction (Brandoni et al). 2006;43:1092-1100

Organic anion transporter 3
Expression of rat renal cortical OAT1 and OAT3 in response to acute biliary obstruction (Brandoni et al). 2006;43:1092-1100

Orthotopic liver transplantation
Hepatology Highlights (Elias). 2006;43:1175-1176
Hepatology Highlights (Kaplowitz). 2006;43:887-889

Ovarian fragment transplantation, intrahepatic
Hepatocellular neoplasms after intrahepatic transplantation of ovarian fragments into ovariectomized rats (Dombrowski et al). 2006;43:857-867

Oxidative liver injury
Alcohol and oxidative liver injury (Dey and Cederbaum). 2006;43:S63-S74

Oxygen free radicals
Renal damage in experimentally induced cirrhosis in rats: Role of oxygen free radicals (Natarajan et al). 2006;43:1248-1257

P

Parenchymal regeneration
The sources of parenchymal regeneration

after chronic hepatocellular liver injury in mice (Vig et al). 2006;43: 316-324

Parenteral nutrition–associated liver disease

Parenteral nutrition–associated liver disease and the role for isolated intestine and intestine/liver transplantation (Buchman et al). 2006;43:9-19 (Perspectives in Clinical Hepatology)

Partial hepatectomy

Functional modification of CD11c+ liver dendritic cells during liver regeneration after partial hepatectomy in mice (Castellaneta et al). 2006;43:807-816

Pathobiology

Liver biology and pathobiology (Kaplowitz). 2006;43:S235-S238 (Highlights of the Highlights)

Pediatric liver transplantation

Progressive histological damage in liver allografts following pediatric liver transplantation (Evans et al). 2006; 43:1109-1117

Pediatrics

Chronic hepatitis B in children after e antigen seroclearance: Final report of a 29-year longitudinal study (Bortolotti et al). 2006;43:556-562

Hepatocellular carcinoma in a 12-year-old child with PiZZ α1-antitrypsin deficiency (Hadzic et al). 2006;43: 194 (Correspondence)

Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B (Sokal et al). 2006;43:225-232

Neonatal screening for biliary atresia (Hoofnagle and Sokol). 2006;43: 646 (This Month from the NIH)

Peginterferon

Duration of peginterferon therapy in acute hepatitis C: A randomized trial (Kamal et al). 2006;43:923-931 (Rapid Communication)

Pegylated interferon α

Pharmacodynamics of PEG-IFN α differentiate HIV/HCV coinfected sustained virological responders from nonresponders (Talal et al). 2006;43:943-953

Pegylated interferon α-2

Early monotherapy with pegylated interferon alpha-2 for acute hepatitis C infection: The HEP-NET Acute-HCV-II Study (Wiegand et al). 2006;43:250-256

Pegylated interferon α-2a

Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40kd)/ribavirin therapy (Jensen et al). 2006;43:954-960, 1410 (Correction)

Phenotype

Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly (Czaja and Carpenter). 2006;43: 532-538

Phosphatidylcholine, oxidized (oxPC)

Localization of oxidized phosphatidylcholine in nonalcoholic fatty liver disease: Impact on disease progression (Ikura et al). 2006;43: 506-514

Pituitary tumor transforming gene PTTG1

Adenovirus-mediated transfer of siRNA against PTTG1 inhibits liver cancer cell growth in vitro and in vivo (Jung et al). 2006;43:1042-1052

Overexpression of pituitary tumor transforming gene 1 in HCC is associated with angiogenesis and poor prognosis (Fujii et al). 2006; 43:1267-1275

PiZZ α1-antitrypsin deficiency

Hepatocellular carcinoma in a 12-year-old child with PiZZ α1-antitrypsin deficiency (Hadzic et al). 2006;43: 194 (Correspondence)

Plasma membrane

Isolation and characterization of lipid microdomains from apical and basolateral plasma membranes of rat hepatocytes (Mazzone et al). 2006; 43:287-296

Plasma volume

Systemic hemodynamics, vasoactive systems, and plasma volume in patients with severe Budd-Chiari syndrome (Hernández-Guerra et al). 2006;43:27-33

Platelets

$CD4^+$ T cells contribute to postischemic liver injury in mice by interacting with sinusoidal endothelium and platelets (Khandoga et al). 2006;43: 306-315

Polycystic liver disease

Effects of angiogenic factor overexpression by human and rodent cholangiocytes in polycystic liver diseases (Fabris et al). 2006;43: 1001-1012

Polycystic liver disease: New insights into disease pathogenesis (Masyuk and LaRusso). 2006;43:906-908 (Editorial)

Porphyria

Seeing purple (Reuben). 2006;43:1403-1409 (Landmarks in Hepatology)

Portal hypertension

Ascorbic acid improves the intrahepatic endothelial dysfunction of patients with cirrhosis and portal hypertension (Hernández-Guerra et al). 2006;43:485-491

Portal vein thrombosis

Noncirrhotic portal vein thrombosis exhibits neuropsychological and MR changes consistent with minimal hepatic encephalopathy (Mínguez et al). 2006;43:707-714

Positron emission tomography

Brain metabolism of ^{13}N-ammonia during acute hepatic encephalopathy in cirrhosis measured by positron emission tomography (Keiding et al). 2006;43:42-50

Pregnancy, intrahepatic cholestasis of

Intrahepatic cholestasis of pregnancy — A heterogeneous group of pregnancy-related disorders? (Beuers and Pusl). 2006;43:647-649 (Editorial)

Intrahepatic cholestasis of pregnancy as an indicator of liver and biliary diseases: A population-based study (Ropponen et al). 2006;43:723-728

Is a leaky gut involved in the pathogenesis of intrahepatic cholestasis of pregnancy? (Reyes et al). 2006;43:715-722

Pregnancy-related disorders

Intrahepatic cholestasis of pregnancy — A heterogeneous group of pregnancy-related disorders? (Beuers and Pusl). 2006;43:647-649 (Editorial)

Primary biliary cirrhosis

Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC (Corpechot et al). 2006; 43:1118-1124

Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis (Wesierska-Gadek et al). 2006;43:1135-1144

Hepatology Highlights (Elias). 2006;43: 383-384

Increased prevalence of primary biliary cirrhosis near Superfund toxic waste sites (Ala et al). 2006;43:525-531

Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis (Lan et al). 2006;43:729-737

Methotrexate for treatment of primary biliary cirrhosis (Bonis and Kaplan). 2006;43:632 (Correspondence)

Methotrexate for treatment of primary biliary cirrhosis (Combes and Emerson). 2006;43:632-633 (Reply)

A novel multidrug-resistance protein 2 gene mutation identifies a subgroup of patients with primary biliary cirrhosis and pruritus (Floreani et al). 2006;43:1152-1154 (Concise Communication)

Polluting the pathogenesis of primary biliary cirrhosis (Talwalkar and Lazaridis). 2006;43:398-400 (Editorial)

Reflections on therapeutic trials in primary biliary cirrhosis: A quality of life oriented counter-view (Jones et al). 2006;43:633 (Correspondence)

Primary sclerosing cholangitis
Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC (Corpechot et al). 2006; 43:1118-1124
Progenitor cells
Antiproliferative effects of interferon alpha on hepatic progenitor cells in vitro and in vivo (Lim et al). 2006; 43:1074-1083
Progressive familial intrahepatic cholestasis
Altered hepatobiliary gene expressions in PFIC1: ATP8B1 gene defect is associated with CFTR downregulation (Demeilliers et al). 2006;43:1125-1134
Hepatology Highlights (Elias). 2006;43: 1175-1176
Propranolol
Influence of beta-2 adrenergic receptor gene polymorphism on the hemodynamic response to propranolol in patients with cirrhosis (Turnes et al). 2006;43:34-41
Proteasome
Hepatology Highlights (Kaplowitz). 2006;43:207-208
Proteasome inhibition induces hepatic stellate cell apoptosis (Anan et al). 2006;43:335-344
Pruritus
Hepatology Highlights (Elias). 2006;43: 383-384
Nasobiliary drainage for cholestatic pruritus (Hofmann and Huet). 2006;43:1170-1171 (Correspondence)
A novel multidrug-resistance protein 2 gene mutation identifies a subgroup of patients with primary biliary cirrhosis and pruritus (Floreani et al). 2006;43:1152-1154 (Concise Communication)

Q

Quality of life
Reflections on therapeutic trials in primary biliary cirrhosis: A quality of life oriented counter-view (Jones et al). 2006;43:633 (Correspondence)

R

Radiofrequency ablation
Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations (Teratani et al). 2006;43:1101-1108
Reactive oxygen species
Alcohol and oxidative liver injury (Dey and Cederbaum). 2006;43:S63-S74
Renal damage
Renal damage in experimentally induced cirrhosis in rats: Role of oxygen free radicals (Natarajan et al). 2006;43: 1248-1257
Research
Hepatitis C databases, principles and utility to researchers (Kuiken et al). 2006;43:1157-1165 (Special Article)
Progress on the action plan for liver disease research (Hoofnagle and Miller). 2006;43:890 (News from the NIH)
Ribavirin
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40kd)/ribavirin therapy (Jensen et al). 2006;43:954-960, 1410 (Correction)
Hepatology Highlights (Alter). 2006;43: 643-645
Interferon α-2b with and without ribavirin in the treatment of hepatitis B e antigen–positive chronic hepatitis B: A randomized study (Liu et al). 2006;43:742-749
Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C (Iwasaki et al). 2006;43:54-63
Targeted delivery of ribavirin improves outcome of murine viral fulminant hepatitis via enhanced anti-viral activity (Levy et al). 2006;43:581-591
RNA, micro (miRNAs)
A novel function for a micro RNA: Negative regulators can do positive for the hepatitis C virus (Appel and Bartenschlager). 2006;43:612-615 (Hepatology Elsewhere)
RNA, short interfering (siRNA)
Adenovirus-mediated transfer of siRNA against PTTG1 inhibits liver cancer cell growth in vitro and in vivo (Jung et al). 2006;43:1042-1052
Ron Thurman Symposium on the Mechanisms of Alcohol-Induced Hepatic Fibrosis
Mechanisms of alcohol-induced hepatic fibrosis: A summary of the Ron Thurman symposium (Purohit and Brenner). 2006;43:872-878 (Special Article)

S

Schistosomiasis
Liver disease in Egypt: Hepatitis C superseded schistosomiasis as a result of iatrogenic and biological factors (Strickland). 2006;43:915-922 (Perspectives in Clinical Hepatology)
Progression of fibrosis in hepatitis C with and without schistosomiasis: Correlation with serum markers of fibrosis (Kamal et al). 2006;43:771-779
Sclerosing cholangitis, primary
Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC (Corpechot et al). 2006; 43:1118-1124
Secretin
Bicarbonate-rich choleresis induced by secretin in normal rat is taurocholate-dependent and involves AE2 anion exchanger (Banales et al). 2006;43:266-275
Sepsis, severe
Adrenal insufficiency in patients with cirrhosis, severe sepsis and septic shock (Tsai et al). 2006;43:673-681
Sepsis-related Organ Failure Assessment (SOFA)
King's criteria, APACHE II, and SOFA scores in acute liver failure (Cholongitas et al). 2006;43:881 (Correspondence)
King's criteria, APACHE II, and SOFA scores in acute liver failure (Larson et al). 2006;43:882 (Reply)
Septic shock
Adrenal insufficiency in patients with cirrhosis, severe sepsis and septic shock (Tsai et al). 2006;43:673-681
Sickness behaviors
Sickness behaviors in chronic cholestasis: An immune-mediated process? (Aspinall and Adams). 2006;43:20-23 (Editorial)
Single Topic Clinical Research
Drug-induced liver injury: Summary of a single topic clinical research conference (Watkins and Seeff). 2006;43:618-631 (Special Article)
Sinusoidal cells
LPS inhibits endothelin-1–induced endothelial NOS activation in hepatic sinusoidal cells through a negative feedback involving caveolin-1 (Kamoun et al). 2006;43: 182-190
Sinusoidal endothelium
$CD4^+$ T cells contribute to postischemic liver injury in mice by interacting with sinusoidal endothelium and platelets (Khandoga et al). 2006;43: 306-315
SOFA (Sepsis-related Organ Failure Assessment)
King's criteria, APACHE II, and SOFA scores in acute liver failure (Cholongitas et al). 2006;43:881 (Correspondence)
King's criteria, APACHE II, and SOFA scores in acute liver failure (Larson et al). 2006;43:882 (Reply)
Sphingosine kinase
Hepatology Highlights (Kaplowitz). 2006;43:207-208
Steatohepatitis
Hepatology Highlights (Kaplowitz). 2006;43:207-208

JNK1 but not JNK2 promotes the development of steatohepatitis in mice (Schattenberg et al). 2006;43:163-172

Steatohepatitis, nonalcoholic
Association between postprandial LDL conjugated dienes and the severity of liver fibrosis in NASH (Cassader et al). 2006;43:1169-1170 (Correspondence)
Hepatology Highlights (Elias). 2006;43:1175-1176
Intermittent disconjugate gaze: A novel finding in nonalcoholic steatohepatitis (Al-Osaimi and Caldwell). 2006;43:883 (Reply)
Intermittent disconjugate gaze: A novel finding in nonalcoholic steatohepatitis (Schartman and Weinstein). 2006;43:882-883 (Correspondence)
Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C (Sanyal et al). 2006;43:682-689

Steatohepatitis, nutritional
COX-2 induction in mice with experimental nutritional steatohepatitis: Role as pro-inflammatory mediator (Yu et al). 2006;43:826-836

Steatosis
Cryoglobulinemia is associated with steatosis and fibrosis in chronic hepatitis C (Saadoun et al). 2006;43:1337-1345
Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice (Ding et al). 2006;43:173-181
Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C (Cammà et al). 2006;43:64-71
Nonalcoholic fatty liver disease: From steatosis to cirrhosis (Farrell and Larter). 2006;43:S99-S112
Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection (Perumalswami et al). 2006;43:780-787

Stellate cells
Hepatology Highlights (Kaplowitz). 2006;43:207-208
Id1 is a critical mediator in TGF-β–induced transdifferentiation of rat hepatic stellate cells (Wiercinska et al). 2006;43:1032-1041
Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo (Zhan et al). 2006;43:435-443
Proteasome inhibition induces hepatic stellate cell apoptosis (Anan et al). 2006;43:335-344

Stem cell transplantation
Liver stem cells and prospects for liver reconstitution by transplanted cells (Shafritz et al). 2006;43:S89-S98

Stem cells
Hematopoietic cells as hepatocyte stem cells: A critical review of the evidence (Thorgeirsson and Grisham). 2006;43:2-8 (Science Frontier)
Liver stem cells and prospects for liver reconstitution by transplanted cells (Shafritz et al). 2006;43:S89-S98
Thermoreversible gelation polymer induces the emergence of hepatic stem cells in the partially injured rat liver (Nagaya et al). 2006;43:1053-1062

Superfund toxic waste sites
Increased prevalence of primary biliary cirrhosis near Superfund toxic waste sites (Ala et al). 2006;43:525-531

Sweden
Improved prognosis for patients hospitalized with esophageal varices in Sweden 1969-2002 (Stokkeland et al). 2006;43:500-505

T

T cell receptor
Identification of a hepatitis C virus–reactive T cell receptor that does not require CD8 for target cell recognition (Callender et al). 2006;43:973-981

T cells
CD4$^+$ T cells contribute to postischemic liver injury in mice by interacting with sinusoidal endothelium and platelets (Khandoga et al). 2006;43:306-315
Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution (Neumann-Haefelin et al). 2006;43:563-572
Hepatitis C vaccines: Inducing and challenging memory T cells (Shiina and Rehermann). 2006;43:1395-1398 (Hepatology *Elsewhere*)
The influence of T cell cross-reactivity on HCV-peptide specific human T cell response (Kennedy et al). 2006;43:602-611
Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis (Lan et al). 2006;43:729-737

Taurocholate
Bicarbonate-rich choleresis induced by secretin in normal rat is taurocholate-dependent and involves AE2 anion exchanger (Banales et al). 2006;43:266-275

Telomerase reverse transcriptase, human (hTERT)
Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma (Mizukoshi et al). 2006;43:1284-1294

Tenofovir disoproxil fumarate
Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients (Benhamou et al). 2006;43:548-555

Thermoreversible gelation polymer
Thermoreversible gelation polymer induces the emergence of hepatic stem cells in the partially injured rat liver (Nagaya et al). 2006;43:1053-1062

Thyroiditis
The clinical and physiological spectrum of interferon-alpha induced thyroiditis: Toward a new classification (Mandac et al). 2006;43:661-672 (Perspectives in Clinical Hepatology)

Toll-like receptor
Differential liver sensitization to Toll-like receptor pathways in mice with alcoholic fatty liver (Gustot et al). 2006;43:989-1000

Toxic waste sites
Increased prevalence of primary biliary cirrhosis near Superfund toxic waste sites (Ala et al). 2006;43:525-531

Transforming growth factor-β
Id1 is a critical mediator in TGF-β–induced transdifferentiation of rat hepatic stellate cells (Wiercinska et al). 2006;43:1032-1041

Transient elastography
Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC (Corpechot et al). 2006;43:1118-1124

Transjugular intrahepatic portosystemic shunt
Prevention of first overt episode of hepatic encephalopathy after TIPS: No easy task (Mullen et al). 2006;43:1155-1156 (Hepatology *Elsewhere*)

Trans-NIH Action Plan for Liver Disease Research
Progress on the action plan for liver disease research (Hoofnagle and Miller). 2006;43:890 (News from the NIH)

Transplantation, intestine/liver
Parenteral nutrition–associated liver disease and the role for isolated intestine and intestine/liver transplantation (Buchman et al). 2006;43:9-19 (Perspectives in Clinical Hepatology)

Transplantation, intrahepatic
Hepatocellular neoplasms after intrahepatic transplantation of ovarian fragments into

ovariectomized rats (Dombrowski et al). 2006;43:857-867

Transplantation, liver
Donor graft adenoviral iNOS gene transfer ameliorates rat liver transplant preservation injury and improves survival (Kaizu et al). 2006;43:464-473
Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation (Blasco et al). 2006; 43:492-499
Hepatology Highlights (Elias). 2006;43: 1175-1176
Hepatology Highlights (Kaplowitz). 2006;43:887-889
Progressive histological damage in liver allografts following pediatric liver transplantation (Evans et al). 2006; 43:1109-1117
The unfinished legacy of liver transplantation: Emphasis on immunology (Starzl and Lakkis). 2006;43:S151-S163

Transplantation, stem cell
Liver stem cells and prospects for liver reconstitution by transplanted cells (Shafritz et al). 2006;43:S89-S98

Transplantation waiting lists
Deaths on the liver transplantation waiting list: An analysis of competing risks (Kim et al). 2006; 43:345-351

Troglitazone
Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo (Yu et al). 2006;43:134-143

Tumor growth
Adeno-associated virus-mediated expression of apolipoprotein (a) kringles suppresses hepatocellular carcinoma growth in mice (Lee et al). 2006;43:1063-1073
Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo (Yu et al). 2006;43:134-143

Tumor necrosis factor α
Hepatology Highlights (Kaplowitz). 2006;43:207-208
Systemic effects of TNF-α secreted by circulating monocytes and fatigue in cirrhosis (Albillos et al). 2006;43: 1399 (Correspondence)
Systemic effects of TNF-α secreted by circulating monocytes and fatigue in cirrhosis (Kerfoot et al). 2006;43: 1399-1400 (Reply)
TNF-α–secreting monocytes are recruited into the brain of cholestatic mice (Kerfoot et al). 2006;43:154-162

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL (Pathil et al). 2006;43:425-434

Tumors
Zonal gene expression in murine liver: Lessons from tumors (Hailfinger et al). 2006;43:407-414

U

UDP-glucuronosyltransferase 1A1 gene *(UGT1A1)*
Coinheritance of Gilbert syndrome–associated *UGTIA1* mutation increases gallstone risk in cystic fibrosis (Wasmuth et al). 2006;43: 738-741 (Concise Communication)

URG11
Enhanced cell survival of Hep3B cells by the hepatitis B x antigen effector, URG11, is associated with upregulation of β-catenin (Lian et al). 2006;43:415-424

Ursodeoxycholic acid
Ursodeoxycholic acid exerts no beneficial effects in patients with symptomatic gallstones awaiting cholecystectomy (Venneman et al). 2006;43:1276-1283

V

Vaccines
Hepatitis A virus: From discovery to vaccines (Martin and Lemon). 2006; 43:S164-S172
Hepatitis C vaccines: Inducing and challenging memory T cells (Shiina and Rehermann). 2006;43:1395-1398 (Hepatology *Elsewhere*)

Valproic acid
HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL (Pathil et al). 2006;43:425-434

Variceal bleeding
Endoscopy critics vs. endoscopy enthusiasts for primary prophylaxis of variceal bleeding (de Franchis). 2006;43:24-26 (Editorial)
Is banding ligation for primary prevention of variceal bleeding as effective as beta-blockers, and is it safe? (Triantos et al). 2006;43:196-197 (Correspondence)
Outcomes, effectiveness, tolerability, and direct costs of prophylactic variceal treatments (Jensen). 2006;43:197-198 (Correspondence)

Variceal hemorrhage
A randomized trial of endoscopic treatment of acute gastric variceal hemorrhage: N-butyl-2-cyanoacrylate injection versus band ligation (Tan et al). 2006;43:690-697, 1410 (Correction)

Varices, esophageal
Improved prognosis for patients hospitalized with esophageal varices in Sweden 1969-2002 (Stokkeland et al). 2006;43:500-505

Vasoactive systems
Systemic hemodynamics, vasoactive systems, and plasma volume in patients with severe Budd-Chiari syndrome (Hernández-Guerra et al). 2006;43:27-33

Vasoconstrictors
The use of vasoconstrictors in patients with cirrhosis: Type 1 HRS and beyond (Moreau and Lebrec). 2006; 43:385-394 (Perspectives in Clinical Hepatology)

Vietnam
Impact of the hepatitis B virus genotype and genotype mixtures on the course of liver disease in Vietnam (Toan et al). 2006;43:1375-1384

W

Water channels
Aquaporins in the hepatobiliary system (Masyuk and LaRusso). 2006;43: S75-S81

Water transport
Aquaporins in the hepatobiliary system (Masyuk and LaRusso). 2006;43: S75-S81

Wedged hepatic vein pressure (WHVP)
Wedged hepatic vein pressure (WHVP): Ready for prime time (Boyer). 2006; 43:405-406 (Editorial)

Z

Zieve, Leslie
True, true . . . but are they related? (Reuben). 2006;43:635-639 (Landmarks in Hepatology)